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ThE BurdEN OF PEdIATrIC ASThMA
Asthma is the most common chronic disease in children in the western world, with 
an estimated prevalence of 5 to 10% 1-2. Up to 25% of children suffer from recurrent 
asthma symptoms 3-4. Uncontrolled asthma is defined as the occurrence of asthma 
symptoms like wheezing, shortness of breath or cough more than twice a week; limita-
tion of physical activities like sports, play or interaction with peers; or the need for 
reliever / rescue treatment with short acting beta-agonists (SABA) more than twice a 
week 5. Over 50% of children with doctor-diagnosed asthma have poor control accord-
ing to the Global Initiative for Asthma (GINA) recommendations 6. Asthma exacerba-
tions needing hospitalization occur with an estimated incidence of 1 to 2 per 1000 
child years 2, 7-8. In the Netherlands, 125 per 100.000 children per year are hospitalized 
because of asthma, in Spain 172, in the Czech Republic 192 and in the UK 197 8-9. The 
burden of asthma is especially felt by children with inadequately controlled asthma, 
who demonstrate greater impairment in asthma related quality of life 10-11. 
Paediatric asthma is also associated with considerable costs for healthcare use, 
prescriptions and productivity losses 12. In 2005 the USA Center of Disease Control and 
Prevention reported that the total economic impact of asthma in school-age children 
was $2 billion, $791 per child with asthma 13. This figure includes both direct medical 
costs ($1 billion a year for medical prescriptions, hospital stays and planned or un-
planned hospital visits) and indirect costs ($265 million a year for future lifetime earn-
ings lost because of asthma related deaths among school-age children; and parental 
productivity losses due to asthma related school/work absence). In the UK allergic 
problems - predominantly asthma - were responsible for an estimated 12.5 million 
consultations with general practitioners (GPs) per year (costing an estimated €300 
million) and for 11% of all medications prescribed in primary care 9. Severe asthma is 
associated with exceptionally high costs, which may amount from €1000,= per patient 
per year if asthma in controlled asthma to €10.000,= for severe uncontrolled asthma 
needing hospitalizations 14.
Risk factors for poor asthma control include poor socio-economic status and ethnic 
minority background 15-17, poor health literacy 18, young age and male sex 8, second hand 
smoking exposure 19, seasonal influences 20-21, poor inhaler technique 22, and exposure 
to allergens, pollutants and viral infections 5. One of the most important modifiable 
risk factors for poor asthma control is non-adherence to asthma medication.
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PrEVALENCE ANd IMPACT OF NON-AdhErENCE TO INhALEd 
COrTICOSTErOIdS 
Adherence to treatment can be defined as “the extent to which a person’s behavior – 
taking medication, following a diet, and/or executing lifestyle changes, corresponds 
with agreed recommendations from a health care provider” 23-24. Inhaled corticoste-
roids (ICS) have an important place in asthma therapy and are prescribed if asthma 
symptoms cannot be sufficiently controlled with SABA alone 5. In clinical trials, ICS 
have proven to be effective in reducing exacerbations compared to placebo or SABA 
alone 25-26. Yet, adherence to ICS therapy is generally low: estimates of primary non-
adherence, not filling initial prescriptions, range from 6-44%. Even when prescriptions 
are filled, secondary adherence (rate of medication use) is low, in the range of 30-70% 
23. Another presentation of poor adherence is discontinuation of ICS use 24. In a Dutch 
study in 165 preschool children, 58.8% continued using asthma medication after the 
first prescription, and not more than 10.3% continued for three years 27. Discontinua-
tion rates in the first 12 months after initial prescription were similar in children aged 
6-14 years: 54%28.
Non-adherence to ICS is associated with an increased risk of insufficient asthma 
control. In studies on this subject, adherence to ICS was 15%-50% higher in children 
with controlled asthma than in those with insufficient asthma control 29-31. Episodes 
of very poor asthma control are called asthma exacerbations. Severe exacerbations 
are defined as asthma-related hospitalizations, visits to the emergency department, 
and/or episodes of systemic corticosteroid use or an increase in a stable maintenance 
dose 5, 32. In a systematic review, high levels of adherence to ICS were associated with 
a lower risk of severe asthma exacerbations both in adults and children 33. However, 
considerable heterogeneity existed in the definitions of adherence and asthma control 
and the conclusions for pediatric asthma were based on only five high-quality studies.
dETErMINANTS OF NON-AdhErENCE 
Factors associated with non-adherence to ICS treatment have been subject to inten-
sive study. Determinants are factors that have been associated with non-adherence 
empirically in observational studies, but that do not necessarily have a causal rela-
tion to it. They can be classified into five dimensions (figure 1.1) 23: an example of a 
condition-related factor is asthma severity, but conflicting evidence exists on the 
effect on adherence rates to ICS 34. 
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•	 Health	 system	 or	 healthcare	 team	 related	 factors	 include	 the	 availability	 and	
accessibility of high quality health care facilities. Also, the quality of the patient-
physician relation and communication is vital for medication adherence 35. 
•	 Social	and	economic	 factors,	 including	age,	gender,	 income	and	parental	educa-
tion are not consistently and independently associated with medication adherence 
36-38. By contrast, ethnicity appears to be associated with adherence to ICS, which 
is lower in children with an ethnic minority background 35, 39-41. However, most data 
about the influence of ethnicity originate from the United States of America (USA) 
and involve children with Afro-American or Latin-American ethnicity. Data on other 
ethnic minority groups in Western-Europe, e.g. Moroccan, Turkish or Surinamese, 
are sparse. Existing literature from the USA is hard to extrapolate to these popula-
tions because of differences in cultural background, economic status and health 
insurance status. 
•	 Examples	of	therapy-related	factors	that	are	positively	correlated	with	adherence	
are once-daily dosing of ICS 42 and combining ICS with long acting beta agonists 
(LABA) 43. 
•	 Patient	 related	 factors	 include	 resources,	 knowledge,	 attitudes,	 beliefs,	 percep-
tions and expectations of the patient. Patients’ knowledge and beliefs about their 
illness, motivation to manage it, confidence (self-efficacy) in their ability to engage 
in illness-management behaviors, and expectations regarding the outcome of 
treatment and the consequences of poor adherence, interact in ways not yet fully 
understood to influence adherence behavior 23. These factors are closely related 
to the underlying mechanisms of adherence behavior and will be discussed in the 
next section.
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Figure 1.1: The five dimensions of adherence 23
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TyPES OF NON-AdhErENCE ANd SELF-MANAgEMENT
Stimuli for non-adherence, or barriers for good adherence, can be divided into inten-
tional and unintentional factors 44. Intentional non-adherence has been described as an 
active process in which the patients chose to deviate from the prescribed medication 
regimen 45. This is provoked by perceptual barriers like negative medication beliefs 
about the necessity or concerns about side effects of treatment 46. Beliefs about neces-
sity and concerns and the ratio between both are associated with adherence to ICS 
47-49. Another perceptual barrier is illness perception, which is the extent to which the 
seriousness of a disease is perceived by the patient 50. As opposed to intentional non-
adherence, unintentional non-adherence is caused by practical barriers: misunder-
standing dosing-instructions or forgetting to take medicines are important causes of 
non-adherence to asthma medication 51. Taking of ICS by children with asthma largely 
depends on parental support. Incorporating medication routines into daily family life 
is associated with better adherence and less health care utilization 52. Although most 
children show some kind of asthma self-management, this is highly age-dependent 53 
and is likely to show considerable variation with family context. Therefore, medication 
management in pediatric asthma should be considered as a family matter. The effect 
of asthma self-management on adherence to ICS needs further elucidation.
MOdELS IN ThE FIELd OF NON-AdhErENCE
Several frameworks have been proposed that brings several concepts together, includ-
ing the Health Belief Model 54 and the Common sense model, figure 1.2 55. These models 
state that adherence is driven by the perceived threat of disease and consequent 
perceived need for treatment, and, on the other hand, general and specific negative 
beliefs about treatment. Apart from the balance between costs and benefits of treat-
ment, other factors may play a role, e.g. self-efficacy and the existence of practical 
barriers for following the prescribed regimen 23, 56.
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QuANTIFyINg NON-AdhErENCE
In clinical practice, information on medication adherence is essential for evaluating 
asthma therapy. Especially if the response to a medication regimen is suboptimal, one 
of the things healthcare providers need to know before making dose adjustments or 
prescribing additional medicines, is to what extend the regimen is followed correctly 
5. This way, unnecessary and possibly counterproductive dose adjustments may be 
prevented. Also, early identification of non-adherence may prevent further deteriora-
tion of asthma control and subsequent asthma exacerbations. 
Many methods exist for measuring levels of medication adherence and each method 
has its strengths and limitations 57-58. Adherence measures can be classified as either 
direct or indirect, depending on whether the actual medication taking behavior or a 
surrogate parameter is measured (Table 1.1). Adherence to asthma medication can be 
measured objectively, e.g. by analyzing medication refills, assessing canister weight 
and by electronic medication monitors. Subjective measures include patient diaries, 
patient questionnaires and physician estimated adherence. Although subjective 
methods usually have low costs and are easy to use, the reliability is limited by social 
desirability bias and by subjective interpretations of responses by the interviewer 
59. In this respect, objective methods are more reliable 58. On the other hand, most 
objective adherence measures are also indirect methods that use surrogate markers 
for medication taking behavior. Since all adherence measures have their limitations, it 
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Figure- 1.2 The Common sense model describing the theoretical relationship of illness perceptions, 
medication beliefs and adherence, copied from R. Horne 55
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used to be commonly accepted belief that there is no such thing as a gold standard for 
adherence measurement 57. Instead, it was suggested that combining methods could 
overcome the limitations of the separate methods. 
In the past decade, however, this idea has been superseded by the technological de-
velopments in electronic medication monitoring, which is increasingly regarded as the 
gold standard for adherence measurement in asthma 33. The technique of electronic 
monitoring (EM) was introduced in 1977 and became known as the Medication Event 
Table 1.1 Methods for measuring adherence 57
Test Advantages disadvantages
Direct methods
Directly observed therapy Most accurate Patients can hide pills in the 
mouth and discard them; 
impractical for routine use
Measurement of the level of 
medicine or metabolite in blood
Objective Variations in metabolism and 
“white coat” adherence can give 
a false impression of adherence; 
expensive
Measurement of the biologic 
marker in blood
Objective; in clinical trials; can 
also be used to measure placebo 
Requires expensive quantitative 
essays and collection of bodily 
fluids
Indirect methods
Patient questionnaires, patient 
self-reports
Simple; inexpensive; the most 
useful method in the clinical 
setting
Susceptible to error with 
increases in time between visits; 
results are easily distorted by the 
patient
Pill counts Objective; quantifiable; and easy 
to perform
Data easily altered by the patient 
(e.g. pill dumping)
Rates of prescription refills Objective; easy to obtain data A prescription refill is not 
equivalent to the ingestion of 
medication; requires a closed 
pharmacy system
Assessment of the patient’s 
clinical response
Simple; generally easy to perform Factors other than medication 
adherence can affect clinical 
response
Electronic medication monitors Precise; results are easily 
quantified; tracks patterns of 
taking medication
Expensive; requires return visits 
and downloading data from 
medication vials
Measurement of physiologic 
markers (e.g. heart rate in patients 
taking beta-blockers)
Often easy to perform Marker may be absent for 
other reasons (e.g. increased 
metabolism, poor absorption, lack 
of response)
Patient diaries Help to correct for poor recall Easily altered by the patient
When the patient is a child, 
questionnaire for caregiver or 
teacher
Simple; objective Susceptible to distortion
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Monitoring System (MEMS) in later years 60. Since then, all sorts of medication packag-
ing devices have been developed 61. The MEMS device registers time and date on which 
the medication container is opened, assuming the medication is subsequently taken. In 
1986 the MEMS-technology was adjusted to be compatible with pressurized, metered 
dose inhalers 62. The first studies with commercially available MEMS devices for pMDI’s 
were published in the early 2000’s 36, 63. In 2007 the first study was published that used 
a MEMS-device for pMDI’s that provided a tailored audio visual reminder function only 
if a dose was missed 64. The so-called Real-Time Medication Monitoring (RTMM) for 
pMDI’s was further developed to record medication events and sent these to a central 
database through the mobile telephone network, thus providing the opportunity for 
immediate patient feedback in case of missed medication doses (Figure 1.3). 
EM has many strengths as a source for adherence calculation: the data give detailed 
insight into adherence patterns, deliberate emptying of inhaler canisters (so called 
“dose dumping”) can be detected and, in the case of RTMM, immediate patient feed-
back is possible. However, the use of EM is limited by high costs, i.e. $220,= for the 
SmartTrack 65 Until these obstacles are removed, the need for adherence measures 
that are both reliable, affordable and easy to use, remains. In particular, early identi-
fication is required of children with severe non-adherence to ICS, who are at risk of 
deterioration or loss of asthma control.
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INTErVENTIONS FOr IMPrOVINg AdhErENCE
Many interventions for improving medication adherence have been investigated 66. 
Interventions using patient education, counseling and daily treatment support, are 
typically aimed at removing intentional barriers for good adherence, such as the 
perceived threat of disease and beliefs about efficacy and side-effects of medica-
tion. Interventions are very heterogeneous and often complex, multidisciplinary 
and sometimes aimed at tailoring support to individual patient needs. The effect on 
medication adherence is generally small and only a few studies have reported effect 
on both adherence and treatment outcomes. Moreover, most trials were at risk of bias 
for randomization and allocation concealment and clinical outcome assessment 66. 
The other category of interventions aiming to improve medication adherence, 
includes those sending reminder messages aimed at reducing the unintentionally 
forgetting of medication intakes 67-69. Reminder messages have been used in many 
forms, e.g. SMS’s (short message service, text-message), audio-visual reminders, tele-
phone reminders and interactive voice response system reminders. The mechanism 
underlying reminder interventions is primarily based on the principles of behavioral 
learning theory. This theory states that behavior, e.g. taking medicines as prescribed, is 
driven by both thoughts (internal cues) and external stimuli (environmental cues). The 
theory suggests that non-adherent behavior can be modified after sufficient repetition 
of external cues, such as reminders 70-71. The persistent exposure to these reminders 
would stimulate the display of the intended behavior leading to better medication 
adherence. 
The efficacy of mobile telephone text messaging for medication adherence in 
chronic diseases was investigated in a meta-analysis of 16 randomized clinical trials 
72. Text messaging significantly improved the odds of being adherent: OR 2.11 (95% 
CI: 1.52-2.93). In a systematic review in patients with asthma, only six studies were 
found that used reminder interventions 67. Although medication adherence improved 
in all studies, no effect was found on asthma related quality of life and asthma related 
outcomes. This lack of efficacy was partially explained by methodological limitation 
like the limited duration (median of 16 weeks) and the absence of baseline adherence 
data. More importantly, in four out of six studies, reminders were sent with a fixed 
time-interval. Regularly sending reminder messages may lead to wearing off of the 
adherence improving effect over time, the so called “ alert-fatigue” 73-74. This problem 
would be overcome by using a tailored SMS-message intervention in which reminders 
are tailored to the patient’s medication taking behavior. This would have a great poten-
tial for reducing unintentional non-adherence. However, the evidence on the efficacy 
of reminder interventions in children with asthma is sparse. 
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AIM ANd OuTLINE OF ThIS ThESIS
This thesis aims to investigate opportunities for identifying and reducing non-adher-
ence to ICS in children with asthma in The Netherlands. The research questions were:
•	 What	is	the	clinical	relevance	of	non-adherence	to	ICS?
•	 What	is	the	role	of	ethnicity	as	a	risk-factor	for	non-adherence?
•	 Can	RTMM	with	tailored	SMS-reminders	improve	adherence	to	ICS,	asthma	control,	
asthma-related	quality	of	life	and	the	risk	of	asthm7a	exacerbations?
•	 What	is	the	role	of	asthma	self-management	by	children	in	daily	life?
•	 Are	patient-reported	adherence	and	refill-adherence	suitable	methods	for	identify-
ing	children	who	are	non-adherent	to	ICS?
These objectives are discussed in part I, part II and part II of this thesis: 
Part I
In chapter 2, the clinical relevance of non-adherence to ICS in children with asthma in 
the Netherlands was investigated. A nested-case control study is described in which 
the association of refill-adherence to ICS with the occurrence of asthma exacerbations 
was investigated using data from the Dutch PHARMO record Linkage System. 
Ethnicity is a known risk-factor of non-adherence to ICS, but its role in asthma treat-
ment in the Netherlands is unclear. Chapter 3 describes the prospective, observational 
COMPLIANCE study into the association of Moroccan and native Dutch ethnicity with 
electronically measured adherence to ICS.
Part II
Although many interventions aimed at improving adherence to ICS have been in-
vestigated, most interventions are complex, heterogeneous and not very effective, 
especially in improving asthma control and asthma-outcomes. A limitations of most 
reminder-interventions is that reminders are sent at regular time-intervals, irrespec-
tive of the patient’s needs. In chapter 4 and 5, the protocol and results of the e-MATIC 
study are presented. In this multi-center, randomized, controlled trial, we investigated 
the effect of RTMM with tailored SMS-reminders, that were only sent if an ICS dose 
was about to be missed, on electronically measured adherence to ICS, asthma control, 
asthma specific quality of life and the frequency of asthma exacerbations. Taking of 
ICS by children with asthma largely depends on parental support and incorporation in 
family medication routines. Most children also have their own role in disease manage-
ment and in using ICS, but this is highly variable, dependent of age and family context. 
Therefore, in chapter 6 self-management of ICS therapy and its role in medication ad-
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herence in children with asthma is explored in an online focus group study in children 
aged 4-8 and 9-12 years old.
Part III
Since the use of EM is still limited by high costs, affordable and easy to use alterna-
tives are needed for identifying children with non-adherence to ICS. In chapter 7, 
the reliability of a patient-reported (proxy) adherence questionnaire, the Medication 
Adherence Report Scale for Asthma (MARS-A) is investigated, with EM adherence as 
the reference standard. 
In chapter 8, the reliability of another screening tool for non-adherence is studied, 
i.e. the so called refill-adherence calculated as the medication possession ratio (based 
on medication dispensing records of ICS), again with EM adherence as the reference 
standard. 
Finally, the results, conclusions and recommendation of the studies described in this 
thesis are discussed in the general summarizing discussion (chapter 9).
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ABSTrACT
Background
Non-adherence to inhaled corticosteroids (ICS) is a major risk factor for poor asthma 
control in children. However, little is known about the effect of adherence to ICS on 
the incidence of asthma exacerbations. The objective of this study was to examine the 
effect of poor adherence to ICS on the risk of exacerbations in children with asthma.
Methods
In this nested case-control study using data from the Dutch PHARMO Record Linkage 
System, children aged 5-12 who had an asthma exacerbation needing oral corticoste-
roids or hospital admission were matched to patients without exacerbations. Refill 
adherence was calculated as medication possession ratio (MPR) from ICS-dispensing 
records. Data were analyzed using a multivariable multiplicative intensity regression 
model. 
results
A total of 646 children were included of whom 36 had one or more asthma exacerba-
tions. The MPR was 67.9% (SD 30.2%) in children with an exacerbation versus 54.2% 
(SD 35.6%) in the control group. In children using long acting beta agonists (LABA), 
good adherence to ICS was associated with a higher risk of asthma exacerbations: 
relative risk 4.34 (95%CI:1.20-15.64).
Conclusions
In children with persistent asthma needing LABA, good adherence to ICS was associ-
ated with an increased risk of asthma exacerbations. Possible explanations include bet-
ter motivation for adherence to ICS in children with more severe asthma, and reduced 
susceptibility to the consequences of non-adherence to ICS due to overprescription of 
ICS to children who are in clinical remission. Further study into the background of the 
complex interaction between asthma and medication adherence is needed. 
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INTrOduCTION
Asthma is the most common chronic disease seen in children in the western world, 
with an estimated prevalence of 5 to 10% 1,2. Inhaled corticosteroids (ICS) have an 
important place in asthma therapy and are prescribed when asthmatic symptoms 
cannot be sufficiently controlled by short acting beta-agonists (SABA) alone. The aim 
of ICS-treatment is reaching and maintaining good asthma control, which is character-
ised by a low frequency and severity of asthma symptoms, no limitation of physical 
activities and a limited need for reliever / rescue treatment with SABA 2. In clinical 
trials, ICS have proved to be effective, reducing exacerbations by 55% compared to 
placebo or SABA alone 3. However, more than half of the childhood population (6-16 
years) with doctor-diagnosed asthma has insufficient control according to the Global 
Initiative for Asthma (GINA) recommendations 4. As a result of poor asthma control, 
asthma exacerbations needing hospitalization occur with an estimated incidence of 1 
to 2 per 1000 child years (data from the USA) 5,6.
Risk factors for poor asthma control include poor socio-economic status and ethnic 
minority affiliation7-9, young age 6, parental smoking 10, negative parental perceptions 
about medication 11 and exposure to allergens, pollutants and viral infections 2. A critical 
factor for maintaining good asthma control seems adherence to ICS treatment, which 
ranges from 40 to 70% in children 12-14. In a study among 102 children, adherence to 
ICS was 17% higher in patients with controlled asthma than in those with uncontrolled 
asthma (p<0.001) 15. A similar result was reported in a recent study in 81 Dutch children 
that showed a trend of higher levels of asthma control with higher levels of adherence 
to ICS (p=0.028) 16.
Although the effect of adherence to ICS on asthma control is generally positive, 
conflicting evidence exists on the occurrence of episodes of very poorly controlled 
asthma: asthma exacerbations, needing a short course of oral corticosteroids or 
hospital admission in children. A recent systematic review reported that high levels of 
adherence to ICS were associated with a reduced risk of severe asthma exacerbations 
in children 17, but increasing evidence exists that the relation between adherence to 
ICS and the occurrence of exacerbations is less straight forward than we used to think. 
Several studies reported a reverse association between adherence and risk of severe 
asthma exacerbations 18-21. Rust et al 22 for example, found that 1.9% of children with refill 
adherence to ICS <50% had a hospital admission for asthma vs. 3.2% in children with 
refill rate > 50% (p<0.01). In another study patients reduced their prescribed controller 
medication without negative consequences 23, whereas other patients continued to 
have poor outcomes despite good adherence 24. Apart from the heterogeneity of the 
study results all studies failed to address an essential methodological issue, being the 
temporal relation between (non-)adherence to ICS use and the asthma exacerbations. 
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The former should precede the latter, otherwise a causal relationship between both 
variables is not plausible. 
To overcome this methodological issue, we designed a study into the temporal rela-
tion between adherence to ICS and the incidence of asthma exacerbations in children 
in a general real-life population of children with asthma. The aim of our study was to 
measure refill adherence to ICS in children with asthma aged 5-12, and to study its 
association with the frequency of asthma exacerbations needing a short course of oral 
corticosteroids or a hospital admission. Our hypothesis was that good refill-adherence 
would be associated with a reduced risk of severe asthma exacerbations.
METhOdS
Setting
In this nested case-control study, a cohort of 150.000 patients was randomly selected 
from a subset of the PHARMO Record Linkage System. The PHARMO RLS contains 
medication-dispensing records from community pharmacies linked to hospital dis-
charge records of more than two million inhabitants of The Netherlands. The comput-
erized drug-dispensing histories contained detailed data about the dispensed medi-
cines, dosing regimens and type of prescriber. The hospital records included detailed 
information on primary and secondary diagnoses, procedures, and dates of hospital 
admission and discharge. All diagnoses were coded according to the International 
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) 25. 
The privacy regulation of the PHARMO institute was approved by the Dutch Data 
Protection Authority. According to Dutch legislation, neither obtaining informed con-
sent nor approval by a medical ethics committee is obligatory for database studies 
without direct patient involvement 26.
Study population
The study population included all children that were ≥5 and ≤12 years of age on the 
cohort entry date and had filled their first prescription of ICS between 1998 and 2008. 
Its dispensing date was considered the cohort entry date. The following types of ICS 
or combinations with beta agonists were allowed: beclomethasone, budesonide, 
fluticasone, ciclesonide, salmeterol/fluticasone and formoterol/budesonide. Patients 
were included if they did not use ICS in the 1 year preceding the cohort entry date. 
Patients had to be registered in the PHARMO database for at least 1 year before and 1 
year after the cohort entry date. Patients taking ICS using a nebulizer were excluded 
from the cohort.
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Outcome measures
Severe asthma exacerbations, requiring admission to hospital or a short course of oral 
corticosteroids, were used as primary outcome measure. The date of the exacerbation 
was called the “index date”. In the hospital discharge records, patients discharged with 
ICD-code 493 (“asthma”) or ICD-code 786.07 (“wheezing”) were counted as asthma-
related admissions to hospital. Short courses of oral corticosteroid use were identified 
from drug-dispensing records as episodes of oral corticosteroid use (Anatomical 
Therapeutic Chemical (ATC) code: H02AB) of not more than 15 days 2. Incorrectly 
registered (e.g. double) corticosteroid medication records, and records of oral cortico-
steroids not prescribed by a general practitioner, paediatrician or pulmonologist were 
not considered.
Asthma exacerbations were not included: (1) if the cohort entry date was less than 
3 months before the index date, as this observation period is too short to calculate a 
reliable measure for refill adherence; (2) if a previous event had occurred less than 
12 months before the event date, as both events may not be independent; (3) if there 
were less than two ICS prescriptions in the year prior to the index-date, since no reli-
able calculation of refill adherence is then possible.
determinants
The primary determinant in our study, i.e. refill-adherence to ICS, was calculated as the 
medication possession ratio (MPR). First, all ICS-dispenses were converted into treat-
ment episodes of consecutive use of ICS following the method of Catalan 27. Switches 
from one to another type of ICS and changes in dose regimen were allowed. If possible, 
atypical ICS-episodes caused by incorrect registration of medication records were 
corrected; otherwise patients were excluded. The refill-adherence was calculated as 
the ratio of the number of daily ICS dosages dispensed and the number of days in the 
episode 28 for a period of 12 months preceding the index date. 
The following co-variables were included: sex, age (at cohort entry date and at index 
date). At index date: type of ICS, type of prescriber of ICS, type of inhaler, daily dose 
and dosing frequency of ICS, time from cohort entry date to index date. Finally, we 
collected the number of dispenses of co-medications within three months and within 
twelve months before the index date.
Matching cases and controls 
Patients who had an asthma exacerbation (“cases”) were matched with control patients 
who at that moment had the same age (±1 year) and had no asthma exacerbation in 
the previous 12 months (incidence density sampling). Under the condition that there 
had not been a previous asthma exacerbation in the preceding 12 months, cases could 
also be analyzed as control patients and control patients could be analyzed more than 
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once at different moments in follow-up. For this reason, the results of this study were 
reported as number of “event moments” (with exacerbation) and matched “control 
moments” (without exacerbation) instead of “cases” and “control patients”. It is noted 
that control moments (without exacerbations) could originate both from patients with 
exacerbations and from patients without.
data-analysis
Using the approach of Dupont 29 and software “PS Power and Sample Size Calcula-
tions” we determined the sample size required to detect a two-fold, 2.5-fold or three-
fold increase in risk of asthma exacerbation between ICS-adherence ≥80% and <80% 
with 0.8 power at the 0.05 significance level. Assuming that each case is matched with 
minimal 30 controls, the probability of ICS-adherence ≥80% among controls is 0.2 and 
the correlation coefficient for ICS-adherence between matched cases and controls is 
0.2, the required sample size is 88, 48 or 32 case patients with 30 matched control(s) 
per case.
A multiplicative intensity model was applied to assess the effect of refill adherence 
to ICS on the occurrence of asthma exacerbations, using statistical software “R” (ver-
sion 2.15.2) with library “survival” 30. The multiplicative intensity model was introduced 
by Aalen in 1978 31 and is a generalization of Cox proportional hazards regression for 
multiple recurrent events per subject, time-dependent covariates, left truncated and 
left censored data and calendar time scale.
Co-variables that showed (borderline) statistical significance (p<0.1) in the univari-
able analysis, were investigated for confounding by adding them to the statistical 
model and leaving them in the model if the regression coefficient changed by more 
than 10%. 
The following co-variables were investigated for effect-modification of the asso-
ciation of adherence with asthma exacerbations: recent use of SABA or short acting 
muscarin antagonistst (SAMA), both as a measure of asthma control; recent use of 
long acting beta agonists (LABA), as a measure of asthma severity; and recent use of 
systemic antibiotics, since asthma exacerbations are often triggered by respiratory 
infections. These potential effect-modifiers were investigated by adding the interac-
tion term to the statistical model; if its regression coefficient was significantly higher 
than 0.0 (p<0.05), the parameter was considered an effect-modifier.
rESuLTS
A total of 934 children matched the inclusion criteria and 646 children also met the 
requirements for correct calculation of refill adherence (Figure 2.1). In this final study 
Non-adherence to ICS and the risk of asthma exacerbations 33
population 365 (57%) children were male and the mean age was 8.1 years (SD 2.2) at 
cohort entry date and 9.6 years (SD 2.1) at index date.
The frequency of recent use of SABA, LABA, combined ICS and LABA, nasal decon-
gestants and systemic antibiotics differed significantly between event moments (with 
an asthma exacerbation) and control moments (without exacerbations): Table 2.1. The 
use of asthma medication not reported in table 2.1 was negligibly low in the 12 months 
preceding the events. 
A total of 40 asthma exacerbations in 36 patients were included in the analysis: 32 
short courses of oral corticosteroids and 8 hospital admissions for asthma. The inci-
dence density rate of asthma exacerbations needing hospital admission was 8.1 / 1000 
patient years, and 43.8 / 1000 patient years for short courses of oral corticosteroids. 
Asthma exacerbations were matched to 1596 control moments without an event with 
a mean of 42 control moments per stratum (range: 4-72).
The mean MPR for ICS was 67.9% (SD: 30.2%) in the 12 months before the event mo-
ments versus 54.2% (SD: 35.6%) for the control moments. The proportion of patient 
moments with MPR ≥80% was 35.0% (SD 48.3) for event moments and 20.2% (SD 40.1) 
for control moments (Table 2.2).
Recent LABA use, within 3 months before the index date, was identified as an ef-
fect modifier. Therefore, data were stratified and 2 separate models were presented 
(Table 2.3). In the non-LABA stratum the intensity ratio of asthma exacerbations was 
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Figure 2.1 Flowchart for patient selection
PHARMO RLS: PHARMO Record Linkage System, ICS: inhaled corticosteroids
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1.07 (95%CI: 0.39-2.92) for refill adherence to ICS ≥ 80% and 4.34 (95%CI 1.20-15.64) in 
patients with recent LABA use, both adjusted for recent SABA use (within 3 months 
before the index date) as the only confounder. 
Table 2.2  Refill adherence to ICS in all children, in children with recent LABA use and in children with-
out recent LABA use.
Adherence measures Event moments (with 
asthma exacerbation)
Control moments (without 
asthma exacerbation) 
All children, n=1.636 n=40 n=1.596
Refill adherence to ICS (%), mean (sd) (IQR) 67.9 (30.2) (49.6;87.5) 54.2 (35.6) (28.5;71.2)
Refill adherence to ICS ≥80%, n (%) 14 (35.0) 322 (20.2)
 
No recent LABA use n=1.342 n=27 n=1.315
Refill adherence to ICS (%), mean (sd) (IQR) 60.3 (28.9) (44.8;72.6) 51.3 (35.8) (27.5;65.6)
Refill adherence to ICS ≥80%, n ( %) ) 5 (18.5) 226 (17.2)
 
Recent LABA use n=294 n=13 n=281
Refill adherence to (%), mean (sd) (IQR) 83.8 (27.4) (72.6;102.6) 67.7 (31.6) (44.3;86.5)
Refill adherence to ICS ≥80% (n ( %) ) 9 (69.2) 96 (34.1)
Table 2.3  Association of refill adherence to ICS with the intensity of asthma exacerbations in children 
using LABA and in children not using LABA.
Adherence measures Intensity ratio of exacerbations (95%CI); p-value
univariable Multivariableb
No recent LABA use n=1.342
Adherence to ICS ≥ 80%a 1.270 (0.471; 3.419); p=0.637 1.067 (0.391; 2.916); p=0.899 
Recent LABA use n=294
Adherence to ICS ≥ 80%a 4.459 (1.287; 15.454); p=0.018 4.340 (1.204; 15.640); p=0.025
a refill-adherence to inhaled corticosteroids; b adjusted for confounding by recent SABA use
ICS: inhaled corticosteroids, LABA: long acting beta agonists, SABA: short acting beta agonists
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dISCuSSION
In children with persistent asthma needing the use of LABA, we found that good refill 
adherence to ICS was associated with an increased risk of asthma exacerbations. No 
association was found for children not using LABA. Therefore, we rejected our hypoth-
esis that good refill-adherence was associated with a reduced risk of severe asthma 
exacerbations.
These results contrast to earlier findings in which high adherence to ICS was associ-
ated with good improved asthma control 15,32 and with a reduced the risk of asthma ex-
acerbations 17. Only a few earlier studies reported a reverse association 18-21. A possible 
explanation for the higher observed level of adherence in children with exacerbations, 
is that the children with exacerbations had a lower level of asthma control to start with, 
which would have motivated them to take their ICS more adherently. Poorly controlled 
asthma would therefore be associated with higher adherence rates. In answer to the 
question why higher levels of adherence not necessarily lead to better asthma control 
and to less asthma exacerbations, Klok et al hypothesized that the minimum level of 
adherence needed for achieving asthma control is higher in patients with ongoing 
persistent asthma, than in patients with asthma in clinical remission 16. Patients in the 
latter group, who are easily overtreated with ICS, would maintain asthma control at a 
lower level of adherence than the former. 
In our study, recent LABA use, as a proxy for asthma severity, was identified as an ef-
fect modifier. Good adherence to ICS was only associated with a higher risk of asthma 
exacerbations in children with more severe asthma (needing the use of LABA). Appar-
ently, the intake of ICS was less critical for maintaining asthma control in children with 
less severe asthma. As a result, these children were possibly less motivated for taking 
ICS adherently. 
A strength of this study is our large patient sample (n=934) and long follow-up 
period (10 years). Also, contrary to earlier studies that used pharmacy data 33,34, we lim-
ited the refill-adherence calculation to the period immediately preceding the asthma 
exacerbation. Regarding the limited biological half-life of ICS, it is considered unlikely 
that non-adherence to ICS leads to the occurrence of an asthma exacerbation more 
than 12 months in the future. Our approach also ruled out the effect of ICS test doses 
and short episodes of ICS use after the occurrence of an exacerbation or pulmonary 
infection, which may otherwise bias adherence calculation. Another strength is that 
pharmacy records were combined with hospital discharge data, so that both asthma 
exacerbations treated with a short course of oral corticosteroids and those needing 
hospital admission could be included into the analysis. 
A limitation of our study is that the use of pharmacy record data tends to overes-
timate the actual medication adherence. In one of the sparse studies evaluating the 
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magnitude of this overestimation, a 9% difference was found between refill adherence 
and electronically measured dose count 35. This overestimation seems too small to 
explain why we have found a higher adherence rate in children with an exacerbation. 
Another potential source of overestimation of adherence to ICS was our inclusion 
criterion that demanded a minimum of two ICS dispenses in the 12 months before the 
index date. This criterion was introduced to ensure valid MPR calculation (ie limited 
discontinuation of ICS use). However, our sensitivity analysis with the inclusion crite-
rion of at least one ICS dispensing in the preceding 12 months, showed a similar asso-
ciation between adherence and exacerbations (data not reported). Like most patient 
databases, PHARMO RSL does not contain detailed data on asthma control. We have 
dealt with this issue by using recent SABA use as a proxy for asthma control, but this is 
only one out of three GINA indicators for asthma control2. It can also not be ruled out 
that asthma exacerbations needing a short course of oral corticosteroids were missed 
if patients used oral corticosteroids as chronic treatment. This is unlikely to change 
the study results, since the chronic use of systemic corticosteroids was rare (0.4%) in 
this study. In addition, asthma exacerbations that were treated with only a temporary 
increased ICS dose might have remained undetected in our study. These mild asthma 
exacerbation, however, were outside the scope of our study, since we focused on se-
vere asthma exacerbations. A final limitation of our database study is that it required a 
highly developed ICT infrastructure for administering pharmacy records and hospital 
discharge data. This may be an obstacle for researchers trying to reproduce the results 
of our study in regions where this infrastructure is lacking. 
Based on the results of this study, clinicians treating children with asthma should be 
aware of the complex relation between adherence to ICS and asthma control. Patients 
having an asthma exacerbation often have good adherence to ICS, while other pa-
tients with poor adherence to ICS do not suffer any clinical consequences. The former 
phenomenon may involve patients who self-manage their ICS therapy according to 
e.g. their current asthma control or disease burden. We think the latter is likely to be 
caused by overprescription of ICS, in case of which stepwise dose reductions or even 
discontinuation of ICS therapy may be required. 
In future research, prospective studies using objective measures are needed to 
further assess the complex relation between asthma control and adherence to ICS, 
both in children who are in clinical remission and in children with unstable asthma. 
This would require longitudinal cohort studies in which objective adherence measures 
such as electronic medication monitoring are used, and in which important poten-
tial confounders, like asthma control, are taken into account. However, this would 
require costly electronic monitoring, long follow-up periods and large study samples 
(considering the generally low incidence of severe asthma exacerbations). In order 
to avoid bias by overprescription of ICS or patient initiated dose-adjustments and 
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interruptions, we suggest a study approach in which, prior to the study, ICS doses are 
titrated to the lowest levels on which asthma control is just maintained. This would 
enhance the clinical impact of non-adherence to ICS, providing a clearer view on the 
complex association of adherence to ICS with asthma control and the risk of asthma 
exacerbations. 
CONCLuSIONS
In children with persistent asthma who also used LABA, adherence to ICS was asso-
ciated with an increased risk of asthma exacerbations. No association was found in 
children who did not use LABA. Prospective studies into the complex relation between 
adherence to ICS and asthma control are needed.
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ABSTrACT
Purpose
To investigate the association of ethnicity with objectively, electronically measured 
adherence to inhaled corticosteroids (ICS) in a multicultural population of children 
with asthma in the city of Amsterdam.
Methods
The study was designed as a prospective, observational multicenter study in which 
adherence to ICS and potential risk factors for adherence to ICS were measured in 
a cohort of Moroccan and native Dutch children with asthma. Electronic adherence 
measurements were performed for 3 months per patient using Real Time Medication 
Monitoring (RTMM). Ethnicity and other potential risk factors such as socio-economic 
status, asthma control and parental medication beliefs were extracted from medical 
records or parent interviews. The association between adherence and ethnicity was 
analyzed using multivariate linear regression analysis.
results
90 children (aged 1-11 years) were included in the study and data of 87 children were 
used for analysis. On average, adherence to ICS was 49.3%. Native Dutch children 
showed higher adherence to ICS than Moroccans (55.9% vs. 42.5%, p=0.044, uni-
variate analysis). After correction for confounders (‘>3 annual visits to the paediatric 
outpatient clinic’, ‘regular use of a spacer during inhalation’) the final regression model 
showed that ethnicity was independently associated with adherence (p=0.028).
Conclusions
In our Western European population of inner city children with asthma poor adher-
ence to ICS is a major concern, and somewhat more in ethnic minorities. Paediatri-
cians involved in asthma treatment should be aware of these cultural differences in 
medication taking behaviour, but further studies are needed to elucidate the causal 
mechanism.
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INTrOduCTION
Asthma is the most common chronic disease in children with a prevalence of almost 
10% 1. Almost all children with asthma use asthma medication, of which inhaled corti-
costeroids (ICS) are a main category 2. Regular use of ICS can improve asthma control 
3-4 and reduce hospital admissions and mortality 5-6. Still, non-adherence is an impor-
tant problem in healthcare in general and is of specific concern in asthma. A World 
Health Organisation report from 2003 7 stated that 6-44% of (all) asthma patients do 
not fill first prescriptions of ICS. Amongst those who do, adherence rates range from 
40% to 70% 7-12. After one year only 8-13% of patients with first prescriptions of ICS still 
use these inhalers 13-14. 
Poor asthma control seems to be a particular problem amongst ethnic minority 
patients 15-16. Some evidence exists that ethnic disparities in asthma may be caused 
by poor adherence to ICS in ethnic minority patients 8,9,17. Van Dellen et al explored 
differences in adherence to ICS between children from different ethnic backgrounds in 
The Netherlands. Their study did not find any difference in adherence between ethnic 
groups 18. However, adherence was measured with pharmacy record data and patient 
self report, which are known to over report adherence and are therefore potentially 
unreliable 19-20. A more reliable method is the use of electronic measurements 10,21-22. 
Another limitation of existing literature is that the majority of studies on the relation 
between ethnicity and asthma originate from the USA. Extrapolation of the results 
to other countries may be complicated by considerable differences in national social 
security system and public health care insurance. Also large differences exist between 
the cultural identity of ethnic minority populations in the USA (e.g. Afro-Americans, 
Latin-Americans) and those in Western Europe (e.g. North-Africans, Turkish people). 
Therefore, additional studies focusing on the role of ethnicity in adherence to ICS 
are needed. This need is emphasized by the fact that approximately 10% of the popula-
tion in the Netherlands is of non-Western origin and even over 50% in some of the 
Netherlands’ larger cities 23, as is the case in many other large urban communities in 
Western Europe.
Therefore, the aim of this study is to determine the association of ethnicity with 
objectively measured adherence to ICS in a multicultural population of children with 
asthma in The Netherlands. 
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SuBJECTS ANd METhOdS
Study design
The study was designed as a prospective, observational, multicenter study in which 
adherence to ICS was electronically measured for 3 months in a cohort of Moroccan 
and native Dutch children with asthma. Patients were included from the St. Lucas 
Andreas Hospital, the BovenIJ Hospital and the Academic Medical Centre / Emma 
Children’s Hospital in Amsterdam. The study design was approved by the medical eth-
ics committee of the VU Medical Centre in Amsterdam and by the institutional review 
boards of the participating hospitals.
Study population 
Patient records were selected from the hospital administration in case children were 
aged 11 years or younger and diagnosed with asthma or wheezing (children under 
six are usually diagnosed based on a symptom score; this is registered as wheezing 
2). Children with Moroccan and native Dutch ethnicity were identified using a name 
recognition technique. In this procedure, the names of potential participants were 
initially screened by an investigator with a Moroccan/Dutch ethnicity. Identification of 
Moroccan and Dutch ethnicity based on names is considered to be highly distinctive 
if carried out by a native speaker 15. Parents of potential participants were contacted 
by telephone to verify whether the children had used an inhaled corticosteroid with a 
pressurized metered dose inhaler (pMDI) for at least the past 3 months and to verify 
ethnicity. If the child or (at least one of) its parents were born in Morocco, it was con-
sidered to have Moroccan ethnicity. Following the definition of Statistics Netherlands, 
children were considered to have Dutch ethnicity if they and both of their parents 
were born in the Netherlands. Only patients using fluticasone alone or fluticasone 
combined with the long acting beta agonist salmeterol could enter the study, because 
of compatibility with the Real Time Medication Monitoring (RTMM) devices. Spacers 
also had to be compatible with the RTMM-device. Eligible patients were invited to visit 
the paediatric outpatient department. An introduction letter and informed consent 
were sent to their home address. Children and their parents who refused to participate 
in the study were excluded.
data collection
Patient contacts
During the initial visit to the paediatric outpatient clinic, the study design, including 
the data collection by the RTMM-device, was further explained and the parents were 
requested to sign the informed consent form. In an interview with one of the parents 
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a number of potential risk factors were registered (section “potential risk factors”). 
Moroccan patients were interviewed by bilingual research assistants. Each patient 
received an RTMM-device (section “outcome measures”) which was attached to their 
own pMDI. After receiving instructions, patients used the RTMM-device for three 
months for inhalation of their normal ICS dose. The patients and their parents knew 
they were being monitored during the study. After three months of using the RTMM-
device, patients were invited for a second visit to the paediatric outpatient department 
in which the RTMM-device was collected and an exit interview took place. During the 
entire study period an independent paediatrician was available for consultation by 
parents or children participating in the study. However, no parents have consulted this 
independent paediatrician. 
Outcome measures
ICS inhalations were registered by the RTMM-devices which operate as follows. Each 
time the pMDI was fired a data message containing patient-ID and time and date of 
administration was sent to the study database using the mobile telephone network. In 
order to prevent incomplete registration caused by insufficient network connection, 
the RTMM-device was prepared to use two different networks: GPRS and GSM (dual 
band). If both networks were unavailable at the time of inhalation, a data message was 
prepared for sending at a later moment.
For each administration, data were compared to the prescribed ICS dosing schedule. 
Adherent administrations were defined as inhalations registered within a 6 hour time-
frame around the prescribed time of inhalation (from 3 hours before until 3 hours after), 
which is a common measure for twice daily dosing regimens 24-26. For each patient the 
proportion of adherent administrations of the number of prescribed administrations 
was calculated and was used as the outcome measure. 
Potential risk factors
Children and their parents were interviewed by healthcare workers specialised in 
ethnic diversity for collection of relevant characteristics that could not be extracted 
from the medical records. Potential risk factors (i.e. secondary determinants, collected 
as potential confounders for the association between ethnicity and adherence) regis-
tered during this study included age, gender, type of ICS (fluticasone or fluticasone/
salmeterol), fluticasone dosage and dosing frequency, Dutch language skills of the 
parents (assessed by investigators), parental level of education (highest education 
that was successfully finished by the parents), family income, quality of housing (e.g. 
degree of insulation, problems with indoor humidity; assessed by parents), parental 
smoking habits (at home), use of a spacer during inhalation, identity of paediatrician 
and hospital. The frequency of hospitalisation and of visits to the paediatric outpatient 
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department in the 12 months preceding the study period were collected as an indica-
tor of the level of asthma control. Finally, parental medication beliefs were measured 
using the Beliefs about Medicines Questionnaire (BMQ) Specific, containing a scale 
for beliefs in the necessity (nec) of ICS and one for concerns (conc) about long term 
toxicity and disruptive effects of ICS 27,28. Both scales range from 5 to 25; higher scores 
indicating stronger beliefs. Subtraction gives a necessity– concerns differential (range 
−20 to + 20), indicating the balance between the patients’ trust in the efficacy and 
concerns about side effects. Combining the separate necessity and concern scales 
four attitudinal groups were created: sceptical (nec<15, conc>15), indifferent (nec<15, 
conc<15), ambivalent (nec>15, conc>15) and accepting (nec>15, conc<15) 29.
data-analysis
The sample size calculation was based on the assumption that in the final linear re-
gression model four independent variables would be included. With a type 1 error of 
0.05, a power of 80% and an estimated effect size of 0.15, a sample size of in total 84 
children was determined. In anticipation of patient drop-out, a few additional patients 
were included.
Patients for whom less than 5 inhalations were registered during the study period 
were excluded from data-analysis, since they apparently stopped using ICS and there-
fore did not match the inclusion criteria. Data were processed and analysed using 
SPSS 18.0. Categorical determinants were first converted into dummy variables. For 
both the primary determinant and the secondary determinants we started with a 
univariate analysis (independent samples T-test or one way ANOVA) on the primary 
outcome measure (percentage of adherent inhalations). Secondary determinants that 
showed a borderline association (p ≤ 0.2) with adherence in the univariate analysis 
were subsequently added to a multivariate linear regression model on the association 
between ethnicity and adherence, and were only left in the ultimate model if they had 
a significant contribution (p < 0.05).
rESuLTS
Of all 1026 patients with correct age and diagnosed with asthma or wheezing, 939 
were excluded for several reasons (figure 3.1). 
All 90 patients included in the study finished the follow-up. At the end of data-col-
lection three more patients were excluded: two patients (one with Dutch and one with 
Moroccan ethnicity) had taken less than five ICS-inhalations in the entire study period 
and were therefore assumed to have stopped ICS therapy before entering the study. 
One patient had used a RTMM-device with technical failure. The final study population 
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included 87 patients of which 44 Dutch and 43 Moroccan. Baseline characteristics of 
the 87 children included in the analyses are presented in table 3.1. Several baseline 
characteristics were unevenly distributed between children with Dutch and Moroccan 
ethnicity, including sex, hospital, parental level of education, quality of housing, pa-
rental Dutch language skills, family income and medications beliefs (BMQ) (table 3.1).
The mean percentage of adherent inhalations was 49.3% (sd 31.2%). Only 18% of 
patients (16/87) showed an adherence rate of more than 80%. More than half of the 
study population (49/87) had less than 50% adherent ICS-inhalations and almost a 
quarter of the participants (21/87) took less than 20% of inhalations adherently. On 
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Figure 3.1 Participant flow diagram
Table 3.1  Baseline characteristics of study population (n=87)
determinant Categories dutch children 
(n (%))
[N=44]
Moroccan children 
(n (%))
[N=43]
Sex# Boys 32 (72.7) 22 (51.2)
Hospital# SLAZ
BovenIJ
AMC
18 (40.9)
20 (45.5)
6 (13.6)
37 (86.0)
6 (14.0)
0 (0.0)
ICS-medication fluticasone
fluticasone/salmeterol
37 (84.1)
7 (15.9)
39 (90.7)
4 (9.3)
Dosing frequency Once daily
Twice daily
8 (18.2)
36 (81.8)
6 (14.0)
37 (86.0)
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Table 3.1  Baseline characteristics of study population (n=87) (continued)
determinant Categories dutch children 
(n (%))
[N=44]
Moroccan children 
(n (%))
[N=43]
Dosage fluticasone 50 µg
125 µg
250 µg
3 (6.8)
37 (84.1)
4 (9.1)
3 (7.0)
39 (90.7)
1 (2.3)
Parental level of 
education#
None
Primary school 
Secondary school
Vocational education
University
0 (0.0)
2 (4.5)
7 (15.9)
15 (34.1)
20 (45.5)
3 (7.0)
6 (14.0)
14 (32.6)
12 (27.9)
8 (18.6)
Quality of housing# Poor
Insufficient
Sufficient
Good
2 (4.5)
4 (9.1)
14 (31.8)
24 (54.5)
16 (37.2)
7 (16.3)
8 (18.6)
12 (27.9)
Smoking at home Yes 4 (9.1) 4 (9.3)
Parental Dutch 
language skills#
Poor
Insufficient
Sufficient
Good
0 (0.0)
0 (0.0)
0 (0.0)
44 (100.0)
2 (4.7)
9 (20.9)
11 (25.6)
21 (48.8)
Year family income#
(average is €30,500 
in 2009)
< 1 x average - low
1-2 x average - intermediate
>2 x average - high
11 (25.0)
26 (59.1)
7 (15.9)
28 (65.1)
14 (32.6)
1 (2.3)
BMQ groups# Sceptical (nec<15, conc>15)
Indifferent (nec<15, conc<15)
Ambivalent (nec>15, conc>15)
Accepting (nec>15, conc<15)
1 (2.3)
13 (29.5)
3 (6.8)
27 (61.4)
5 (11.6)
6 (14.0)
21 (48.8)
11 (25.6)
BMQ-necessity 
(score 5 to 25)
≤ 15
> 15
14 (31.8)
30 (68.2)
11 (25.6)
32 (74.4)
BMQ-concerns# 
(score 5 to 25)
≤ 15
> 15
40 (90.9)
4 (9.1)
17 (39.5)
26 (60.5)
BMQ-necessity minus 
concerns (score -20 
to +20)#
≤ 0
> 0
4 (9.1)
40 (90.9)
15 (34.9)
28 (65.1)
Use of a spacer 
during inhalations
Yes 39 (88.6) 35 (81.4)
determinant Mean ± sd Mean ± sd
Age (months)# 64.7 ± 35.7 53.0 ± 23.0
Number of annual hospital admission for asthma 0.3 ± 0.6 0.5 ± 0.8
Number of annual visits to outpatient clinic for asthma 3.8 ± 2.8 4.1 ± 2.4
# Determinant were significantly different between Dutch and Moroccan children at p < 0.05
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average, patients did not use any ICS on 36.9% of the study days. On 63.1% of the days 
at least one ICS inhalation was taken and at least two inhalations on 40.7% of the days. 
Overall, native Dutch children showed a higher percentage of adherent ICS inhalations 
than children with Moroccan ethnicity (55.9% vs. 42.5%, p=0.044, univariate analysis). 
Determinants that did not show any association with adherence in univariate 
analysis were age, sex, hospital, paediatrician, dosing frequency, daily dose, smoking 
habits parents, parental Dutch language skills, hospital admissions for asthma, BMQ-
necessity and BMQ-necessity minus concerns.
The remaining secondary determinants showed an association with adherence (p ≤ 
0.2) in the univariate analyses and are presented in table 3.2. 
These determinants were subsequently added to the model in a multivariate linear 
regression analysis estimating the association of ethnicity with adherence. The final 
model contained ‘>3 annual visits to the paediatric outpatient clinic’ and ‘regular use 
of a spacer during inhalation’ as confounders and resulted in an independent, statisti-
cally significant association of ethnicity with adherence (p=0.028, table 3.3). 
Table 3.2  Secondary determinants with a (borderline) association with adherence in the univariate 
analysis (p ≤ 0.2)
determinant Categories Adherence (%)
Mean ± sd
p-value
ICS-medication fluticasone
fluticasone / salmeterol
47.2 ± 31.1
63.7 ± 28.6
0.103
Parental level of education Vocational or lower
College / University
44.9 ± 30.2
58.7 ± 31.7
0.054
Quality of housing Poor -Insufficient
Sufficient – Good
42.8 ± 28.3
52.6 ± 32.2
0.169
Year family income < 1 x average - low
1-2 x average - intermediate
>2 x average – high
42.9 ± 32.5
52.6 ± 29.5
64.3 ± 28.3
0.140
Number of visits to outpatient 
clinic for asthma
≤3
>3
43.7 ± 28.8
55.9 ± 32.9
0.068
BMQ groups Sceptical (nec<15, conc>15)
Indifferent (nec<15, conc<15)
Ambivalent (nec>15, conc>15)
Accepting (nec>15, conc<15)
22.2 ± 29.5
51.4 ± 37.4
47.8 ± 30.4
53.5 ± 29.0
0.147
BMQ-concerns 
(score 5 tot 25)
≤15
>15
52.8 ± 30.7
42.7 ± 31.5
0.152
Use of a spacer during 
inhalations
Yes
No
53.4 ± 30.5
26.1 ± 25.0
0.003
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dISCuSSION
In this study, an average of 49% of prescribed ICS inhalations was taken within the 
predefined 6 hour timeframe around the planned time of inhalation. This result cor-
responds with adherence rates found in earlier studies in asthma patients (ranging 
from 40 to 50%) in which adherence was objectively assessed by measuring canister 
weight, dose counting or electronic measurement 10,12,30-31. 
In this study, a significantly higher adherence rate was found in native Dutch 
children (55.9%) than in Moroccan children (42.5%), even after adjustment for con-
founders known to be associated with adherence (p=0.028). This is in agreement 
with several studies from the USA looking at the association of ethnic disparities with 
ICS-adherence 9-10,17,30. In spite of the different ethnic background of minority patients 
in these American studies (Afro-American, Asian and Latin-American), and other socio-
economic differences (i.e. insurance status, income/social security system), we found 
similar adherence rates and ethnic/racial differences in our population. This difference 
in adherence rate between Dutch and Moroccan children was not (fully) explained by 
the determinants we collected, including those that showed a significant association 
with ethnicity (e.g. parental level of education, quality of housing, parental language 
skills, family income, medications beliefs, table 3.1) or with adherence (use of a spacer 
during inhalation, table 3.2). This is in contrast with other studies, in which socioeco-
nomic status and negative patient beliefs are found to mediate the ethnicity-adherence 
relationship 8,30. Other cultural issues may contribute to the observed ethnicity related 
difference in adherence. 
Several limitations of this study need to be discussed. First, this study was designed 
to investigate ethnicity as an independent risk factor for non-adherence to ICS. This as-
sociation was adjusted for covariates that were unevenly distributed between ethnici-
ties or that had an association with adherence. However, larger studies looking into 
specific risk factors within ethnic subgroups need to be designed to identify factors 
that may explain the association between ethnicity and adherence to ICS. Further-
more, investigation of culture specific determinants of adherence to asthma medica-
tion is needed for all major ethnic minority populations in large Western-European 
cities. Although electronic monitoring such as Real Time Medication Monitoring is 
Table 3.3  Multivariate analysis of the percentage of adherent inhalations related to ethnicity
Categories Adherence (%) 
 μ ± sd
univariate 
p-value
Multivariate 
p-value
Adjusted for
Dutch (n=44)
Moroccan (n=43)
55.9 ± 30.4
42.5 ± 30.8
0.044 0.028 >3 annual visits to the paediatric 
outpatient clinic, regular use of a 
spacer during inhalation
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considered more sensitive for measuring non-adherence than other, subjective tools 
for adherence measurement 10,19,32 and although we have found a mean adherence rate 
of 49%, we think that we may still have overestimated the actual adherence to ICS. The 
participating patients were aware that they were being observed, so they may have 
acted more adherent than usual. Also, the RTMM-devices can only detect that the pMDI 
is being fired. This means that deliberate faking of the adherence measurement has 
remained undetected. A common critique of electronic medication monitoring based 
on the time and date the inhaler is fired, is that it cannot be confirmed that the medica-
tion is actually taken or that no more or no less than the prescribed dose is taken. 
Only drug assays can confirm ingestion. However, studies comparing the sequence 
of medication events with projected and periodically measured concentrations of 
the drug in plasma, confirmed the validity of medication event monitors. Mismatches 
between medication events and actual dosing were too rare to create substantial 
differences between projected and actual concentrations of the drug in plasma 33-36. 
Patients who had decided to quit taking ICS (without consulting a physician) have not 
been included into this study. At patient selection, the parents of 203 patients claimed 
that their child did not use a fluticasone containing pMDI anymore. Only 2 patients 
were excluded for this reason after finishing the study period (less than 5 inhalations 
were registered in 3 months). If some of the excluded patients still had an indication 
for taking ICS, they would have had a 0% adherence rate. Taking this into account, 
the mean adherence rate would be even considerably lower than 49%. Although a 
considerable number of potential risk factors for poor adherence were collected in 
this study, we may have missed one or more. For example, we have not collected data 
on the number and type of drugs concomitantly used with ICS, on asthma control, 
asthma severity, patient self efficacy and parental asthma knowledge. This may have 
resulted in insufficient adjustment of the association between ethnicity and adherence. 
Healthcare insurance status was deliberately not collected in this study. According to 
Dutch law, every Dutch citizen is required to have a basic healthcare insurance (which 
covers medication costs). Children receive insurance for free. Therefore, the authors 
believe that non-adherence caused by lack of healthcare insurance is not relevant for 
The Netherlands. Finally, this study was carried out in a mixed population of children 
with -spirometry confirmed- diagnosis asthma and children with wheezing. The latter 
have not been officially diagnosed with asthma. These children may therefore have 
benefited less from ICS treatment than others, which may have influenced adherence 
behavior and medication beliefs. 
A strength of this study is the use of RTMM as an objective and reliable method 
for adherence measurement. This method provides less room for bias, e.g. by socially 
acceptable patient response (patient self report), misjudgement of patient behaviour 
(adherence questionnaires) and overestimation of adherence based on pharmacy 
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dispensing data (refill rate, persistence). The results of this study also provide a better 
understanding of medication behaviour of a multicultural population of European in-
ner-city children with asthma. This is especially relevant since ethnic minority children 
are abundant in large European cities and have not been intensively studied before 23. 
In conclusion, our multicultural population of children with asthma showed an aver-
age adherence to ICS of 49%. The results indicate a significantly higher adherence rate 
in native Dutch children than in Moroccan children. Therefore, we conclude that in 
our Western European population of inner city children with asthma poor adherence 
to ICS is a major concern, and somewhat more in ethnic minority children. Paediatri-
cians involved in asthma treatment should be aware of these cultural differences in 
medication taking behaviour, but further studies are needed to elucidate the causal 
mechanism.
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ABSTrACT
Background
Many children with asthma do not have sufficient asthma control, which leads to 
increased healthcare costs and productivity loss of parents. One of the causative 
factors are adherence problems. Effective interventions improving medication adher-
ence may therefore improve asthma control and reduce costs. A promising solution 
is sending real time text-messages via the mobile phone network, when a medicine is 
about to be forgotten. As the effect of real time text-messages in children with asthma 
is unknown, the primary aim of this study is to determine the effect of a Real Time 
Medication Monitoring system (RTMM) with text-messages on adherence to inhaled 
corticosteroids (ICS). The secondary objective is to study the effects of RTMM on 
asthma control, quality of life and cost-effectiveness of treatment.
Methods
A multicenter, randomized controlled trial involving 220 children (4-11 years) using ICS 
for asthma. All children receive an RTMM-device for one year, which registers time 
and date of ICS doses. Children in the intervention group also receive tailored text-
messages, sent only when a dose is at risk of omission. Primary outcome measure is 
the proportion of ICS dosages taken within the individually predefined time-interval. 
Secondary outcome measures include asthma control (monthly Asthma Control 
Tests), asthma exacerbations, healthcare use (collected from hospital records, patient 
reports and pharmacy record data), and disease-specific quality of life (PAQLQ ques-
tionnaire). Parental and children’s acceptance of RTMM is evaluated with online focus 
groups and patient questionnaires. An economic evaluation is performed adopting 
a societal perspective, including relevant healthcare costs and parental productivity 
loss. Furthermore, a decision-analytic model is developed in which different levels of 
adherence are associated with clinical and financial outcomes. Also, sensitivity analy-
ses are carried out on different price levels for RTMM.
Conclusion
If RTMM with tailored text-message reminders proves to be effective, this technique 
can be used in daily practice, which would support children with suboptimal adher-
ence in their asthma (self)management and in achieving better asthma control and 
better quality of life.
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BACKgrOuNd 
Asthma is the most common chronic childhood disease in industrialised countries and 
its prevalence has been increasing in the past years 1, 2. As in adults, asthma in children 
is associated with more hospitalisations, a decreased quality of life 3, 4 and a substan-
tial economic burden 5. Children themselves report several negative consequences 
of asthma: feeling ill, limitations in peer interactions and medication annoyances 6. 
Other problems include limited sports participation and school attendance 7. These 
phenomena indicate that many children do not have sufficient asthma control, in spite 
of the availability of effective maintenance therapy in the form of inhalation cortico-
steroids (ICS). In a Dutch study 55% of the children with doctor-diagnosed asthma had 
insufficient control 8. Poor adherence to ICS is an important risk factor for insufficient 
asthma control 9, 10. Studies show that adherence to ICS ranges from 40 to 70% 11-17. 
The disruptive effect of non-adherence on asthma treatment implies that solutions 
are needed for improving adherence. Up to now, many interventions focus on educa-
tion of parents and children. Review studies show that such educational interventions 
can result in a lower risk of hospital admissions but the effect on other outcomes is 
less clear 18, 19. A meta review on adherence showed that although education seems 
plausible for explaining adherence, the effects of educational interventions aimed 
to improve adherence were yet unclear 20. A promising, yet complex, approach is to 
combine several interventions, e.g. improving the patient-doctor relationship, training 
the doctor’s communication skills and simplifying asthma medication 21. 
Lately, information and communication technology (ICT)-solutions have been pro-
posed to improve adherence and their effectiveness has been shown 22-24. Examples 
are internet-based monitoring of asthma symptoms 25 and audiovisual reminding to 
take asthma medication 26. Reminding patients through the sending of text-messages 
is a simple method with low intrusiveness and relatively low costs 27. Text-message 
reminding might be especially suitable for unintentionally non-adherent patients, e.g. 
patients who forget to take their medication 28. Several systematic reviews have shown 
that text-messaging is effective in the improvement of health outcomes or in chang-
ing health behaviour 24, 29, 30. Examples include improved blood glucose levels in obese 
type 2 diabetes patients 31, higher level of physical activity 32, higher smoking cessation 
rates 33, 34 and improved self-efficacy in young patients with diabetes type 1 35. In adult 
asthma patients positive results of daily text-message alerts have been reported as 
well: adherence to inhaler medication was 18% higher in patients receiving a 12 week 
intervention with text-message reminders 36. 
A concern with repetitive sending of text-messages before every intake may be that 
patients get accustomed to receiving reminders leading to wearing-off of the adher-
ence improving effect. To avoid this “alert-fatigue”, a more sophisticated approach is 
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needed for optimal and enduring adherence improvement. Such an approach may 
consist of sending time-tailored text-message reminders that are sent only if a drug 
dose is at risk of omission. This technique needs the use of Real Time Medication 
Monitoring (RTMM), which is an adaptation of the Medication Event Monitoring Sys-
tem (MEMS). Like MEMS, RTMM uses an electronic medication dispenser that records 
the date and time the dispenser is opened. MEMS has proven to provide objective and 
reliable data of adherence and it has been used to measure medication adherence of 
various patient populations 37, 38. RTMM delivers the same type of data but, as opposed 
to MEMS, RTMM registers medication intake data in real time at a central data-server. 
This real time information is directly available, which enables sending text-messages 
to patients who are at risk of missing a dose of their medication. 
The effect of sending time-tailored text-messages has not been studied extensively 
before. One randomized controlled trial for oral medication in adult diabetic patients 
has shown RTMM to be effective 39. Also, preliminary results of a study in HIV-infected 
adults using RTMM show that patients receiving tailored text-message reminders 
improve adherence to antiretroviral therapy as well as rates of viral suppression 40. 
The application of RTMM in children using inhalation medication has not been studied 
before and therefore needs further investigation. Since enhancement of inhalation 
therapy with RTMM is still an innovative and expensive technique, RTMM equipment 
and software are only available for research purposes. Before this technique can be 
further developed into a design suitable for regular care, more data are needed on 
cost-effectiveness and patient acceptance. 
Therefore, in this study we investigate the impact of RTMM with time-tailored text-
message reminding on adherence to ICS in children with asthma. Secondary aim is 
to determine the effect of RTMM on asthma-control. Finally, cost-effectiveness and 
patient acceptance of RTMM are studied.
METhOdS
design
This study is a one year, multicenter, randomized controlled trial in children who use 
ICS for asthma. All children receive an RTMM-device which registers time and date 
of administered ICS doses. Children in the intervention group receive “time-tailored” 
text–messages that are only sent when a dose is at risk of omission. Patients in the 
control group do not receive such text-messages.
Improving adherence with SMS-reminders - e-MATIC study protocol 63
Ethical approval
The medical ethics committee of the Erasmus Medical Center has approved the study 
protocol (protocol number MEC-2011-143, Netherlands Trial Registry code NTR2583, 
www.trialregister.nl).
Study data are coded in order to guarantee privacy of participants. Before entering 
the study, all participants are asked for written informed consent.
Participants
Patients are recruited from five outpatient clinics in the Netherlands: St Lucas Andreas 
Hospital, Academic Medical Center, BovenIJ Hospital (all in Amsterdam), Erasmus 
MC (in Rotterdam) and Groene Hart Ziekenhuis (in Gouda). The inclusion criteria for 
participants are:
•	 Age at start of the study is 4 to 11 years. Children aged 12 years or older tend to show 
a more individual medication behaviour, with a smaller role for parents compared 
to younger children. Also, the Asthma Control Test, a questionnaire for measuring 
asthma control, was only validated for children aged 4 to11 years 41, 42.
•	 Doctor diagnosed asthma for at least six months. This criterion aims to exclude pa-
tients with transient wheezing e.g. due to viral respiratory tract infections. Shortly 
after the diagnosis of asthma, patients may also be better motivated for treatment 
than in later stages of their disease. That is why we have chosen to aim for patients 
with chronic asthma. These are also the patients who are on maintenance therapy 
with ICS.
•	 ICS use for at least three months. In the first period of ICS use, adherence rates may 
be higher than normal. Therefore, only patients with chronic ICS use are included 
10. 
•	 Use of a pressurized metered dose inhaler (pMDI). The RTMM-devices used for 
electronic adherence measurement are only compatible with pMDIs. Children us-
ing ICS with nebulizers or dry powder inhalers can therefore not be included. 
•	 Use of fluticasone, fluticasone/salmeterol or beclomethasone. The experimental 
RTMM-devices have been developed to accommodate only fluticasone (Flixotide®), 
fluticasone/salmeterol (Seretide®) or beclomethasone (QVAR®) inhalers. Children 
using other types of ICS can therefore not be included. Unless clinically indicated, 
childrens’ asthma medication will not be changed to fit this inclusion criterium.
•	 At least one parent/caregiver has a mobile phone. In the intervention group real-
time text-message reminders are sent via the mobile telephone network. Also, 
alerts for low battery status of the RTMM-devices are automatically communicated 
with text-message reminders.
We aim to include 44 children per hospital into the study. From the hospital admin-
istrations of each participating hospital, records are randomly selected of children 
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aged 4-11 years and diagnosed with asthma at least 6 months ago. After verification 
of the other inclusion criteria, a patient information leaflet is handed out or sent to 
the parents of the potential participants. Parents are contacted and invited to visit the 
paediatric outpatient department for an intake interview. In case of participation, at 
least one of the childs’ parents has to give written informed consent. If a hospital is 
unable to include the required number of patients, they will be recruited from one of 
the other participating hospitals. 
Children are randomly assigned to the intervention group or the control group. We 
use block randomization per hospital with blocks of 16 patients. Initially, physicians, 
researchers, and patients are blinded for randomisation. However, randomisation is 
unblinded after start of the study period, when patients find out whether they receive 
text-message reminders or not.
A flowchart of patient selection, randomisation and data collection is shown in 
Figure 4.1.
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Figure 4.1 Patient selection
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Intervention
All children, both in the intervention and in the control group, receive an RTMM device 
for one year. ICS inhalations are registered by the RTMM-device which operates as 
follows: each time the pMDI is fired a data message containing patient-identification 
and time and date of administration is sent to the study database using the mobile 
telephone network. In order to prevent incomplete registration caused by insufficient 
network connection, the RTMM-device is designed to use two different networks: the 
mobile data-network and the regular mobile telephone network. If both networks are 
unavailable at the time of inhalation, a data message is prepared for sending at a later 
moment. 
Only in the intervention group, time-tailored text-message reminders are sent to the 
parents and, if the child has a mobile phone, also to the child, in order to warn that a 
dose is at risk of being forgotten. Parents and children are not always together, for ex-
ample if children are at school. As such, there may be a problem if the child has missed 
its dose and is already at school when the text-message is received by its parents. In 
that case, parents will not be able to verify if the child takes its medication. To ensure 
that text-messages are sent before the child goes to school (morning dose) or to bed 
(evening dose), a text-message is sent automatically if no ICS dose has been registered 
within 15 minutes after the planned time of inhalation. Such a short time interval may 
be less important when children are not at school, for example during weekends. For 
that reason, time intervals are individually defined (‘time-tailored’) for each patient for 
each day of the week. This is also thought to improve patient-acceptance of RTMM, 
reducing the so called “alert fatigue”. Patients in the intervention group who live in 
an area with a very poor mobile network connection may occasionally receive an un-
necessary text-message reminder if an ICS administration can not be reported to the 
RTMM-database in time. When the RTMM-network connection is re-established, the 
data message is sent. This phenomenon is closely monitored during the study period. 
data collection 
Outcome measures
The primary outcome measure is adherence to ICS, defined as the proportion of all 
prescribed dosages taken by the child within a six hour time-frame around the planned 
time of inhalation, i.e. from 3 hours before until 3 hours after. This is a common mea-
sure for twice daily dosing regimens 43-46. In addition, we will look at other time-frames, 
missed doses and extra doses. These data are calculated from the RTMM data on ICS 
use, which are collected as described earlier in the “intervention”-section. 
Secondary outcome measures are asthma control, frequency of asthma exacerba-
tions, disease specific quality of life, healthcare use for asthma and school/work 
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absence. These data are also used for calculation of the cost effectiveness of RTMM in 
children with asthma. 
Asthma control is measured in several ways. The childhood Asthma Control Test 
(ACT) is filled out each month during the entire study in order to avoid seasonal differ-
ences 47. The ACT is a questionnaire validated for children aged 4-11 years 41, 42. The ACT 
is a simple 7-item questionnaire, which has been shown to be useful in the detection 
of poorly controlled asthma. The ACT-score is calculated by adding the scores of all 
items; the ACT-score ranges from 0 to 27. The cut-off score is 19 points: 19 points or less 
means uncontrolled asthma, 20 points or more means controlled asthma. The ACT can 
also be used for measuring changes in asthma control. The minimally important dif-
ference between consecutive ACT scores is 3 points 48: if two consecutive ACT-scores 
differ three points or more, the improvement or deterioration of asthma control is 
substantial and clinically relevant. In this study, asthma control is also measured using 
the frequency of asthma exacerbations and healthcare use. Pharmacy record data 
retrieved from the community pharmacy, are checked once at the end of the study 
period for high dose, short term oral corticosteroid use indicating asthma exacerba-
tions. These pharmacy record data are also screened for new prescriptions of asthma 
medication, indicating a recent visit to a physician. Finally, the pharmacy record data 
are used to calculate medication costs.
Apart from screening pharmacy record data, healthcare use is also collected at the 
start and end of the study period by screening patient records and the hospital admin-
istration for visits to the outpatient clinic and for hospital admissions. Healthcare use 
and asthma related absence from school (child) or work (parent) are also assessed in 
a patient interview every 3 months. Asthma-specific quality of life is assessed by filling 
the standardized Paediatric Asthma Quality of Life Questionnaire (containing 23 items 
with a 7 point scale per item) (PAQLQ(S)) at the beginning and end of the study period 
49. The domains include activities, asthma symptoms and emotional function. The 
PAQLQ score ranges from 1 to 7 and is calculated as the average score of all items in 
a specific domain as well as an overall score. The PAQLQ can also be used to measure 
changes in quality of life. The minimally important difference in consecutive PAQLQ 
scores is 0.5. This is the minimum difference between two consecutive PAQLQ-scores 
that should be interpreted as a relevant improvement or deterioration of asthma-
specific quality of life. A difference of 1 point indicates a moderate change and 1.5 is 
considered a large change 50.
Co-variables
We collect data on several factors that may be associated with adherence to medi-
cation, including age, gender, ethnicity (country of birth of child and parents), type 
of ICS (fluticasone, fluticasone/salmeterol or beclomethasone), ICS-dose, dosing 
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frequency of ICS, type of asthma related co-medication (betasympathicomimetics, 
antihistaminergic agents, decongestives, antibiotics etc), use of a spacer, parental 
level of education, parental Dutch language skills (assessed by investigators on a 5 
point scale), smoking habits of parents (at home), family stability (child lives with both 
parents together / only with mother / only with father / both parents alternatively) 9, 
family income, professional occupation of parents, pets, mutations of asthma medica-
tion during the study period, existing spirometry data (from the past 3 months) and 
the occurrence of adverse events. Parental medication beliefs are measured using the 
Beliefs about Medicines Questionnaire Specific (BMQ Specific). This contains a scale 
for beliefs in the necessity of ICS and one for concerns about long term toxicity and 
disruptive effects of ICS. Both scales range from 5 to 25, with higher scores indicating 
stronger beliefs 51, 52. The data are collected from medical records at the beginning and 
end of the study period. In addition, at the beginning and end of the study period, and 
each 3 months in between, parents are interviewed by research assistants for collec-
tion of relevant data that cannot be extracted from medical records or questionnaires. 
Research assistants are trained by the research team before taking patient interviews. 
Acceptance of Real Time Medication Monitoring (RTMM)
Since this study is an early evaluation of a medical innovation, we will pay special 
attention to the acceptance of RTMM using online focus groups (OFGs). These OFG 
discussions provide a convenient and comfortable way of joining group discussions 
and enable dialogue between participants who may not otherwise have spoken with 
each other. Discussions in computer-based focus groups produce the same quantity 
and quality of information obtained from face-to-face focus groups and are equally 
enjoyed by participants 53. An additional advantage of OFGs is the larger contribution 
of less talkative participants in the discussion. The method also allows participants to 
join the discussion from their home and at a convenient time. OFGs are cost- and time-
efficient due to the automatic and accurate capture of the discussion data. Children’s 
familiarity with the internet further pleads in favour of this methodology in our study. 
The OFGs are conducted following recently developed guidelines for online data col-
lection 54. 
In this study the OFGs are used to assess factors that would positively or negatively 
influence acceptance of RTMM and to capture more detailed information on how chil-
dren and parents manage RTMM use. Eight children in the intervention group aged 9-11 
years are asked to participate in an OFG. For younger children, eight parents are asked 
to participate in an OFG. Thus, two focus groups are created: one for children and one 
for parents. Participants are asked to respond anonymously to questions introduced 
by the researcher and to each others’ comments. Questions concern participants’ 
views on the usefulness and acceptability of specific components of the intervention. 
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The researcher acts as moderator by regularly checking the postings and by asking 
additional questions to clarify participants’ views. The OFGs are carried out in the 
second half of the follow-up period. Table 4.1 provides a chronologic overview of all 
data that are collected in this study. 
Data monitoring
Data are initially collected on a case report form (CRF) and on questionnaires (hard 
copy). After each patient interview data are manually copied to a digital CRF. Data 
entry errors are minimized by using multiple choice options and fixed data fields. At 
the end of the study 10% of entered data are checked by a second person. If data entry 
errors are found, additional portions of 10% of the data are checked until no errors are 
found within a portion. Also, a periodic back-up of the study database of each hospital 
is made and checked for missing data. Access to the research databases is secured by 
passwords. Changing the format of the study documentation or study databases is 
restricted to the primary investigator. New versions are distributed from the central 
study location. 
Table 4.1: Collection of outcome measures and co-variables in chronologic order 
Elapsed time since inclusion (months) 0 1 2 3 4 5 6 7 8 9 10 11 12
Study visit / patient interview X   X   X   X   X
Registry of patient characteristics X             
Adherence to ICS 
(continuous Real Time Medication Monitoring, RTMM) X X X X X X X X X X X X X
Asthma control in past month 
(Asthma Control Test, ACT) X X X X X X X X X X X X X
Asthma control in past 3 months
(collecting spirometry data) X   X   X   X   X
Collecting data on healthcare use and school / work 
absence in the past 3 months   X  X  X  X
Collecting number of visits and admissions to 
hospital for asthma in the past 12 months X            X
Screening public pharmacy dispensing data from 
the past 12 months (measuring asthma control, 
healthcare use and medication costs)             X
Medication Beliefs
(Beliefs about Medicines Questionnaire, BMQ) X            X
Asthma specific quality of life in past week
(PAQLQ) X            X
Patient acceptance of RTMM
(Online Focus Groups, OFG’s)        X X X X X X
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data analysis
The sample size calculation was based on the primary outcome measure: adherence 
to ICS. We use the adherence data from our observational study 15 in which adherence 
to ICS was electronically measured with RTMM in children (<12 years old) with asthma. 
In this dataset, 4 subgroups with different adherence patterns could be distinguished: 
patients with very poor adherence (≤5%), poor adherence (mean 34%), good adher-
ence (mean 78%) and excellent adherence (≥95%). We assumed that patients with 
very poor adherence would not show any relevant improvement, since it is likely that 
they deliberately stopped taking ICS. The adherence rate in this group is not likely to 
be improved by the text-message intervention. The group with excellent adherence 
is also not expected to show improvement, since adherence is already nearly 100%. 
Adherence in both intermediate groups (poor, good adherence) is expected to im-
prove by 10-15%. This estimated effect size was based on an adherence improvement 
reported in a systematic review on the effect of (non-tailored) reminder systems on pa-
tient adherence to treatment 55. Since the time-tailored text-message reminders used 
in our study are considered potentially more effective, we estimated the improvement 
at 15%. 
Using these assumptions, we have simulated the adherence data of the control and 
treatment groups. Since the four adherence subgroups cannot be analyzed in one 
single regression model, we used a mixture of regressions (“mixture model”) in order 
to assess the effect of the intervention. We also calculated levels of statistical power 
at different group sizes. Requiring a power of at least 0.8 and assuming an adherence 
improvement of 15%, we calculated that a group size of 110 per arm is needed to detect 
the expected difference. Data analysis is based on an intention-to-treat principle. All 
patients with a follow-up of at least three months, regardless of whether they actually 
finish the intervention, are included in the analysis. The two groups are compared 
for baseline characteristics. Co-variables that may influence adherence levels, and 
therefore may confound the effect of the text-message intervention on adherence, are 
added to the multivariable model. In addition, a sensitivity analysis is carried out using 
a per-protocol approach. In this analysis the effect is studies of patients who complete 
less than three months of follow-up and of patients who appear to have stopped using 
ICS early in follow-up (less than 1% of total prescribed inhalations are administered 
during the complete follow-up). Data are analysed with SPSS for Windows.
For calculation of the cost-effectiveness a prospective economic evaluation from a 
societal perspective is performed alongside the clinical trial. The one-year costs of all 
relevant health care utilization are included as well the direct non-healthcare costs and 
the costs of productivity losses when parent stay home to take care of their children. 
Costs will be related to adherence, asthma control and asthma-specific quality of life to 
calculate the following incremental cost-effectiveness ratios (ICERs):
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1. costs per 10% improvement in adherence,
2. costs per additional patient with minimal clinically important improvement in 
asthma control
3. costs per additional patient with the minimal clinically important improvement in 
asthma quality of life. The uncertainty around the ICERs will be displayed on cost 
effectiveness-planes and cost-effectiveness acceptability curves.
Subsequently, a decision-analytic model is developed that includes different levels or 
forms of adherence and the outcomes, both clinical and costs, attributed to each level 
or form of adherence as well as different price levels for RTMM. For the base-case, this 
model is filled with estimates of the relationship between adherence on the one hand 
and asthma control, symptoms, exacerbations, quality of life and healthcare utilization 
on the other hand. These estimates are obtained from the clinical trial, where potential 
associations between adherence and outcomes are studied. This model is used to run 
extensive one-way and multivariate sensitivity analyses to simulate the anticipated 
benefits of improved adherence in terms of health outcomes and costs.
dISCuSSION
We designed a randomised controlled trial in children aged 4 to 11 using inhaled cor-
ticosteroids (ICS) for asthma. We will investigate the clinical and cost effectiveness 
of an intervention with Real Time Medication Monitoring (RTMM) with text-message 
reminders. Medication taking behaviour is monitored on a real-time basis, enabling 
immediate patient feedback through “time-tailored” text-message reminders that are 
only sent if the ICS is at risk of omission.
In this study, RTMM with text-message reminders is used as an adherence improving 
intervention. Three categories of adherence-enhancing strategies have been defined: 
enabling, consequence and stimulant 56. Enabling strategies arm patients with the 
tools necessary for adherence, e.g. patient education and simplified medication regi-
mens. Consequence strategies aim to reinforce adherence by providing incentives for 
acceptable adherence, e.g. instructing patients to maintain records of pill-taking or 
having patients monitor blood pressure at home. Stimulant strategies are aimed at 
prompting dose-taking. The RTMM with text-message reminders used in this study, is 
a stimulant strategy and therefore primarily targets unintentional non-adherence, e.g. 
forgetting to take a dose. This could limit the expected effect of our intervention, since 
adherence to ICS may also be influenced by intentional factors, like illness percep-
tions (perceived susceptibility and severity of the disease), the perceived benefits of 
treatment and theoretical barriers to treatment (e.g. concerns about (potential) side 
effects) 57. However, RTMM with text-message reminders may also diminish intentional 
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non-adherence by providing patients with feedback, while appealing to a desire to 
appear adherent when use is scrutinized by an outside party 55. Receiving informa-
tion that an inhalation is about to be missed, may also enable patients to adjust their 
medication taking behaviour, thus improving self-efficacy and asthma related quality 
of life 58.
A strength of this study is the use of RTMM as an objective and reliable method for 
adherence measurement. This method provides minimal room for bias, e.g. by socially 
acceptable patient response (patient self-report), misjudgement of patient behaviour 
(adherence questionnaires) and overestimation of adherence based on pharmacy re-
fill data (refill rate, persistence) 13, 59, 60. The RTMM device has been designed as a small 
add-on to the ICS inhaler. Since it does not need to be carried separately, it provides a 
patient-friendly way of measuring and stimulating adherence to ICS. This multi-centre 
study is the first to investigate RTMM with text-message reminders in a large sample 
of children with asthma. It is also the first to study the cost-effectiveness of RTMM in 
asthma. More data on cost-effectiveness are needed since the costs of this innovative 
technique are still substantial (approximately €750,= per patient per year) and are 
keeping physicians from using it in daily clinical practice. Health insurance companies 
also require more data on cost-effectiveness before covering costs for applying RTMM 
in asthma therapy.
Although electronic monitoring such as Real Time Medication Monitoring is con-
sidered more sensitive for measuring non-adherence than other, subjective tools for 
adherence measurement 13, 61, 62 the actual adherence to ICS may still be overestimated. 
All participating patients are aware that they are being observed, so they may act more 
adherent than in average daily practice. A common critique of electronic medication 
monitoring based on the time and date the inhaler is fired, is that it cannot be con-
firmed that the medication is actually taken. Only drug assays can confirm ingestion. 
However, studies comparing the sequence of medication events with projected and 
periodically measured concentrations of the drug in plasma, confirmed the validity 
of medication event monitors. Mismatches between medication events and actual 
dosing were too rare to create substantial differences between projected and actual 
concentrations of the drug in plasma 63-66. Another concern with adherence measure-
ment of ICS is the fact that registered doses may not have been administered correctly 
due to poor inhalation technique. This may have a negative influence on the effective-
ness of ICS therapy 67 and therefore on asthma related quality of life and on patients’ 
motivation to adhere to therapy. This phenomenon is considered evenly distributed 
within intervention and control group, so we expect that the effect on the outcome 
measures adherence to ICS and “asthma control” is limited. A potential limitation of 
this study is the high quantity of outcome-measures and co-variables (table 4.1). This 
may provoke partial non-response, leading to missing data. Another concern is the 
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fact that both children using fluticasone and those using a combination of fluticasone 
and the long acting beta-agonist salmeterol are included into this study. It is well 
known that co-inhalation of a long acting beta-agonist can inhalation causes broncho-
dilatation resulting in a relief from asthmatic symptoms. This may be rewarding for the 
asthma patient, possibly resulting in a better adherence. Besides, patients needing a 
combination of fluticasone and salmeterol may have more severe asthma than those 
who’s symptoms can be sufficiently controlled by ICS alone and may therefore be bet-
ter motivated to adhere to their asthma therapy. To overcome this limitation we collect 
data on the type of ICS (fluticasone or fluticasone/salmeterol) as a co-variable, which 
enables us to include it as a confounder in the multi-variable analysis or to perform 
stratified analysis.
One of the inclusion criteria of this study is the use of ICS for at least three months. 
This is verified by checking medical records and by asking potential participants which 
drugs are used for asthma. This procedure, however, does not account for patients 
who have stopped using ICS without consulting a physician. If a part of the patients 
that are not included for not using an ICS still had an indication for taking ICS, they 
have a 0% adherence rate. Patients who, on the other hand, are included into the study, 
but in fact already have stopped using ICS, also have a 0% adherence rate. Since these 
phenomena are expected to be equally distributed among patients in the intervention 
and control group, the only potentially relevant effect is a decrease in statistical power. 
In order to quantify the effect of the latter (patients, who stopped using ICS but still 
enter the study) a sensitivity analysis is carried out in which the patients who took less 
than 1% of prescribed doses are excluded.
It is expected that RTMM has most value in patients with therapy resistant poor 
asthma control. In daily practice, it is often unclear whether the prescribed asthma 
treatment is suboptimal (e.g. dose is too low, inconvenient inhaler) or the treatment 
is adequate, but the patient does not adhere to it. In the current study, however, we 
have chosen not to make a pre-selection of patients with poor asthma control or (sus-
pected) non-adherence. Instead, asthma control is measured during the entire follow 
up, which enables us to investigate if poor asthma control at baseline is associated 
with response to the RTMM intervention. 
It is crucial for correct sending of text-messages and for correct adherence mea-
surement that any changes in mobile telephone (used for receiving text-message 
reminders), ICS dose, ICS dosing frequency and type of ICS, is correct at any moment 
during the study period. To ensure this, patients are requested to inform the investi-
gators about any relevant changes. In addition these data are verified in the patient 
interview each three months of the study period. If RTMM-devices are detected that 
have not been actuated for more than a month, patients are contacted once to check 
for technical failures. This intervention is documented. 
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The trial-based cost-effectiveness analysis proposed here aims to explicitly estimate 
the cost-effectiveness of RTMM. However, at this early stage of development of RTMM 
with text-message alerting, adherence in stead of asthma control was used as the 
primary outcome measure. Therefore, the trial may not allow definite conclusions 
on the impact of this intervention on the cost of asthma treatment. Hence, we will 
apply appropriate decision-analytic modelling techniques to simulate the anticipated 
benefits of improved adherence. Such a model needs to relate the different levels of 
exposure to ICS to levels of asthma control. A model like that allows extensive sensitiv-
ity analyses on both clinical outcomes and costs that are attributed to each level of 
adherence. 
CONCLuSIONS
RTMM with text-message reminders has the potential to support non-adherent pa-
tients in improving their asthma (self)management and in achieving better asthma 
control and better quality of life. RTMM could also provide physicians with the right 
information to treat patients who have poorly controlled asthma despite ICS therapy. 
Additional evidence on the (cost) effectiveness of this innovative adherence improv-
ing strategy would contribute to making it available for use in daily clinical practice.
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ABSTrACT 
Introduction
Real time medication monitoring (RTMM) is a promising tool for improving adherence 
to inhaled corticosteroids (ICS), but has not been sufficiently tested in children with 
asthma. We aimed to study the effects of RTMM with SMS reminders on adherence to 
ICS, asthma control, asthma-specific quality of life, and asthma exacerbation rate; and 
to study the associated cost-effectiveness.
Methods
In a multicenter randomised controlled trial, children (4-11 years) using ICS were re-
cruited from five outpatient clinics and were given an RTMM device for 12 months. The 
intervention group also received tailored SMS reminders, sent only when a dose was 
at risk of omission. Outcome measures: adherence to ICS (RTMM data), asthma control 
(c-ACT questionnaire), quality of life (PAQLQ questionnaire) and asthma exacerbations. 
Costs were calculated from a healthcare and societal perspective.
results
We included 209 children. Mean adherence was higher in the intervention group: 
69.3% vs. 57.3% (difference 12.0%; 95%CI: 6.7%-17.7%). No differences were found for 
asthma control, quality of life or asthma exacerbations. Costs were higher in the inter-
vention group, but not statistically significant.
Conclusion
RTMM with tailored SMS reminders improved adherence to ICS, but not asthma con-
trol, quality of life or exacerbations in children using ICS for asthma.
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INTrOduCTION
Asthma is a serious global health problem and its prevalence is increasing in many 
countries, especially in children 1. Asthma is associated with hospitalizations, de-
creased quality of life and a substantial economic burden 2, 3. In a Dutch study,4 55% of 
the children with doctor-diagnosed asthma had insufficient asthma control according 
to GINA guidelines 5 in spite of the availability of effective maintenance therapy in the 
form of inhalation corticosteroids (ICS) 6. This may be explained by poor adherence to 
ICS, which is on average 50% or less 7, 8. 
Factors associated with non-adherence are broadly categorized into intentional 
and unintentional factors 9. Intentional non-adherence may be due to limited illness 
perception, lack of confidence in the efficacy of treatment or to perceived barriers 
e.g. side effects. Many educational and self-management interventions for improving 
intentional non-adherence have been studied, with limited effects 10. Non-intentional 
non-adherence, on the other hand, is primarily associated with forgetfulness. To cope 
with this, interventions have been developed that focus on sending reminders to 
take the medicine. Systematic reviews have shown that sending text-message (SMS) 
reminders to patients can be effective in improving health outcomes 11 or in changing 
health behavior 12. 
A downside of repetitive sending of SMS reminders at pre-set time intervals is that 
effects may wear off over time. This “alert fatigue” may be overcome by tailored 
SMS reminders that are sent only if a drug dose is at risk of omission. Tailoring SMS 
reminders requires the use of Real Time Medication Monitoring (RTMM), which is an 
advanced version of the Medication Event Monitoring System (MEMS) technology that 
has been proved to provide objective and reliable adherence data in various patient 
populations 13. Three randomised controlled trials have evaluated the effect of RTMM 
with real-time patient feedback on adherence to ICS,14-16 one of which included children 
14. All studies reported higher adherence rates in patients receiving reminders: differ-
ences ranged from 18 to 54 percentage points. The study in children found that asthma 
control had improved as well, but only in the first 2 months after randomisation 14. 
Moreover, the follow-up was limited to 6 months, so the persistence of the treatment 
effect was unclear. Furthermore, all studies used audio-visual reminders that were not 
available to parents, in real time, an essential consideration for improving adherence 
in children. In conclusion, our knowledge of the effect of RTMM with time-tailored SMS 
reminders is limited, especially in children with asthma, and no data exist on long-term 
use of RTMM. 
Therefore, we conducted the randomised controlled e-Monitoring of Asthma 
Therapy to Improve Compliance in children (e-MATIC) trial to compare the effects and 
cost-effectiveness of RTMM with tailored SMS reminders with RTMM alone, in children 
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with asthma and their parents. We hypothesized that RTMM with SMS reminders 
would improve adherence to ICS and would subsequently improve asthma control, 
asthma-related quality of life and reduce asthma exacerbations. 
METhOdS
Study design
The e-MATIC study was a one year, multicenter, randomised controlled trial in children 
who use ICS for asthma. A comprehensive paper has been published on the e-MATIC 
study protocol 17. All children received an RTMM device, which was connected to the 
pressurized metered-dose inhaler (pMDI) and recorded the time and date of admin-
istered ICS doses. Immediately after each actuation of the pMDI, data were sent to 
the study database through the mobile telephone network. In the intervention group 
only “time-tailored” SMS reminders were sent to the parents, and – if they possessed 
a mobile phone – also to the children, when a dose had not been recorded within 15 
minutes of the planned time of administration. 
Ethical approval was obtained from the medical ethics committee of the Erasmus 
Medical Center in the Netherlands. Parents of all participants provided written 
informed consent. The e-MATIC study was registered with the Netherlands Trials 
Registry, number NTR2583 at www.trialregister.nl.
Participants
Children were recruited from five outpatient clinics in the Netherlands. From the hos-
pital administrations of each participating hospital, records were randomly selected of 
children aged 4–11 years who had doctor-diagnosed asthma for at least 6 months and 
who visited the outpatient clinic in the past 12 months. After verifying the other inclu-
sion criteria, the use of ICS (fluticasone, fluticasone/salmeterol or beclomethasone) 
delivered via a pressurized metered-dose inhaler (pMDI) for at least three months and 
having at least one parent/caregiver with a mobile phone, we contacted the parents 
and invited them to visit the pediatric outpatient department for an intake interview. A 
patient information leaflet was sent to the parents of the potential participants. If par-
ents did not respond to our telephone calls, we retried 3 of 4 times before excluding 
the patient. Before patient inclusion, we obtained verbal and written informed consent 
from the parent or guardian.
randomisation and masking 
At registration in the RTMM-software interface, children were automatically assigned 
to the intervention or control group. Computer-generated block randomisation was 
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used per hospital with block size of 16 patients. Although physicians, researchers, and 
patients were initially blinded for randomisation, patients were generally unblinded 
shortly after the start of the study period, when they found out whether they received 
SMS reminders or not.
Measurements and data collection 
The primary outcome measure was timing adherence to ICS, defined as the proportion 
of all prescribed doses recorded by the RTMM device (e-haler® / adhaler®, manufac-
turer: Evalan BV in Amsterdam) within a six-hour time frame around the planned time 
of inhalation, ie from 3 hours before to 3 hours after. 
Secondary outcome measures were asthma control, frequency of severe asthma 
exacerbations and asthma-specific quality of life. Asthma control was measured with 
the childhood Asthma Control Test (c-ACT), which was filled out each month of the 
follow-up period. The c-ACT is a 7-item questionnaire validated for detecting poorly-
controlled asthma in children aged 4-11 years 18. The frequency of asthma exacerba-
tions was also collected as a measure of asthma control. Severe asthma exacerbations 
were defined as asthma-related hospitalizations, visits to the emergency department 
(ED) and/or episodes of systemic corticosteroid use 5, 19. Hospital admissions and ED 
visits were collected from hospital records and oral corticosteroid burst therapy from 
community pharmacies’ dispensed-drug data. Asthma-specific quality of life was as-
sessed by filling out the standardized Pediatric Asthma Quality of Life Questionnaire 
(PAQLQ), at the beginning and end of the study period 20.
Patient characteristics were collected from medical records at the beginning and 
end of the study period. In addition, at the beginning and end of the study period, 
and each 3 months in between, parents were interviewed by research assistants about 
healthcare use, including GP contacts, and school / work absence. Completed c-ACT 
and PAQLQ-questionnaires were also collected. Research assistants were trained by 
the research team before interviewing patients. 
Costs were calculated from a healthcare perspective and a societal perspective. The 
healthcare perspective contained costs of outpatient hospital visits, hospital admis-
sions, emergency room visits, general practitioner (GP) contacts and medication. For 
the societal perspective, parental production losses were also included for absence 
from paid work in order to care for their child. Resource use in hospitals was retrieved 
from hospital databases. For calculation of medication costs, lists of dispensed medi-
cation were obtained from community pharmacies. Costs (Euros, 2014) were calcu-
lated by multiplying the volume of resource use by a cost per unit. Standard unit costs 
from the Dutch Manual for Costing Studies,21 adjusted for inflation, were used for all 
healthcare resource use (appendix I). Medication prices were based on the official list 
prices of drugs published on the internet,22 including value added tax and increased 
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by a standard prescription reimbursement for the pharmacist. The cost of production 
loss was calculated according to the Friction Cost Approach 23.
Statistical analysis
Based on a power of 0.8 and a significance level of 0.05, a group size of 110 patients 
per arm was needed to detect a adherence difference of 15% between the interven-
tion and control group 17. Data were analysed on an intention-to-treat basis. Patients 
with a follow-up of 7 days or more who actively used the RTMM device (adherence of 
1.0% or higher) were included in the data analysis. A per-protocol analysis was carried 
out including only patients with a minimum follow-up of 90, 180 and 270 days after 
randomisation. 
Timing adherence was calculated per month; costs were calculated per three-
month period. Timing adherence, c-ACT, PAQLQ and costs were analysed in multilevel 
regression models for repeated measures (linear model with correlated errors and 
an exchangeable covariance matrix). For each outcome measure, the measurements 
at all moments in time were analysed simultaneously in a single regression model. 
Measurement (month) number and the interaction of measurement and treatment 
were used as explanatory variables. This made it possible to interpret the regression 
coefficients of the interaction terms as the effect estimates for the respective mea-
surement times. The regression results were used to calculate adjusted means. 
Multilevel modeling exploits the fact that observations within patients are cor-
related. This allows the unbiased estimation of regression coefficients and to make 
optimal use of all the available data, even when some measurements are missing. This 
is achieved by adjusting the regression estimates for an optimal fit with the observed 
data as well as with the imposed correlation structure: all observations yield informa-
tion on (the likelihood of) outcomes at all moments in time, even if these latter data 
are missing. This implies that all patients contributed to the estimates of the adjusted 
means in all intervals, although not everyone had measurements for all moments 24.
Adjusted exacerbation rates per treatment were calculated after applying negative 
binomial regression with treatment as explanatory variable, offset for time in study. 
Uncertainty around the point estimates was addressed using bootstrapping. Data 
were analysed in Stata 12.1.
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rESuLTS
Participants
During the recruitment period (January 12th 2012 – December 7th 2012), out of the 563 
children screened for eligibility, 219 were included in the study: 108 in the interven-
tion group and 111 in the control group. Ten patients were excluded from the intention 
to treat analysis: 7 in the intervention group and 3 in the control group (figure 5.1). 
The baseline characteristics of the remaining 209 patients are presented in table 5.1. 
The groups were well balanced with regards to prognostic factors, notably asthma 
control, asthma-related quality of life, treatment location, type of RTMM device and 
medication belief. Mean follow-up was 261.1 (SD 105.3) days in the control group and 
251.2 (SD 123.4) days in the intervention group. This difference in follow-up was small 
and not statistically significant (hazard ratio for intervention vs. control: 1.08, p=0.569). 
Reasons why patients left the study prematurely were not systematically registered. 
No serious adverse events occurred during follow-up. 
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Figure 5.1 Patient Flow Chart
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Table 5.1 Patient characteristics
Category Intervention 
(n (%))
(n=101)
Control 
(n (%))
(n=108)
Age at inclusion (mean, SD) Years 7.8 (2.2) 7.7 (2.1)
Gender (n, %) Male 59 (58.4) 72 (66.7)
Hospital (n, %) AMC
EMC
GHZ
BovenIJ
SLAZ
9 (8.9)
21 (20.8)
41 (40.6)
18 (17.8)
12 (11.9)
9 (8.3)
22 (20.4)
43 (39.8)
18 (16.7)
16 (14.8)
Type of RTMM device (n, %) e-haler (1st generation)
adhaler (2nd generation)
26 (25.7)
75 (74.3)
26 (24.1)
82 (75.9)
Type ICS (n, %) Fluticasone 
Fluticasone / salmeterol 
Beclomethasone (extra fine particles)
23 (22.8)
17 (16.8)
61 (60.4)
16 (14.8)
20 (18.5)
72 (66.7)
Dosing frequency ICS (n, %) Once daily
Twice daily
13 (12.9)
88 (87.1)
10 (9.3)
98 (90.7)
ICS dose (mean, SD) Percentage of DDD 35.9 (18.2) 36.6 (21.4)
Family status (n, %) Two parent family
Single parent family 
85 (84.2)
16 (15.8)
96 (88.9)
12 (11.1)
Ethnicity (n, %) Dutch
Non-Dutch
63 (62.4)
38 (37.6)
73 (67.6)
35 (32.4)
Parental level of education 
(n, %)
None / Primary school
Secondary school
Intermediate vocational education
Higher vocational education
University
Unknown
7 (3.5)
39 (19.3)
86 (42.6)
44 (21.8)
24 (11.9)
2 (1.0)
9 (4.2)
30 (13.9)
78 (36.1)
67 (31.0)
30 (13.9)
2 (0.9)
Pets (n, %) Pet with fur or feathers 41 (40.6) 41 (38.0)
Quality of housing (n, %) Poor
Insufficient
Sufficient
Good
5 (5.0)
16 (15.8)
21 (20.8)
59 (58.4)
3 (2.8)
11 (10.2)
25 (23.1)
67 (63.9)
Parental tobacco use (n, %) Current smoker
Former smoker
Never smoked 
Unknown
34 (16.8)
50 (24.8)
115 (56.9)
3 (1.5)
45 (20.8)
61 (28.2)
107 (49.5)
3 (1.4)
Parental Dutch language 
skills (n, %)
Poor/moderate
Good
Excellent 
Unknown
13 (12.9)
16 (7.9)
169 (83.7)
4 (2.0)
17 (7.9)
18 (8.3)
178 (82.4)
3 (1.4)
Parental employment (n, %) Employed
Unemployed 
Unknown
157 (77.7)
41 (20.3)
4 (2.0)
170 (78.7)
42 (19.4)
4 (1.9)
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Effect of SMS reminders on adherence to ICS
SMS reminders were sent about 56.8% of ICS doses in the intervention group. Approxi-
mately half of these reminders (53.3%) led to timely administration. Figure 5.2 shows 
the adjusted monthly adherence over the course of the study period. Especially dur-
ing the first months of the study, patients in the intervention group were substantially 
more adherent than patients in the control group. In both treatment groups, adher-
ence decreased steadily during the first six months, after which it remained stable and 
statistically significant for most measurement times (Figure 5.2). 
Over the full study period, adherence in the intervention group was 69.3% (95%CI: 
65.5%; 73.4%) and 57.3% (95%CI: 52.8;61.7%) in the control group. The overall differ-
Table 5.1 Patient characteristics (continued)
Category Intervention
(n (%))
 (n=101)
Control 
(n (%))
(n=108)
Family income (national 
average in 2012 was €2546,- 
per month) (n, %)
<1x average
1-2x average
>2x average
Unknown
27 (26.7)
52 (51.5)
19 (18.8)
3 (3.0)
26 (24.1)
46 (42.6)
28 (25.9)
8 (7.4)
Asthma control at inclusion 
(mean, SD)
Total c-ACT1 score 20.6 (4.4) 20.4 (3.9)
Poorly controlled asthma at 
inclusion (n, %)
Total c-ACT1 score ≤ 19 39 (39.8) 38 (36.5)
Asthma-specific quality of 
life at inclusion (mean, SD)
PAQLQ2 score 6.1 (0.8) 5.9 (0.8)
Medication Beliefs at 
inclusion3 
BMQ3 necessity score (mean, SD)
BMQ3 necessity score >15 (n (%))
BMQ3 concerns score (mean, SD)
BMQ3 concern score >15 (n, %)
19.3 (3.7)
83 (83.0)
12.9 (3.1)
22 (22.0)
18.6 (3.5)
92 (85.2)
12.5 (3.2)
22 (20.4)
1c-ACT: 7-item questionnaire for detecting poorly controlled asthma in children aged 4-11 years18 . 
Ranges: 0-27 points, cut-off score: 19 points (≤19 points: uncontrolled asthma, ≥20 points: controlled 
asthma). c-ACT questionnaires at baseline were completed by 98 patients in the intervention group 
and 104 in the control group.
2 PAQLQ: 23 item questionnaire for measuring Pediatric Asthma Quality of Life Questionnaire 20. Do-
mains include activities, asthma symptoms and emotional function. Range: 1-7. PAQLQ questionnaires 
at baseline were completed by 100 patients in the intervention group and 108 in the control group.
3BMQ: Beliefs about Medicines Questionnaire Specific (BMQ Specific), which has one scale for beliefs 
in the necessity of ICS and one for concerns about long term toxicity and disruptive effects of ICS. 
Both scales range from 5 to 25, with higher scores indicating stronger beliefs 25. BMQ questionnaires 
at baseline were completed by 100 patients in the intervention group and 108 in the control group.
Abbreviations: SD = standard deviation, RTMM = Real Time Medication Monitoring, AMC = Academic 
Medical Center in Amsterdam, EMC = Erasmus University Medical Center in Rotterdam, GHZ = Groene 
Hart Ziekenhuis in Gouda, BovenIJ = BovenIJ Hospital in Amsterdam, SLAZ = Sint Lucas Andreas Hospi-
tal in Amsterdam, ICS = Inhaled corticosteroid, DDD = Defined Daily Dose defined by the World Health 
Organization
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ence was statistically significant: 12.0% (95%CI: 6.7%;17.7%). The average estimated 
treatment effect over the first six months (15.0%, 95%CI: 9.3%;20.7%) was larger than 
in the second part of the year (9.0%, 95%CI: 2.4%;16.3%), but both were statistically 
significant (Appendix IIa) . The results from the per-protocol analysis were comparable 
(Appendix IIb). Results were similar when the analysis was restricted to patients with 6 
or 9 months of follow-up (Appendix IIc and IId). 
Effect of SMS reminders on asthma control, quality of life and asthma 
exacerbations
The adjusted means of the c-ACT scores and PAQLQ scores at the end of follow-up 
and the frequency of asthma exacerbations were not different between the interven-
tion and control group (Table 5.2). Mean c-ACT scores remained high and stable over 
time in both treatment groups (Appendix III).
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Figure 5.2 The effect of the SMS intervention on adherence to ICS: adjusted mean adherence per treat-
ment group, and the difference, over the course of the study period.
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Costs
Total costs were higher in the intervention group, but the differences were not statisti-
cally significant: €731 versus €636 (difference €96, 95%CI -55;271) from the healthcare 
perspective and €1043 versus €764 (difference 297 (95%CI -13;437) from a societal per-
spective (Figure 5.3, Appendix V). Apart from the costs of the SMS intervention, only 
the costs for parental production losses due to absence from work were statistically 
significantly higher in the intervention group. When particularly high costs for one 
parent were excluded from the analysis, the difference in production losses decreased 
from €185 to €115 (95%CI -55; 271).
Table 5.2  The effect of the SMS intervention on asthma control (c-ACT) and quality of life (PAQLQ) at 
the end of follow-up and on the frequency of asthma exacerbations. 
Intervention
(n=101)
Control
(n=108)
difference 95% CI p-value
c-ACT1 score 21.10 22.17 -1.07 -3.51;0.56 0.203
PAQLQ2 score 6.19 6.25 -0.06 -0.41;0.15 0.659
Asthma exacerbations3 
(year-1)
0.23 0.37 -0.14 -0.61;0.25 0.432
1 c-ACT: 7-item questionnaire for detecting poorly controlled asthma in children aged 4-11 years18. 
Range: 0-27 points, cut-off score: 19 points (≤19 points: uncontrolled asthma, ≥20 points: controlled 
asthma).
2 PAQLQ: 23 item questionnaire for measuring Pediatric Asthma Quality of Life Questionnaire.20 Do-
mains include activities, asthma symptoms and emotional function. Range: 1-7.
3 An exacerbation was defined as an asthma-related hospitalization, a visit to the emergency depart-
ment or an episode of systemic corticosteroid use.5 The p-value was taken from the negative bino-
mial regression model.
1-3 The differences and p-values with regards to c-ACT and PAQLQ presented in this table are the effect 
estimates and their p-values from the multilevel regression models for month 12. The confidence 
intervals were the results of bootstrapping procedures.
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Figure 5.3 Mean adjusted costs per patient
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dISCuSSION
The strength of the e-MATIC study was its prospective, randomised, controlled, multi-
center design and, compared to other studies on medication adherence, a large study 
population and long follow-up period. Our study was the first to investigate RTMM 
with SMS reminders for 12 months in children with asthma. We found that the children 
receiving RTMM with time-tailored SMS reminders had higher timing adherence to ICS 
than the children with RTMM alone. The difference gradually declined during the first 
6 months (adjusted mean 15.0%), but remained stable and statistically significant over 
the last 6 months (adjusted mean difference 9.0%).
The effect of RTMM with SMS reminders found in this study was larger than the 
estimates of treatment effects of most reported educational and self-management 
interventions aimed at improving adherence 10 and in the same range as that of 
periodical SMS reminders or telephone calls in patients with asthma 26. The effect in 
our study (9 percentage points difference after 6-12 months) was smaller than in the 
only previous trial studying RTMM with real-time reminders in children with asthma 
(52% after 6 months) 14. However, in that trial children were recruited from the ED after 
being diagnosed with an asthma exacerbation. The poor asthma control (mean c-ACT 
score <19) and low adherence (median: 30%) at baseline may have contributed to the 
larger improvement in adherence than found in our population of clinically stable out-
patients. In addition, the effect on adherence to ICS may have been overestimated by 
using a short follow-up period of 6 months, after which the effect is at risk of wearing 
off, as shown in our study. 
No differences were found for asthma control (c-ACT score 21.1 vs. 22.2), quality 
of life (mean PAQLQ score 6.2 vs 6.3) or asthma exacerbations (annual rate 0.23 vs. 
0.37). This disconnect between improved adherence but no improvement in health 
outcomes has been found in earlier studies on the effect of patient reminder systems 
in asthma patients 15, 26. Interestingly, others have found an association between low 
adherence to ICS and higher risk of severe asthma exacerbations, but only in a limited 
number of high quality studies 27. Recently, Chan et al found a higher mean c-ACT score 
and a lower risk of exacerbations in children and adolescents with unstable asthma 
receiving RTMM with audiovisual reminders. This effect, however, was absent after the 
first 2 months of follow-up 14.
The overall 12% improvement in adherence to ICS found in this study is not likely to 
be sufficient for clinically relevant improvement of asthma control. Parameters other 
than adherence, such as genetic factors 28 and environmental triggers 29 also contribute 
to asthma control. Klok et al.30 hypothesized that asthma patients who have reached 
clinical remission and still receive treatment with ICS, may maintain asthma control at 
a lower level of adherence than patients who have active asthma. This seems to apply 
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to our study, since the majority of the population had good asthma control (c-ACT 
>19) despite suboptimal adherence rates. In the control group, for example, 63.5% of 
patients maintained good asthma control on an adherence level of 57.3%. This sug-
gests that each patient has an individually defined critical ICS dose at which asthma 
control is only just maintained. As long as the ICS dose that is actually taken is higher 
than the critical ICS dose, asthma control does not deteriorate. Such overtreatment 
may explain the lack of effect on asthma control in our population. Another factor that 
might have contributed to our findings is the fact that c-ACT based asthma control 
was reported to have up to 30% non-compatibility with GINA guideline base asthma 
control. Although the c-ACT is a validated questionnaire 18 and it is widely used for 
healthcare and research purposes, it seems to overestimate asthma control levels in 
children with poor asthma control or poor symptom perception 31- 32.
Apart from the costs of the SMS intervention itself, there was no statistically sig-
nificant difference in costs between the intervention and control group, either from a 
healthcare perspective or from a societal perspective. The intervention costs were not 
outbalanced by a reduction in clinical costs for treating fewer asthma exacerbations 
in the intervention group. 
RTMM is an objective and reliable method for measuring adherence 17. Nevertheless, 
we may still have overestimated adherence. Being aware of the observations, children 
may have taken their medication more adherently than normal. Although it is too 
rare to introduce substantial errors, participants might even have fired their inhaler 
in order to fake the RTMM measurements 33. Also, ICS doses recorded may not have 
been inhaled with the correct inhalation technique. This could have interfered with the 
pharmacological action of ICS and therefore with patients’ motivation to adhere to ICS 
therapy, and with the effect of ICS on asthma control and quality of life.34 However, in 
this randomized trial, these phenomena are considered evenly distributed over both 
study arms. 
During patient recruitment, 99 patients declined participation in the study. In ad-
dition, 110 patients did not respond to our telephone calls, despite the fact that we 
retried 3 of 4 times (Figure 5.1 of the manuscript). If non-response to telephone calls or 
refusing to participate would be associated with non-adherence to ICS-treatment, this 
may have caused pre-selection of patients with good adherence. This would have re-
duced the overall room for improvement of adherence, leading to an underestimation 
of the effect of the SMS intervention. However, we don’t have any indication for the 
existence of such an association and it might well be that non-response is associated 
with better adherence rather than poorer adherence.
We found that patients in the control group had a longer follow-up period: 261.1 (SD 
105.3) days vs. 251.2 (SD 123.4). This difference in follow-up was small and not statisti-
cally significant (hazard ratio for intervention vs. control: 1.08, p=0.569). Reasons 
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why patients left the study prematurely were not systematically registered and could 
therefore not be analysed. We don’t have any indications that dropping-out of the 
study was associated with non-persistence to ICS, since the majority of the drop-out 
patients continued to use ICS after leaving the study. The difference in drop-out rate 
was addressed in the multilevel regression model, since it contained the treatment 
variable as a predictor of adherence. 
Based on the RTMM-data, no distinction could be made between intentional and un-
intentional non-adherence to ICS. Theoretically, SMS-reminders are aimed at reducing 
the forgetting of ICS-doses, which is a typical unintentional phenomenon. However, 
participating in a trial and particularly when receiving repetitive reminders, may have 
raised awareness of the necessity of ICS-treatment or of concerns about ICS-treatment. 
Eventually, this may have reduced or stimulated intentional non-adherence to ICS. 
A question that has yet to be answered, is which children should receive an RTMM 
device with SMS reminders as investigated in this study. Explorative post hoc subgroup 
analyses indicated that the effect on adherence to ICS might have been higher in cer-
tain subgroups, including patients with good asthma control at baseline and patients 
who experienced a worsening of asthma control during the study. In clinical practice, 
the need for this intervention may be greatest in children who have poor asthma 
control despite prescription of ICS, and in children who are suspected of unintentional 
non-adherence. If motives for non-adherence are unclear, patients might also benefit 
from tailored SMS reminders combined with for example educational interventions, 
which aim at intentional non-adherence. These hypotheses should be tested in future 
research. If using RTMM, one should be aware that continuous full access to the mobile 
telephone network is required for sending real-time SMS reminders. We also recom-
mend incorporating the measurement of inhalation technique into RTMM technology 
for asthma medication, since this is an important modifier of the association between 
adherence and asthma control 34. 
In recent years, the attention paid to asthma self-management has increased: chil-
dren should be more involved in asthma treatment and are recommended to have 
an individual symptom-based action plan 5. In our study, a part of the population has 
succeeded in maintaining asthma control at low levels of adherence to ICS. By deviat-
ing from the dosing instructions of their paediatrician and still keeping asthma control, 
in fact they have already self-managed their asthma treatment. Without proper guid-
ance, however, patients self-managing their asthma are at risk of relapsing into poor 
asthma control. Therefore, healthcare professionals should make sure the ICS dose 
is tailored at the patient’s needs. Together with the patient, an individual symptom-
based action plan should be written that covers not only adhering to the agreed ICS 
dosing schedule, but also self-monitoring of asthma symptoms, recognizing and 
responding to worsening asthma and regular review of asthma control, treatment and 
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skills by a healthcare provider5. Subsequently, patients should be supported to adhere 
to their written action plan. RTMM with SMS reminders may help children to manage 
their asthma symptoms independently. However, this approach requires a change of 
treatment aims: from maximizing medication adherence to giving patients the means 
to manage and control their asthma symptoms themselves. 
CONCLuSIONS
RTMM with SMS reminders effectively improved adherence to ICS in children with 
asthma. In our population, there was no evidence of better asthma control, improved 
asthma-specific quality of life or fewer asthma exacerbations due to the intervention. 
Apart from the costs of the SMS intervention, there was no difference in costs between 
the intervention and control group.
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APPENdICES 
Appendix I 
Unit costs 
Type of resource unit cost (2014 €)
Pharmacy fee per prescription 7.85
GP, consultation 30.85
GP, phone consultation 15.43
GP, home visit 47.38
Nurse practitioner, consultation 29.75
Pulmonologist/pediatrician, consult 79.33
Pulmonologist/pediatrician, phone consult 39.67
Emergency room visit 166.38
Inpatient hospital day 479.29
Treatment without overnight stay 276.56
Production loss, mother, per day 257.83
Production loss, father, per day 300.05
Appendix IIa
Mean adjusted adherence, during first six months and last six months, intention to treat analysis. 
Intervention
(n=101)# 
 95%CI  Control 
(n=108)#
 95%CI  difference  95%CI
Full study period 69.3% 65.5%;73.4% 57.3% 52.8%;61.7% 12.0% 6.7%;17.7%
First six months 
period
73.1% 69.3%;76.6% 58.1% 53.8%;62.5% 15.0% 9.3%;20.7%
Second six 
months period
65.4% 60.6%;71.3% 56.5% 50.8%;62.6% 9.0% 2.4%;16.3%
Appendix IIb 
Mean adjusted adherence, during first six months and last six months, per-protocol analysis of all pa-
tients with a minimum follow-up of 90 days after randomization 
Intervention 
(n=87)#
 95%CI  Control 
(n=99)#
 95%CI  difference  95%CI
Full study period 71.3% 67.5%;75.5% 59.8% 55.8%;65.0% 11.4% 5.9%;17.0%
First six months 
period
75.2% 71.5%;78.6% 60.7% 56.5%;65.3% 14.4% 8.4%;20.1%
Second six 
months period
67.3% 62.7%;73.3% 58.9% 53.6%;67.0% 8.4% 1.8%;15.2%
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Appendix IIc
Mean adjusted adherence, during first six months and last six months, modified per-protocol analysi of 
all patients with a minimum follow-up of 180 days days after randomisation
Intervention 
(n=72)
 95%CI  Control 
(n=82)
 95%CI  difference  95%CI
Full study period 75.0% 71.8%;78.2% 63.9% 59.4%;68.3% 11.1% 5.7%;17.1%
First six months 
period
79.0% 75.8%;82.3% 65.0% 60.2%;69.5% 14.0% 8.3%;20.4%
Second six 
months period
70.9% 
 
66.7%;75.0% 62.9% 
 
60.2%;69.5% 8.1% 1.6%;14.6%
Appendix IId
Mean adjusted adherence, during first six months and last six months, modified per-protocol analysis 
all patients with a minimum follow-up of 270 days after randomisation
Intervention 
(n=62)#
 95%CI  Control 
(n=67)#
 95%CI  difference  95%CI
Full study period 77.2% 74.1%;80.2% 67.3% 62.9%;71.8% 9.9% 4.2%;15.4%
First six month 
period
81.1% 77.9%84.4% 68.0% 63.1%;72.9% 13.1% 6.9%;18.9%
Second six 
month period
73.4% 69.3%;77.1% 66.6% 61.5%;72.2% 6.7% 0.0%;13.0%
# There are slight differences between the numbers of patients in figure 5.2 and in this Appendix. This 
is due to incidental missing values and to different cut-off points for monthly adherence and follow-up.
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Appendix III
Adjusted mean c-ACT-score per treatment group, and the difference, over the course of the study pe-
riod.
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Appendix IV
Healthcare resource use (mean, standard deviation) per patient, unadjusted for time in study
resource  Intervention (n=101)  Control (n=108)
GP, consultations 0.60 (1.56) 0.49 (1.27)
GP, phone calls 0.020 (0.14) 0.074 (0.35)
GP, home visits 0 (0) 0.056 (0.43)
Nurse practitioner, consultations 0.0099 (0.10) 0.0093 (0.096)
Outpatient hospital visits 1.65 (2.07) 1.83 (1.85)
Emergency room visits 0 (0) 0.06 (0.5)
Day-care treatment in hospital 0 (0) 0.065 (0.67)
Inpatient hospital days 0 (0) 0.10 (0.77)
Hospital, phone calls 0.13 (0.39) 0.19 (0.63)
Absence from work, days 0.88 (3.06) 0.33 (1.66)
Appendix V 
Mean adjusted costs per treatment group
Category Intervention (€)  95%CI (€)  Control (€)  95%CI (€)  difference (€)  95%CI (€)
GP 29 15;42 27 16;37 2 -16;19
Hospital 171 137;219 311 199;420 -141 -241;31
Medication 346 284;410 297 252;335 50 -24;132
Production loss 312 141;453 129 25;209 183 14;365
RTMM costs 185 0
Total costs
Healthcare 
perspective
731 647;820 636 491;758 96 -55;271
Societal 
perspective
1043 813;1127 764 583;929 297 -13;437
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ABSTrACT
Background
Poor adherence to controller medication (inhaled corticosteroids, ICS) is a major cause 
of poor asthma control in children. Interventions for improving adherence to ICS are 
not very effective. Tailoring ICS intake on asthma symptoms as part of asthma self-
management is a promising alternative for the currently dominant strategy of maxi-
mizing medication adherence. The aim of the study was to explore self-management 
of ICS intake in children with asthma and their parents. 
Methods
Three small-scale explorative Online Focus Groups (OFGs) with 8 participants each 
were carried out in children aged 9-12, parents of children aged 9-12 and in parents of 
children aged 4-8. Five themes were adressed: the daily routine of ICS intake, forget-
ting ICS intakes, recognizing asthma symptoms, medication beliefs and the child’s 
social environment. Three additional children and their parents were interviewed 
about their medication beliefs. The Individual and Family Self-Management Theory 
(IFSMT) was used as a guide. 
results
Participating children and their parents have a daily routine of taking their ICS, which 
works as a memory aid for taking ICS doses. Most children take the initiative for taking 
ICS themselves. They recognize asthma symptoms, but mostly need help from parents 
for undertaking action. Medication beliefs and knowledge of participants about ICS 
are generally poor. The social environment of children is supportive.
Conclusions
A daily routine for ICS use seems essential for good adherence. While children can 
take ICS and recognize asthma symptoms, not all manage to respond without parental 
help. Self-management behaviour seems to be a result of habituation, rather than 
reflective thinking. Self-management seems to be limited by misunderstanding the 
differences between controller medication (ie ICS) and reliever medication, and by the 
lack of belief in the efficacy of ICS. Physicians should pay special attention to these 
barriers when promoting self-management of asthma in children. The results of this 
explorative OFG study further addressed and confirmed in larger qualitative and 
quantitative studies. 
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INTrOduCTION 
Asthma is the most common chronic childhood disease in industrialized countries and 
its prevalence is still increasing 1. Children experience several negative consequences 
of asthma such as feeling ill and limitations in sports participation, peer interac-
tions and school attendance 2. Almost all of these children use reliever medication 
for immediate reduction of asthma symptoms. The majority (60 %) also use inhaled 
corticosteroids (ICS) 3, 4. The use of this so called controller medication plays a key 
role in preventive treatment of persistent asthma, if used on a continuous base. Early 
termination of the use of ICS can lead to recurrence of symptoms and unnecessary 
pulmonary damage 4. Although adherence to ICS is associated with good asthma 
control 5 adherence rates are low: on average 50% or less 2, 6-9. 
Many interventions for improving adherence to ICS have been investigated, but the 
effects on adherence and clinical outcomes are limited 10. Tailoring ICS intake on asth-
ma symptoms as part of an asthma self-management plan is suggested as a promising 
alternative for the currently dominant strategy of maximizing medication adherence1. 
However, to date, limited attention has been paid to self-management of (families 
of) children with asthma. Self-management refers to the dynamic and continuous 
process of self-regulation in which patients (try to) monitor and control symptoms 
of their disease and prevent exacerbations like asthma attacks, and know when and 
where to seek care 11-13. Self-management of chronic conditions leads to improvement 
of health outcomes, increased quality of life, decreased demand for health services 
and contributes to the overall health of the society14. However, children with asthma of 
every age, to a greater or lesser extent, are dependent on their parents or caregivers. 
This means that self-management of children with asthma is a family matter. 
According to the Individual and Family Self-Management Theory (IFSMT) health 
outcomes improve when individuals and families are seen through both the individual 
lens and the family lens 14. The IFSMT defines self-management as a complex dynamic 
phenomenon that consists of three dimensions: context, process and outcomes. The 
context dimension refers to risk and protective factors that protect or challenge indi-
viduals or families in engaging in self-management. These factors include condition 
specific factors, physical and social environment, and individual and family charac-
teristics. The process dimension refers to the knowledge, beliefs and self-regulation 
skills and abilities, and the social facilitation of individuals and families. Finally the 
outcomes dimension refers to outcomes as a result of engaging or not engaging in 
self-management, e.g. health status, quality of life or well-being and cost of health 14. 
These three dimensions (context, process and outcome) seem to be interrelated in 
adults with asthma as associations were found between cognitive variables (context 
and process dimension) and contributions to the patient’s clinical asthma status 
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(outcomes dimension). Other factors like a younger age (among adults) and higher 
education (context dimension) were also associated with higher self-management 
factors (process). In a study in children with asthma 15, differences in self-management 
were found between children aged 7 years and children aged 12 (context dimension). 
Younger children relied on adults to manage their asthma, while older children were 
more independent. These findings also suggested that the adherence among older 
children decreases, due to the wish of independence from the family and a desire to 
assimilate with their peers 9. Yet, not much is known about how children manage their 
asthma themselves and to what extend and what way parents support in, or take over 
this (medication) management. Therefore, this small-scale study aimed to explore 
context, process and outcome dimensions of asthma self-management in children 
and their parents. 
METhOdS 
design 
Three Online Focus Groups (OFGs) were asynchronously conducted: one with children 
aged 9-12 years, one with parents of children aged 9-12 years and one with parents of 
children aged 4-8 years. An OFG is a relatively new method, where focus group dis-
cussions take place on the internet. OFGs have shown to produce the same quantity 
and quality of information obtained from face-to-face focus groups and are equally or 
even better enjoyed by participants 16-18. OFGs provide a convenient and comfortable 
way of joining group discussions and enable dialogue between participants who may 
not otherwise have spoken with each other. Participants are unconstrained by place 
and time and can therefore contribute to the (group) discussion at their own time and 
place. Besides, participants can take their own amount of time in answering questions, 
which gives more room for reflection. Childrens’ familiarity with the internet further 
pleads in favor of this methodology in our population. 
Population 
Participants were recruited from the e-MATIC study population; a randomized con-
trolled trial on the effect of Real Time Medication Monitoring with text-message (SMS)-
reminders on adherence to ICS in outpatients aged 4-12 years with persistent asthma19. 
Participants were required to sufficiently master the Dutch language. Children aged 
9-12 years and parents with children between 4-12 years were eligible for the study. 
Purposive sampling was used to select participants for the OFGs. As such, selections 
were made in order to explore a wide range of perspectives and experiences of self-
management in children with asthma and their parents 20. To obtain heterogeneity, 
Self-management of ICS use studied through online focus groups 105
the following characteristics were sought to be distributed across the OFGs: (1) age (2) 
ethnicity, (3) asthma control and (4) type of ICS.
Parents of children meeting the inclusion criteria were asked by telephone whether 
their child, they themselves as parents, or both would participate in the study. Ad-
ditional information regarding the study was sent by (e-)mail. Potential participants 
were approached until a sufficient level of heterogeneity and number (8 participants) 
per focus group were reached. After the OFG’s. additional patients were recruited to 
collect data on themes that had not been sufficiently addressed. Considering the ex-
plorative character of this study, patient inclusion was not continued until saturation 
was reached. 
data collection
To prepare the discussion topics of the OFGs, the concepts of the IFSMT were opera-
tionalized resulting in five themes (figure 1). Themes 1 to 3 (“daily routine”, “forgetting” 
and “recognizing and dealing with symptoms”) refer to the process dimension of the 
IFSMT as they refer to self-regulation skills and abilities. The fourth theme “medication 
beliefs” about the efficacy of ICS-therapy, referred to the outcome dimension. The last 
theme “environment” had the aim to give insight in the context dimension. For each 
theme initial questions were posted on the OFG website to start the discussion (see 
box 1).
Box 1 OFG Themes and questions
Theme 1: Daily routine [proces]
  Q:What is a normal day like for you or your child? When do you or does 
your child take in your or his/ her medication?
Theme 2: Forgetting and memory aids [proces]
 Q: Do you, or your child sometimes forget the medication? When and 
why? 
Theme 3: Recognizing and dealing with symptoms [proces]
  Q: Can you (or your child) recognize symptoms of an upcoming asthma 
attack? How do you, or does your child notice this?
Theme 4: Medication beliefs [outcome]
  Q: Does the medication help to keep your (child’s) asthma under control?
Theme 5: Social environment [context]
  Q: How does your (child’s) social environment (friends, family, neigh-
bors) react on your (child’s ) asthma and the RTMM device? Positive or 
negative?
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The OFG discussions lasted a week from Monday till Sunday. Every day, at 12 a.m. a new 
theme was posted, to which participants were asked to respond during the remaining 
days. The OFGs were asynchronously conducted: participants could read others com-
ments and could respond at any time. To ensure anonymity, personal nicknames were 
granted to each participant and they were asked not to mention their name or other 
identifiable characteristics with the aim to optimize self-disclosure and reduce social 
desirability bias. 
Three members of the research team acted as moderator by regularly checking 
the postings, asking additional questions, paraphrasing written responses, asking for 
clarification or by checking whether responses were interpreted correctly. All OFG 
discussions were available for data analysis in the form of a text chat. After the OFGs, 
responses inadditional interviews for themes that had been insufficiently discussed, 
were written down as field notes and were repeated to the participants, to make sure 
the researcher interpreted them correctly. 
data-analysis
Data from participants who had responded to at least one theme, were included in the 
data analysis. OFG-data and field notes of the additional interviews were combined 
and analyzed using a modified thematic analysis approach 21 in which the transcripts 
of recorded conversations were first read and reread. Summaries were written of each 
individual child’s or parent’s responses. Fragments of the transcripts were structured 
according to the themes that were defined in advance of the data collection (Box 1). 
Then, each theme was analysed by exploring similarities differences between children, 
and between children and parents. Finally, opportunities and barriers for self man-
agement of ICS were identified and analysed according to the IFSMT. The thematic 
analysis and was performed by one member of the research team (LE) and checked 
by a second member (EV). 
Ethics
The medical ethics committee of the Erasmus Medical Center has approved the e-
MATIC study protocol (protocol number MEC-2011-143, Netherlands Trial Registry code 
NTR2583) and written informed consent was obtained for each participant .
rESuLTS
Out of the e-MATIC study population, 26 parents were approached for participation in 
the OFGs. Five agreed with participation of their child, 13 with participation of them-
selves and three with participation of both themselselves and their child. One parent 
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was included into the study, but did not respond to any theme and was therefore ex-
cluded from the data-analysis. Since the 4th theme about medication beliefs was barely 
discussed during the OFGs, three additional children aged 9-12 years and their parents 
were recruited for additional telephone interviews about this theme. Participant selec-
tion was based on the same criteria as in the OFGs. Finally, data from 18 parentsand 11 
children (24 unique children) were included in the data analysis. A patient flow chart is 
shown in figure 6.1 and characteristics of participants are shown in table 6.1. 
	  
	  
	  
	  
	  
	  
	  
Parents	  approached	  for	  
participation	  of	  child	  and/or	  
parent	  	  (n=26)	  
No	  informed	  consent	  (n=5)	  
e-­‐MATIC	  study	  population	  
(n=219)	  
Included:	  	  
8	  children	  and	  16	  parents	  
(21	  unique	  children*)	  	  
	  
children	  9-­‐12	  years	  
(n=8*)	  
	   	  
parents	  of	  children	  9-­‐12	  years	  
(n=8*)	  
	  
	   	  
parents	  of	  children	  4-­‐8	  years	  
(n=8)	  
	   	  
Patients	  withdrawn	  (n=1)	  
• No	  response	  to	  any	  
question	  in	  the	  OFG’s	  
	   	  
Analysed:	  
children	  9-­‐12	  years	  
(n=11
#
)	  
	   	  
Analysed:	  
parents	  of	  children	  9-­‐12	  years	  
(n=10
#
)	  
	  
	   	  
Analysed:	  
parents	  of	  children	  4-­‐8	  years	  
(n=8)	  
	   	  
*	  In	  3	  children	  both	  child	  and	  
parent	  participated	  in	  the	  study	  
#	  In	  6	  children	  both	  child	  and	  
parent	  participated	  in	  the	  study	  
Purposive	  sampling	  
Additional	  interviews:	  
(n=3*)	  
	   	  
Additional	  interviews:	  
(n=3*)	  
	   	  
Selection	  criteria:	  	  
• Age	  
• Ethnicity	  
• Asthma	  control	  
• Type	  of	  ICS	  
Figure 6.1 Participant flow chart
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Combined themes: daily routine + forgetting and memory aids 
All children and (their) parents stated to have developed a certain routine in intake 
of ICS. Children took their ICS twice a day, mainly in the morning and evening. Some 
children took their ICS as soon as they woke up and just before going to bed. Others 
linked the intake moment to a particular time or prior to or directly after a certain 
activity such as tooth brushing, breakfast or dinner. Also, storing the ICS inhaler in a 
prominent and highly visible location, helped not to forget the ICS intake. In some oc-
casions, children en parents had different opinions on their daily routine: (child, aged 
11) ‘I do not really have fixed moments, sometimes I take it in with fitness training’; 
while his mother stated: ‘Our son uses his medication in the morning, before tooth 
brushing, right after waking up and in the evening after diner, before going to bed, he 
‘puffs’ one time and then brushes his teeth’ (mother of child aged 11).
Especially parents of children in the age of 9-12 expected and preferred their chil-
dren to take responsibility at this age for taking ICS. However, not all children live up 
to these expectations. In fact, only a minority of the children in the age of 9-12 take 
initiative or remember to take their ICS: ‘Our son doesn’t think about it, that initiative 
Table 6.1: Characteristics of the participants of the online focus group discussions
Children 9-12 
years (n=11*)
Parents of children 
9-12 years (n=10*)
Parents of children 
4-8 years (n=8)
Sex Male (n (%) 7 (63.3) 8 (80.0) 4 (50.0)
Age (years) Mean (sd) 11.2 (1.0) 10.9 (1.1) 6.4 (1.1)
randomisation 
e-MATIC study
SMS-intervention (n (%) 4 (36.4) 4 (40.0) 3 (37.5)
ICS Fluticason (n (%) 2 (18.2) 2 (20.0) 2 (25.0)
Fluticason/salmeterol (n (%) 2 (18.2) 0 0
Beclomethason (n (%) 7 (63.6) 8 (80.0) 6 (75.0)
hospital AMC (n (%) 1 (9.1) 1 ( (10.0) 0
EMC (n (%) 0 1 (10.0) 0
GHZ (n (%) 8 (72.7) 7 (70.0) 3 (37.5)
BovenIJ (n (%) 2 (18.2) 1 (10.0) 5 (62.5)
SLAZ (n (%) 0 0 0
ACT at baseline Insufficient (≤19) (n (%) 3 (27.3) 2 (20.0) 2 (25.0)
Ethnicity Dutch (n (%) 8 (72.7) 9 (90.0) 6 (75.0)
Moroccan (n (%) 2 (18.2) 0 1 (12.5)
Other (n (%) 1 (9.1) 1 (10.0) 1 (12.5)
Abbreviations: SD = standard deviation, AMC = Academic Medical Center in Amsterdam, EMC = Eras-
mus University Medical Center in Rotterdam, GHZ = Groene Hart Ziekenhuis in Gouda, BovenIJ = Bo-
venIJ Hospital in Amsterdam, SLAZ = Sint Lucas Andreas Hospital in Amsterdam
* In 6 children both child and parent participated in the study
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really has to come from us’ (parent of child aged 10). Also other parents of children of 
all ages need indicated to regularly remind their child to take ICS. Accordingly, most 
children aged 9-12 admitted they sometimes forget their ICS and could tell when and 
why they forgot their medication: ‘Yes, mainly in the weekend, because then I’m going 
to the horse riding school and I’m thinking about that all the time! Sometimes, I also 
forget on Friday nights, because I’m staying up late’ (child, aged 10).
In the end, however, children seldomly miss an ICS dose as parents remind them. 
And in case medication is forgotten, this is mainly due to the absence of the daily 
routine, like the weekends or during holidays, or on exceptionally busy moments full 
of interruptions: ‘It happens, although very occasionally, that we forget the medication 
in the morning (oops), in a hurry to go to school’ (parent of child aged 7).
recognizing and dealing with symptoms 
Most of the children in the age of 9-12 mentioned to recognize symptoms of poor 
asthma control. Nevertheless, two of them noted not to be able to identify the symp-
toms of an upcoming asthma exacerbation. One of these children indicated that his 
parents have to tell him. A number of parents agreed upon this. They also thought 
their child was not capable of recognizing symptoms of an upcoming asthma exacer-
bation. Parents considered themselves capable of recognizing these symptoms. This 
contrast was illustrated by a child aged 10: “I notice it when I’m more wheezy. Then 
running, jumping on a trampoline, cycling, singing and dancing is no longer possible 
(..). Yes, I notice it when it becomes worse, then mama says to me that I have to take my 
medication’, while the mother of the child indicated: ‘My daughter does not notice it 
when she is wheezy. We notice it because of her (bad) mood and headache’. 
Most children aged 9-12 who do recognize asthma symptoms, said not to take any 
action when recognizing the symptoms, unless their parents did it, or pointed it out 
to them. Only two children in the age of 9-12 mentioned to take action themselves 
when recognizing an upcoming asthma attack. One of these two said to go inside 
and take it easy for a while, while the other child said to take his reliever medication 
while sitting straight up in a chair. In spite of the fact that most children said not to 
undertake any action when feeling wheezy, they do take their reliever medication with 
them to school or take it before physical activity. For children in the age of 4-8, some 
parents indicated their child could recognize these symptoms and some children even 
asked for SABA. Two parents indicated that their children do not point out when they 
feel more wheezy. Parents of children aged 4-8 indicated that they make the decision 
when and how frequently the reliever medication will be used by their child. None of 
the children or parents mentioned to change their ICS taking behavior in response to 
occurring asthma symptoms. Instead, the general approach to poor asthma control 
was taking reliever medication or resting. 
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Medication beliefs 
In response to the question whether the use of ICS was considered to be effective 
against asthma, only a minority of children 9-12 years and their parents said to believe 
so. Two parents said not to know whether the medication was helpful. Most children 
said not to feel difference before and after taking the ICS. They expressed that the 
reliever medication has more effect than the ICS. This perceived lack of efficacy, how-
ever, was not seen as a reason to discontinue the use of ICS. By contrast, most parents 
of children in the age of 4-8 were positively convinced of the efficacy of ICS: “Until 
now, we still assume that we keep the asthma symptoms under control because of the 
medication” (parent of child, aged 6).
Social environment 
In response to the question how classmates, friends and other people in their social 
environment responded to the child’s asthma, a large majority of the children and 
parents stated that they react in a pleasant way. Schoolteachers take into account the 
disease of the child, e.g. by offering special classes, or by being understanding when 
a child is absent because of his or her asthma. Although in general there are more 
children with asthma in the social environment, a number of children did not want to 
use their medication at school or were hesitant of disclosuring their asthma. Accord-
ing to the parents, this mainly appears to be a personal characteristic rather than the 
influence of classmates or friends. 
dISCuSSION
We conducted three online focus groups in 24 children with persistent asthma aged 
4-12 or their parents, in which we adressed five themes related to asthma (self-)man-
agement with inhaled corticosteroids. 
Children with asthma and their parents develop a daily routine of taking ICS and 
they use this as a memory aid. Although children are not always aware of it, the daily 
routine supports children in taking initiative in taking ICS. When the daily routine is 
absent, for example during weekends or holidays, children more easily forget their 
medication. This confirms findings from studies in other patient populations 22. Just 
like in adolescents forgetting seems the most important reason for non-adherence in 
children aged 4-12 23. The development of a daily medication routine therefore seems 
to be an important supportive factor in asthma self-management. Because daily rou-
tine mostly exists during weekdays, solutions for unintentional non-adherence should 
focus on times where the daily routine is absent.
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Parents and children aged 9-12 agree that the initiative for taking ICS doses lies 
with the child. Nevertheless, the fact that only few doses are actually missed, is due 
to frequent parental reminders. These results confirm and complement earlier find-
ings that younger children relied on their parents to manage their asthma and older 
children were more independent, allthough sometimes asking for help of an adult 
15. There appears to be a natural way of balancing the responsibility for medication 
taking between parents and children. Parents effectively adapt to the capabilities and 
needs of their children. 
Children, regardless of their age, were often able to recognize symptoms of poor 
asthma control. Although the symptoms were not always matched to an upcoming 
asthma exacerbation, some ask their parents for reliever medication. Doing so, they 
try to manage their breathlessness themselves. Interestingly, they are not always 
aware of doing this. It seems that children do not necessarily think reflective about 
their asthma intake or asthma symptoms. For example, children take their reliever 
medication with them to school, or use it before physical activity. This however should 
be interpreted as a result of habituation rather than a deliberate action 24. The IFSMT 
refers to these concepts as ‘planning and action’ 14. Parents tend to think reflectively 
about their child’s asthma and subsequently undertake action to deal with asthma 
symptoms. Parents therefore mostly conduct the ‘planning’ part of self management 
because they think reflectively. Children generally conduct the ‘action’ part, although 
as a result of habituation. 
The fourth theme of the OFG’s, ‘medication beliefs”, refers to the belief of the children 
and parents that a taking ICS continuously will result in the desired outcome, ie con-
trolling asthma symptoms 14. Most parents of children aged 4-8 years old believed that 
consequent use of ICS helps to control asthma symptoms. By contrast, most children 
aged 9-12 and their parents have limited understanding and belief in the preventive and 
protective effects ICS. Instead , they focus on immediate relief of asthma symptoms. 
Children feel immediate relief after using reliever medication, but when using the ICS, 
the result only appears after persistent use. This might have caused the observed lack 
of confidence in the therapeutic effects of ICS . The underlying knowledge gap about 
the nature of the disease and the therapeutic properties of the medication is known 
to be associated with a poor clinical asthma status 11. In order for patients to engage 
in the recommended health behaviors, they need information about the medication 
and embrace health beliefs consistent with the behavior 25. Patient-centred commu-
nicating of the relative benefits and risks to patients is needed to facilitate informed 
adherence 26. Only then, starting to use ICS can be a shared decision of parents, child 
and phycisian 27. 
The social environment of participating children was supportive for asthma treat-
ment. The role of parents was essential in alle age categories. which emphasizes that 
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a chronic disease like asthma in fact is a family matter and therefore has to be seen 
through the individual as well ass the family lens, bearing in mind that every child and 
family is different (context) 14.
We used the OFG approach. According to other studies 16, 17, 28 OFGs have the ad-
vantage of larger contribution of less talkative participants in the discussion, and 
are an effective format to collect sensitive or personal health information, due to 
the anonymity afforded, which also may reduce social desirability bias. However, 
some parents were less inclined to admit that they, or their child sometimes forgot 
the medication. This could be the result of feeling responsible regarding their child’s 
asthma, but could also be a result of social desirability bias, in spite of the anonymity 
afforded during the OFGs. Moveover, three of the OFGs’ participants barely reacted to 
any theme. Especially in the group of children 9-12, the participants did not respond 
to each theme. The theme medication beliefs has hardly been adressed in the OFGs. 
To retrieve additional information three individual interviews were held focusing on 
this team. Results were combined with the OFG-data, but no formal data saturation 
was rechead as is the custom in full-scale qualitative research. Another limitation of 
our study was that children and their parents were recruited from the e-MATIC study 
population and might therefore have been more than averagely motivated for asthma 
therapy. By contrast, we observed that some parents and children were less involved 
in the OFGs than hoped for. Populations in earlier studies 28-30 that used OFGs and in 
which participants were highly involved consisted of children and women with cancer. 
It is conceivable that children with cancer mature more quickly and therefore may 
have took the OFGs more seriously and responded more and adequately, compared 
to children with a relative less severe condition, like asthma. This was confirmed by 
a study of Koster et al, who performed OFGs in adolescents with asthma and also 
encountered less involvement compared to studies with children and women with 
cancer 23. 
CONCLuSIONS
The way in which children and their parents manage the child’s asthma is highly 
individual. Yet, the presense of a daily routine for ICS use appeared to be essential for 
good adherence in all children. Most children are able to take ICS and to recognize 
symptoms of poor asthma control, but only a few of the older children manage to 
properly repond to these without help of their parents. The observed self-management 
behaviour seems to be a result of habituation, rather than reflective thinking. The 
other important barrier for asthma self-management seems to be the knowledge-gap 
about the pharmacologic properties of ICS and reliever medication, and the lack of 
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belief in the efficacy of ICS. Physicians should pay special attention to these barriers 
when promoting self-management of asthma in childeren. This explorative OFG study 
in children with persistent asthma has fielded some are very interesting results that 
ask for further study. However, our current findings should only be cautiously extrapo-
lated to the general population of children with asthma.
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ABSTrACT
Introduction
Non-adherence to inhaled corticosteroids (ICS) is a major risk factor for poor asthma 
control. An objective and reliable method for measuring adherence is electronic 
monitoring. This technique, however, is costly and time consuming. Therefore, an 
alternative, reliable and low-cost method for screening for non-adherence is needed. 
In this study, the Dutch version of the self-reported 9-item asthma-specific Medication 
Adherence Report Scale questionnaire (MARS-A) was studied as a screening tool for 
non-adherence to ICS in children with persistent asthma aged 12 years or younger.
Methods
In each subject, adherence to ICS was measured at baseline with the MARS-A and 
continuously for three months with Electronic Monitoring. The association between 
MARS-A and EM adherence was studied. With dichotomized EM taking adherence 
cut-off at 50% as a reference standard, MARS-A scores were analyzed as a total score, 
a sub-score for intentional non-adherence and a sub-score for unintentional non-
adherence. Optimal cut-off values for predicting EM taking adherence to ICS <50% 
were assessed with a ROC-analysis. Subsequently, sensitivity, specificity and other 
binary classification characteristics were calculated. 
results
Adherence data of 87 Moroccan and native Dutch children aged 18-136 months were 
analyzed. The association with EM taking adherence was significant for both MARS-A 
intentional score (p<0.001) and MARS-A unintentional score (p=0.036) and optimal 
cut-off values were 10 and 2 respectively. The intentional sub-score had a sensitivity 
of 64.1% for EM taking adherence <50%. Specificity was 73.9%, positive predictive 
value (PPV) 87.2%, negative predictive value (NPV) 42.5% and overall accuracy 66.7%. 
Sensitivity of the MARS-A unintentional sub-score was 70.3%, specificity 39.1%, PPV 
76.3%, NPV 31.2% and accuracy 62.1%. 
Conclusion
The Dutch 9-item MARS-A is an easy, low-cost and sensitive screening tool for early 
identification of potentially clinically relevant non-adherence to ICS in children with 
asthma. In clinical practice, the MARS-A can be used to screen for patients who may 
benefit from early additional monitoring or adherence improving interventions.
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INTrOduCTION
Good adherence to inhaled corticosteroids (ICS) is associated with improved asthma 
control and a reduction of severe asthma exacerbations in children with asthma 1. 
However, in clinical practice the effectiveness of asthma treatment is limited by poor 
adherence to ICS, which is generally estimated to be 50% or lower 2, 3. 
Identification of non-adherent patients is difficult, since common measures for 
medication adherence, e.g. clinician estimated adherence, patient reported adherence 
and refill-rate based on pharmacy dispensing records, tend to overestimate adherence 
levels 4, 5. Therefore, reliable, low-intrusive and affordable tools are needed to identify 
patients who are at risk for developing non-adherence to ICS. Despite the possibility 
of evoking socially desirable answers, self-reported measures are available that meet 
these requirements 6.
Several medication adherence questionnaires have been reported in literature 7. 
The 8-item Morisky Medication Adherence Scale (MMAS-8) was originally validated 
in American hypertensive patients but has been used in other populations and other 
languages as well 8. It has been used in patients with asthma 9, but no asthma spe-
cific version is available. Another 4-item asthma specific adherence questionnaire was 
tested in 100 adults with pharmacy claim data as a reference standard 10. Sensitivity 
for non-adherence (refill-rate <80%) was good, but specificity was poor. However, the 
validity of the results was limited by the use of pharmacy claims data as a reference 
standard, which is known for underestimating non-adherence 11. The asthma specific 
Test of Adherence (TAI) was recently cross-validated against the MMAS-8 and elec-
tronic monitoring in a large sample of patients with asthma or COPD 12, but only in 
Spanish adults. Another commonly used screening tool for non-adherence in several 
populations is the Medication Adherence Report Scale (MARS) 13-16. An asthma specific 
version of the MARS is the 9-item MARS-A 17. It aims to reduce social pressure on pa-
tients to report high adherence by phrasing questions in a non-threatening way and 
challenging respondents to “recall and report acts that obstruct the use of preventer 
medication” 17. English and Spanish versions were validated for three months in a 
population of inner-city adults with asthma and showed good internal validity, good 
criterion validity and strong construct validity 18. The MARS-A has already been trans-
lated into Dutch (appendix I) and used in a large cohort study 19. Its validity in Dutch 
children with asthma, however has not been studied.
Therefore, this study aimed to investigate the validity of the 9-item Dutch MARS-A 
in children with asthma in the Netherlands, to find the optimum cut-off value for the 
MARS-A as a screening tool for objectively measured, potentially clinically relevant 
non-adherence to ICS, measured with Electronic Monitoring (EM) and to describe its 
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binary classification characteristics, such as sensitivity, specificity and positive predic-
tive value.
Although the items of the MARS-A all relate to non-adherent drug taking behaviour, 
not all items address the same underlying motivational factors. Intentional non-
adherence, for instance, is caused by intentional barriers, eg. lack of belief in the 
necessity, concerns about side-effects, limited illness perception etc., resulting in 
deliberate deviation from the prescribed or agreed ICS dosing schedule. By contrast, 
unintentional non-adherence is mainly caused by practical barriers for medication use, 
like forgetting to take ICS-doses or by not knowing how to take it or not being able to 
20. Therefore, prior to the study, the 9-item MARS-A (“MARS-A total”) was split into two 
sub-domains for intentional non-adherence (“MARS-A intentional”) and unintentional 
non-adherence (MARS-A unintentional) respectively, appendix I. 
METhOdS
Study design
In a cohort of pediatric outpatients with asthma, we conducted a diagnostic test study 
of the Dutch version of the 9-item Medication Adherence Report Scale for Asthma 
(MARS-A) questionnaire with adherence to inhaled corticosteroids (ICS) collected 
with Electronic Monitoring (EM) as a reference standard. We used the dataset of the 
COMPLIANCE study, a prospective, observational, multicenter study in children with 
asthma in Amsterdam, The Netherlands 21. In each participant adherence data were 
collected both with the MARS-A and with electronic monitoring (EM). 
Participants
The study population included 87 Moroccan and native Dutch children aged 11 years 
or younger who were treated for persistent asthma in the outpatient clinic of the Sint 
Lucas Andreas Hospital, the BovenIJ Hospital or the Academic Medical Center in Am-
sterdam, The Netherlands. All children used fluticasone (Flixotide®, GlaxoSmithKline) 
or fluticasone/salmeterol (Seretide®, GlaxoSmithKline) through a pressurized metered 
dose inhaler (pMDI) that was compatible with the EM device.
data collection
Primary outcome measures were: electronically measured taking adherence to ICS 
and patient reported adherence measured with the MARS-A intention and MARS-A 
unintentional.
We used EM data as a reference standard for adherence to ICS, since this is an objec-
tive and reliable adherence measure 4, 22. All patients received an Real Time Medication 
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Monitoring (RTMM) device for electronic monitoring of ICS intakes for 3 months. The 
EM device (e-haler®, manufacturer Evalan Bv in Amsterdam) was connected to the 
pMDI and each time the pMDI was actuated, the dose was electronically registered 
and sent to the research data-base. The level of adherence to ICS was calculated by 
dividing the number of registered doses by the number of prescribed ICS doses. In this 
study, both “taking adherence” and “timing adherence” were calculated 6. EM taking 
adherence to ICS was defined as the percentage of days of the follow-up period on 
which exactly two ICS doses were electronically registered, separated by a time inter-
val of at least 15 minutes. EM timing adherence was calculated as part of a sensitivity 
analysis, and was defined as the percentage of planned ICS-doses that was registered 
within a 6-hour timeframe (+/- 3 hours) around the planned time of inhalation. EM data 
only became available for the research team after the last patient finished the study.
We used an existing translation of the original, English 9-item MARS-A 17 as the index 
test (appendix I). The MARS-A is scored on a 5-item Likert scale and its sum score ranges 
from 9-45, with lower scores indicating better adherence. In face-to-face interviews 
with parents and their child, questionnaires were filled out once at baseline by mem-
bers of the research team who were not involved in the regular clinical care. This way, 
data collection was consistent throughout the study population. The research team 
member read out questions and answer options literally and recorded the responses.
All co-variables collected in the COMPLIANCE study, were also available for the cur-
rent MARS-A validation study 21. 
data-analysis
The internal consistency was investigated with factor analyses. A Cronbach’s alfa of > 
0.7 was considered acceptable. The MARS-A ‘intentional’ was analysed separately from 
the MARS-A ‘unintentional’. The MARS-A total data were part of a sensitivity analysis. 
The correlation of EM taking adherence with the MARS-A scores was investigated by 
visually analyzing the scatter plots of the continuous outcome measures. The associa-
tion was statistically tested with linear regression analysis. Linearity of the relation of 
the MARS-A scores with EM adherence was investigated using scatter plots. Normality 
of the EM adherence data was assessed by visually analyzing the histograms. Co-vari-
ables were not investigated for confounding since MARS-A and EM adherence were 
both measured in the same patients. Effect modification by ethnicity was tested since 
this was associated with EM adherence to ICS 21 and since the responses to the MARS-A 
questionnaire might be influenced by health literacy, which is culturally dependent 23.
In absence of a linear association between MARS-A scores with EM adherence, both 
were dichotomized. The cut-off point for EM adherence was set at 50% since this is the 
mean adherence rate to ICS in children with asthma 2, 24 and because we considered 
50% to be a clinically relevant cut-off point for adherence to ICS in asthma. Since also 
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higher cut-off values were reported in literature 1, especially for refill adherence, EM 
adherence was also cut-off at 70% and studied as part of a sensitivity analysis. The 
optimal cut-off value for the MARS-A scores was assessed by generating Receiver 
Operator Characteristics (ROC) curves against EM taking adherence cut-off at 50%. 
Cut-off points for MARS-A were selected by maximizing the difference between sen-
sitivity and 1 minus specificity . The purpose of early identification of non-adherent 
patients by using the MARS-A is to be able to undertake action to prevent deteriora-
tion of asthma control. Therefore, our primary focus was maximizing sensitivity for 
patients with EM adherence <50%, while keeping specificity at an acceptable level. In 
order to be informative, the MARS-A had to give a better prediction of non-adherence 
than chance. This was investigated by calculating the area under de ROC-curve which 
was required to be significantly higher than 0.5.
At the selected optimal cut-off values, MARS-A scores were dichotomized and 2x2 
tables were calculated with dichotomized EM adherence. Binary classification char-
acteristics (sensitivity, specificity, positive predictive value (PPV), negative predictive 
value (NPV), positive likelihood-ratio (PLR), negative likelihood-ratio (NLR) and accu-
racy (ACC)) were calculated 25 using the MARS-A as index test and EM adherence as 
reference standard (appendix II).
rESuLTS
Participants
The study population included 87 children aged 18-136 months who participated in the 
COMPLIANCE study 21. In addition to age and sex of participants, table 7.1 shows the 
baseline characteristics that were statistically associated with electronically measured 
adherence to ICS in the that study.
Table 7.1 Baseline characteristics of the study population (n=87)
determinant Categories Frequency
Sex1 Male 54 (62.1)
Ethnicity1 Dutch
Moroccan
44 (50.6)
43 (49.4)
Type of ICS-medication1 Fluticasone
Fluticasone/salmeterol
79 (90.8)
11 (9.2)
Parental level of education1 Vocational school or lower
College / University
59 (67.8)
28 (32.2)
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Adherence scores
The internal consistency, indicated by the Cronbach’s alfa, of the MARS-A total (0.76) 
and MARS-A intentional (0.75) were good. Apart from the single item MARS-A uninten-
tional score (item 2: “I forget to use it”), we also investigated a second unintentional 
sub-score of item 2 plus item 9 (“I use it regularly every day”), but the Cronbach’s alfa 
was 0.28, which is unacceptably low. Item 8 of the MARS-A (“I use it only as a reserve, 
if my other inhaler doesn’t work”) was uninformative as all respondents reported a 
score of 1 on this item.
Median EM taking adherence was 21.1% (Inter Quartile Range, IQR: 5.4%-51.7%) and 
median EM timing adherence was 45.7% (IQR 21.5%-78.6%). Median scores for MARS-A 
were 10 (IQR: 8-13) for MARS-A intentional, 2 (IQR 1-3) for MARS-A unintentional and 11 
(IQR 10-16) for MARS-A total. 
Figure 7.1 shows the scatter plots of MARS-A intentional and MARS-A unintentional 
scores with EM taking adherence defined as percentage of days with 2 registered ICS 
doses. Scatter plots of MARS-A scores with EM timing adherence and of MARS-A total 
versus EM taking adherence are presented in appendix III. EM taking adherence was 
correlated with MARS-A intentional score (R2=0.175, p<0.001) and MARS-A uninten-
tional score (R2=0.051, p=0.036). Ethnicity was not an effect modifier. Visual analysis 
showed that EM taking adherence data (figure 7.2, appendix IV) were not normally 
Table 7.1 Baseline characteristics of the study population (n=87) (continued)
determinant Categories Frequency
Quality of housing1 Poor
Insufficient
Sufficient
Good
18 (20.7)
11 (12.6)
22 (25.3)
36 (41.4)
Year family income1
(average is €30,500 in 2009) 1
< 1 x average – low
1-2 x average - intermediate
>2 x average - high
39 (44.8)
40 (46.0)
8 (9.2)
BMQ groups1 Sceptical (nec<15, conc>15)
Indifferent (nec<15, conc>15)
Ambivalent (nec>15, conc>15)
Accepting (nec>15, conc<15)
6 (6.9)
19 (21.8)
24 (27.6)
38 (43.7)
BMQ-concerns (score 5 to 25) 1 ≤ 15
> 15
57 (65.5)
30 (34.5)
Use of a spacer during 
inhalations1
Yes 74 (85.1)
Age (months)2 58.9 ± 30.5 
Number of annual visits to outpatient clinic for asthma2 4.0 ± 2.6 
1 n (%), 2 mean ± sd, BMQ: Beliefs about Medicines Questionnaire, Nec: BMQ necessity score (range 
5-25), Conc: BMQ concerns score (range 5-25) 26.
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distributed, even after log-transformation. Also, linearity between MARS-A scores 
and EM taking adherence was only moderate (figure 7.1). Therefore, it was decided to 
dichotomize MARS-A scores and EM taking adherence from this point forward instead 
of using linear regression analysis.
dichotomization of MArS-A scores
In order to identify optimal cut-off values for MARS-A scores, Receiver Operator 
Characteristics (ROC) curves were calculated for total, intentional and unintentional 
MARS-A scores against EM taking adherence cut-off at 50% (figure 7.3). As part of the 
sensitivity analysis, ROC-curves of MARS-A against EM timing adherence cut-off at 
50% and 70% and against EM taking adherence cut-off at 70% are presented in appen-
dix V. Cut-off values with optimal sensitivity for EM non-adherence <50% combined 
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Figure 7.1: Scatter plots of MARS-A scores (intentional and unintentional) versus EM taking adherence
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Figure 7.2: Histograms of EM taking adherence and MARS-A total score
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with acceptable specificity were identified a score of 10 for MARS-A intentional, 2 for 
MARS-A unintentional and 11 for MARS-A total respectively.
Binary classification characteristics 
At the selected cut-off values for MARS-A scores and EM taking adherence, binary 
classification characteristics were calculated. Sensitivity of the MARS-A intentional 
(cut-off at 10) for non-adherence was 64.1%, specificity 73.9%, positive predictive value 
(PPV) 87.2% and negative predictive value (NPV) 42.5%. In 66.7% of the patients EM 
taking adherence cut-off at 50% were correctly predicted by MARS-A intentional. The 
MARS-A unintentional sub-score (cut-off at 2) had a sensitivity of 70.3% and specificity 
of 39.1%. PPV was 76.3%, NPV was 31.2% and accuracy was 62.1%. These and other 
characteristics are presented in table 7.2.
As part of the sensitivity analysis, binary classification characteristics for MARS-A 
against EM timing adherence cut-off at 50% and 70% and against EM taking adher-
ence cut-off at 70% are presented in appendix VI.
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Figure 7.3: Receiver Operator Characteristics (ROC) curve for MARS-A scores (total, intentional and 
unintentional) versus EM taking adherence cut-off at 50%
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dISCuSSION
This study aimed to validate the Dutch 9-item MARS-A for identifying non-adherence 
to ICS in children with asthma using electronically measured adherence as a reference 
standard. Apart from the original 9-item MARS-total, we investigated two subscales, 
one for intentional and one for unintentional non-adherence. The MARS-A is quick and 
easy to use for self-reporting by children and their parents when filled out by members 
of the research team in a face-to-face interview. Good internal consistency was found 
for MARS-A intentional (Cronbach’s alfa: 0.75) and MARS-A total (0.76). Continuous 
MARS- scores correlated well with EM adherence. Optimized cut-off values were 10 
(MARS-A intentional), 2 (MARS-A unintentional) and 11 (MARS-A total). The validity of 
the one-item MARS-A unintentional score was questionable: the correlation with EM 
scores was poor , the area under the ROC-curve was not significantly higher than 0.5 
and, as such, uninformative, and the selection of a cut-off value was problematic since 
no value provided both acceptable (i.e. >50%) sensitivity and specificity.
Both the intentional and the unintentional subscales had good sensitivity for non-
adherence (64.1%, 70.3%) and good PPV’s (87.2%, 76.3%). This means that the MARS-A 
was able to identify approximately two third of children with EM-adherence under 
50%; and that four out of five children with non-adherent MARS-A scores also had EM 
adherence under 50%. Specificity for MARS-A intentional was good (73.9%) but not for 
MARS-A unintentional (39.1%). The former means that almost three quarters of good 
intentional adherence can be accurately predicted by the MARS-A. The latter implies 
that respondents have difficulties reporting to what extent they forget ICS intakes. 
Obviously, if ICS doses are genuinely forgotten, this is an unconscious process, which 
is hard to recall, especially since most pMDI’s do not have a dose-counter. Another rea-
son specificity was low, is that we focused on optimizing sensitivity for non-adherence, 
Table 7.2:  Binary classification characteristics of MARS-A scores (total, intentional and unintentional) 
versus EM taking adherence cut-off at 50% 
MArS-A intentional 
cut-off 10 
 <10: adherent
 ≥10 non-adherent
MArS-A unintentional 
Cut-off 2 
 <2: adherent 
 ≥2 non-adherent
MArS-A total 
cut-off 11 
 <11: adherent
 ≥11: non-adherent
SENS 0.641 0.703 0.750
SPEC 0.739 0.391 0.696
PPV 0.872 0.763 0.873
NPV 0.425 0.312 0.500
ACC 0.667 0.621 0.735
SENS = sensitivity; SPEC = specificity; PPV = positive predictive value; NPV = negative predictive value; 
ACC = accuracy.
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meanwhile accepting sub-optimal specificity values. We aimed at optimal sensitivity 
for non-adherence, since early identification of non-adherent patients enables under-
taking action for prevention of deterioration of asthma control. Positive predictive 
values were good (87.2%, 76.3%), which indicates a high probability of non-adherence 
if MARS-A scores were above cut-off. By contrast, negative predictive values were low 
(42.5%, 31.2%), meaning that more than half of the patients overestimated adherence 
to ICS. Although this is not uncommon in patient reported adherence 27, it might have 
been enhanced by the fact that the MARS-A data were collected in patient interviews. 
This may have stimulated patients to respond in a socially acceptable way. 
Findings from the primary analysis on EM taking adherence cut-off at 50% were 
generally consistent with the results of the sensitivity analyses, in which other refer-
ence standards were used (EM taking adherence cut-off at 70%, EM timing adherence 
cut-off at 50% and 70%). This implies a robust correlation between MARS-A scores and 
EM adherence. 
Our results correspond with those of the only comparable study on the MARS-A using 
electronically measured adherence as reference standard 18. In 318 adults with asthma, 
adherence to ICS was measured with the MARS-A, and in 53 patients electronically as 
well. Using timing adherence cut-off at 70% as a reference standard, in our study sen-
sitivity and PPV for non-adherence were higher, but specificity and NPV were lower. 
Cut-off scores (45/50 vs. 11/45) were hard to compare since they were calculated on a 
different number of questions and on an inverse scale. Also, the authors seem to have 
optimized the cut-off score for identifying good adherence to ICS instead of screening 
for patients with poor adherence. We think the latter is more reasonable, since patients 
who are at risk of poor adherence to ICS are the ones who need additional support. 
A strength of our study was that it is the first to validate the Dutch translation of 
the MARS-A in children with asthma. We used EM as a reference standard, which is 
a reliable measure for adherence providing only limited room for underreporting 
of non-adherence 4, 24, 28. Another important strength of this study was the use of 
separate sub-scales with each having a single construct: intentional adherence and 
unintentional adherence. Although both involve deviation of the ICS dosing schedule, 
the behavioral background is fundamentally different. We think that making this 
distinction is essential, since both require different approaches for improving adher-
ence. Treating patients with intentional non-adherence requires improving illness 
perceptions, beliefs about the necessity and concerns about side effects of ICS use 
(theoretical barriers), while unintentional non-adherence is usually driven by practical 
barriers like forgetting ICS-doses 29.
A limitation of the Dutch 9-item MARS-A is that it was not translated back and forth 
by a sworn translator. Instead, we validated the available Dutch translation. A devia-
tion from the original MARS-A was that we used it on parents as a proxy, which was 
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inevitable regarding the young children in our population. We also had the MARS-A 
filled out by trained members of the research team rather than by parents. Although 
this approach is a potential source of bias caused by social desirability and interviewer 
characteristics, Bender et al reported that adherence estimates did not differ between 
interview modes (audio computer-assisted self-interviewing, face-to-face interview-
ing or paper questionnaires) in a randomized controlled trial with 104 children with 
asthma 30. Filling out the MARS-A in patient interviews also enabled us to collect the 
MARS-A data consistently throughout the study population and to cope with written 
language barriers in non-native subjects with poor Dutch language skills. Another 
limitation of our study was that we were not able to investigate test-retest variability 
since the MARS-A questionnaire was filled out only once at start of follow-up. We think 
the impact on the study outcomes is limited since substantial variation in the short 
follow-up period of 3 months is unlikely. Finally, participation in a clinical trial may 
in itself stimulate medication adherence 6. However, this so-called Hawthorne effect 
would have occurred in both electronically measured and patient reported adherence 
and may therefore have levelled out to a certain extent. 
In clinical practice, the MARS-A can be used for early identification of children who 
are non-adherent to ICS or at risk of becoming so. Unlike other adherence measures 
such as refill-rates or EM, the MARS-A enables to reveal potential non-adherence if 
ICS use has started only recently. Deterioration of asthma control due to persistent 
non-adherence may thus be prevented if patient with high MARS-A scores are addi-
tionally monitored or EM and if necessary receive adherence improving interventions, 
e.g. educational interventions or real time medication monitoring (RTMM) with SMS-
reminders. Since these measures are still complex 31 and costly 32, early identification 
of non-adherent patients with the MARS-A may also improve their cost-benefit ratio. 
A recommendation for future studies is the development of a more comprehensive 
scale for unintentional non-adherence, since the current MARS-A has only one item on 
that sub-domain. In the factor analysis, we found a factor zero for question 8 (“I use it 
only as a reserve, if my other inhaler doesn’t work”). This raises the question whether 
that item should still be part of the MARS-A. Other opportunities for research include: 
the addition of a scale for social desirability 33, which is a weakness for any adherence 
questionnaire; and adding a recall period, e.g. 30 days, for longitudinal adherence 
measurement 7. Finally, the criterion validity of the MARS-A should be confirmed in a 
study with clinically relevant outcome measures like asthma control.
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CONCLuSIONS
The Dutch 9-item MARS-A is an easy, low-cost and sensitive screening tool for early 
identification of potentially clinically relevant non-adherence to ICS in children with 
asthma, especially for intentional non-adherence. In clinical practice, the MARS-A can 
be used to screen for patients who may benefit from early additional monitoring or 
adherence improving interventions.
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Appendix I Dutch 9-item MARS-A 
De volgende vragen gaan over uw houding ten opzichte van de ontstekingsremmende 
inhalatiegeneesmiddelen van uw kind:
•	 Hier	volgen	uitspraken	die	andere	patiënten	gedaan	hebben	over	hun	medicatie.
•	 Wij	verzoeken	u	aan	te	geven	in	hoeverre	u	het	met	deze	uitspraken	een	of	oneens	
bent.
•	 Er	zijn	geen	goede	of	foute	antwoorden.	Wij	zijn	benieuwd	naar	uw	persoonlijke	.
Nooit Zelden Soms Vaak Heel 
vaak
1. Ik verander de dosis# ❏ ❏ ❏ ❏ ❏
2. Ik vergeet mijn medicijnen te gebruiken@ ❏ ❏ ❏ ❏ ❏
3. Ik stop een tijdje met het gebruiken van mijn 
medicijnen#
❏ ❏ ❏ ❏ ❏
4. Ik gebruik mijn medicijnen alleen als ik mij 
benauwd voel#
❏ ❏ ❏ ❏ ❏
5. Ik besluit een dosis over te slaan# ❏ ❏ ❏ ❏ ❏
6. Ik gebruik minder van mijn medicijnen dan de 
dokter heeft voorgeschreven#
❏ ❏ ❏ ❏ ❏
7. Als het kan, gebruik ik mijn medicijnen niet# ❏ ❏ ❏ ❏ ❏
8. Ik gebruik mijn medicijnen alleen als reserve, 
wanneer mijn andere (nood)inhalator niet 
werkt#
❏ ❏ ❏ ❏ ❏
9. Ik gebruik mijn medicijnen in de regel iedere 
dag#$
❏ ❏ ❏ ❏ ❏
# + @  MARS total
#  MARS-A intentional 
@  MARS-A unintentional
$ Inverse score
Original 9-item MARS-A 17
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Appendix II Definitions and calculation of binary classification characteristics
- sensitivity (SENS): a/(a+c): proportion of patients who are truly non-adherent (low 
EM adherence) that have low patient reported adherence (high MARS-A score). 
- specificity SPEC): d/(b+d), ): proportion of patients who are truly adherent (high EM 
adherence) that have high patient reported adherence (low MARS-A score).
- positive predictive value (PPV): a/(a+b): proportion of patients with low patient 
reported adherence (high MARS-A score) who are truly non-adherent (low EM 
adherence)
- negative predictive value (NPV): d/(c+d): proportion of patients with high patient 
reported adherence (low MARS-A score) who are truly adherent (high EM adher-
ence)
- positive likelihood-ratio (PLR): SENS/(1-SPEC): ratio of the proportion of patients 
with low patient reported adherence (high MARS-A score) in patients who are truly 
non-adherent (low EM score) versus in patients who are truly adherent (high EM 
adherence) 
- negative likelihood-ratio (NLR): (1-SENS)/SPEC: ratio of the proportion of patients 
with high patient reported adherence (low MARS-A score) in patients who are truly 
non-adherent (low EM score) versus in patients who are truly adherent (high EM 
adherence) 
- accuracy (ACC): (a+d)/(a+b+c+d): proportion of all patients that had whether both 
low EM adherence and low patient reported adherence(high MARS-A score), or had 
both high EM adherence and high patient reported adherence (low MARS-A score).
Index test and reference test for calculation of binary classification characteristics, with positive test 
results indicating non-adherence.
Positive reference test 
(EM adherence < cut-off)
Negative reference test
(EM adherence ≥ cut-off)
Positive index test
(MARS-A score ≥ cut-off)
a b
Negative index test
(MARS-A score < cut-off)
c d
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Scatterplots of the 9-item MARS-A scores (total, intentional and unintentional) versus RTMM (=EM) tak-
ing adherence (percentage of days with 2 ICS doses) and timing adherence (percentage of ICS doses 
taken in time: +/- 3 hours) 
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APPENDIX V 
Receiver Operator Characteristics (ROC) curves of the 9-item MARS-A scores (total, intentional and 
unintentional) versus taking adherence (% of days with 2 ICS doses) and timing adherence (% of ICS doses taken 
in time: +/- 3 hours) cut-off at 50% and 70%.  
 
MARS scores vs EM taking adherence cut-off 50% 
  
 AUC 95% CI 
MARS-A total 0.739 0.632-0.847 
MARS-A intentional 0.717 0.607-0.828 
MARS-A unintentional 0.628 0.491-0.746 
 
MARS scores vs EM taking adherence cut-off 70% 
 
 AUC 95% CI 
MARS-A total 0.686 0.540-0.832 
MARS-A intentional 0.685 0.534-0.836 
MARS-A unintentional 0.560 0.399-0.721 
Selected cut-off value 
Selected cut-off value 
2 
2 
11 
11 
10 
10 
Receiver Operator Characteristics (ROC) curves of the 9-item MARS-A scores (total, intentional and 
unintentional) versus taking adherence (% of days with 2 ICS doses) cut-off at 50% and 70%. 
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MARS scores vs EM timing adherence cut-off 50% 
 
 AUC 95% CI 
MARS-A total 0.712 0.603-0.821 
MARS-A intentional 0.679 0.567-0.791 
MARS-A unintentional 0.661 0.546-0.776 
 
 
MARS scores vs EM timing adherence cut-off 70% 
 
 AUC 95% CI 
MARS-A total 0.687 0.575-0.798 
MARS-A intentional 0.663 0.548-0.777 
MARS-A unintentional 0.622 0.501-0.743 
 
  
Selected cut-off value 
Selected cut-off value 
2 
2 11 
11 
10 
10 
Receiver Operator Characteristics (ROC) curves of the 9-item MARS-A scores (total, intentional and 
unintentional) versus timing adherence (% of ICS doses taken in time: +/- 3 hours) cut-off at 50% and 
70%.
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Binary classification characteristics of the 9-item MARS-A scores (intentional, unintentional, total) ver-
sus EM taking adherence (percentage of days with 2 ICS doses) and EM timing adherence (percentage 
of ICS doses taken in time: +/- 3 hours) cut-off at 50% and 70%. 
MARS-A intentional cut-off at 10 (<10: adherent, >=10 non-adherent)
Timing adherence 
(±3h)
Cut-off 50%
Timing adherence 
(±3h)
Cut-off 70%
Taking adherence 
(2dd)
Cut-off 50%
Taking adherence 
(2dd)
Cut-off 70%
SENS 0.681 0.632 0.641 0.579
SPEC 0.625 0.633 0.739 0.727
PPV 0.681 0.766 0.872 0.936
NPV 0.625 0.475 0.425 0.200
PLR 1.816 1.722 2.456 2.132
NLR 0.511 0.582 0.486 0.579
ACC 0.655 0.632 0.667 0.598
MARS-A unintentional cut-off at 2 (<2: adherent, >=2 non-adherent)
Timing adherence 
(±3h)
Cut-off 50%
Timing adherence 
(±3h)
Cut-off 70%
Taking adherence 
(2dd)
Cut-off 50%
Taking adherence 
(2dd)
Cut-off 70%
SENS 0.766 0.719 0.703 0.671
SPEC 0.425 0.400 0.391 0.273
PPV 0.610 0.695 0.763 0.864
NPV 0.607 0.429 0.312 0.107
PLR 1.332 1.199 1.155 0.923
NLR 0.551 0.702 0.759 0.1206
ACC 0.609 0.609 0.621 0.621
MARS-A total cut-off at 11 (<11: adherent, >=11: non-adherent)
Timing adherence 
(±3h)
Cut-off 50%
Timing adherence 
(±3h)
Cut-off 70%
Taking adherence 
(2dd)
Cut-off 50%
Taking adherence 
(2dd)
Cut-off 70%
SENS 0.787 0.737 0.750 0.684
SPEC 0.550 0.567 0.696 0.727
PPV 0.673 0.764 0.873 0.945
NPV 0.687 0.531 0.500 0.250
PLR 1.749 1.700 2.464 2.509
NLR 0.387 0.464 0.359 0.434
ACC 0.678 0.678 0.735 0.690
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Introduction
Although non-adherence to inhaled corticosteroids (ICS) is one of the major causes 
of poor asthma control, adherence rates in children with asthma remain low. A valid 
method for detection of non-adherence is electronic monitoring, but this method is 
associated with high costs. Therefore, reliable and affordable adherence measures are 
needed to identify children non-adherent to ICS therapy. The medication possession 
ratio (MPR) may be such a measure.
Methods
In a cohort of outpatient children with asthma aged 4-11 who participated in the e-
MATIC study, adherence to ICS was measured by calculating the MPR with medication-
dispensing records that were retrospectively collected from community pharmacies 
for a 12 months observation period. Taking-adherence to ICS was prospectively 
measured with electronic monitoring (EM) and used as reference standard. The op-
timal cut-off value of MPR for predicting EM-adherence <50% was established with 
Receiver Operator Characteristics (ROC)-analysis. Dichotomized adherence measures 
were used to calculate diagnostic test characteristics, including sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV) and accuracy (ACC).
results
Adherence data of 93 children were analysed. Median MPR of ICS was 76.7% (IQR: 
33.2%-100.0%), which was considerably higher than EM-adherence: 45.6% (IQR: 26.3%-
74.9%). Both measures were significantly and positively correlated. The optimal cut-off 
for MPR was <80%. Sensitivity for EM-adherence <50% and PPV were both 70.0%, the 
specificity and the NPV were both 65.1%, overall accuracy was 67.7%. 
Conclusions
MPR of ICS is an objective and easy to use adherence measure. Although MPR sys-
tematically overestimates EM-adherence by 15-30%, sensitivity for identifying children 
with severe non-adherence to ICS for asthma was 70%. In clinical practice, MPR can be 
used to screen for patients who may benefit from additional monitoring or adherence 
improving interventions.
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INTrOduCTION
Children with good adherence to inhaled corticosteroids (ICS) have better controlled 
asthma and less severe asthma exacerbations 1. However, studies in children with 
asthma report adherence levels of 50% or lower 2, 3. Therefore, monitoring of adher-
ence to ICS and identifying children with non-adherence is essential for prevention of 
treatment failure or loss of asthma control.
In clinical practice, the detection of non-adherence is hampered by overestimating 
adherence by both clinicians 4, 5 and patients 6, presumably due to desirability and 
recall bias. An alternative, objective and reliable method for adherence measurement 
is electronic monitoring (EM) 7-9. Although EM of ICS intake has been used in clinical 
trials 10, it is still rather complex and costly for routine use in daily care 11, 12. Therefore, 
affordable, easy to use and objective tools are needed to screen for patients with poor 
adherence to ICS. 
An adherence measure that may meet these requirements is refill-adherence based 
on medication-dispensing records 13. It is generally calculated as the medication pos-
session ratio (MPR), which is the ratio of the number of daily ICS dosages dispensed 
and the number of days in a certain time period. The MPR can be easily calculated by 
healthcare providers who have accurate and complete medication dispensing-data 
available, e.g. community pharmacists. MPR is an objective measure that has been 
widely used as reference standard for evaluating other adherence measures, e.g. 
self-reported adherence 14-16 and adherence based on Medicaid claims data 17. How-
ever, good evidence on the reliability of MPR of inhaled medication is sparse. To our 
knowledge, there is only one study evaluating MPR of ICS for asthma with another 
objective adherence measure as reference standard. In 102 asthmatic children and 
adolescents aged 3-14 years, adherence to ICS was measured with four methods for 12 
months 18. Mean MPR was 70.0% (95% CI: 67.6-72.4) which was significantly higher than 
EM-adherence: 51.5% (95% CI: 48.3-54.6) and canister weight: 46.3% (95% CI: 44.1-48.4). 
Since this single study reported a considerable 20% discrepancy between MPR and 
other objective adherence measures, additional research is needed on the reliability 
of MPR to measure adherence to ICS.
Therefore, we aimed to study the validity of MPR to identify children with asthma 
with severe non-adherence to ICS. The objective was to find the optimal cut-off value 
of MPR for ICS for predicting EM-adherence and to describe its diagnostic test charac-
teristics with adherence calculated on EM-data as a reference standard.
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Study design
An observational cohort study was performed, within the design of the e-MATIC study 
19. In a cohort of school-aged outpatient children with asthma, we studied the validity 
of MPR of ICS as a predictive measure for EM-adherence. Adherence to ICS was elec-
tronically measured with EM-devices that registered actuations of the ICS containing 
pressurised metered dose inhalers (pMDI’s) during a 12 months follow-up period. Over 
the same period, MPR of ICS was calculated for each patient, based on medication-
dispensing records that were retrospectively collected from community pharmacies. 
Ethical approval for collecting EM-data and medication-dispensing records as part of 
the e-MATIC study 19, was obtained from the medical ethics committee of the Erasmus 
Medical Center in the Netherlands (Netherlands Trials Registry, number NTR2583). 
Parents of all participants provided written informed consent. 
Participants
The study population included children with asthma who participated in the control 
group of the e-MATIC study 19, in which the effect was investigated of sending tailored 
SMS-reminders on adherence to ICS, asthma control, asthma-specific quality of life 
and the frequency of asthma exacerbations. Participants were 4-11 years of age and 
were treated in one of 5 paediatric outpatient clinics in The Netherlands. All children 
used fluticason (Flixotide®, GlaxoSmithKline), beclomethason with extra-fine particles 
(QVAR®, TEVA) or fluticason/salmeterol (Seretide®, GlaxoSmithKline) through a pres-
surized metered dose inhaler (pMDI) that was compatible with the EM-device. All 
patients received an EM-device for the duration of the study, and the children in the 
intervention group also received SMS-reminders, if an ICS-dose was more than 15 min-
utes too late. In the current study, only patients from the control group of the e-MATIC 
study were included, because the SMS-reminders not only enhanced ICS-intake, but 
may also have stimulated the filling of ICS-prescriptions and may therefore bias the 
measurement of MPR of ICS. Exclusion criteria were: unavailability of medication-
dispensing records, follow-up period of less than 90 days (leading to unreliable MPR) 
and no active use of the EM-device (arbitrarily defined as EM-adherence <1%) . 
data collection
The primary outcome measures were MPR (index test) and electronically measured 
adherence (reference test) to ICS. 
After the last patient finished the e-MATIC study, medication-dispensing records 
of all patients were collected from the inclusion date until the end of the follow-up. 
Community pharmacies, as indicated by parents as the provider of their children’s ICS, 
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were sent written requests with a copy of the signed informed consent form. Since 
collecting medication from more than one pharmacy can happen especially in larger 
cities, we carried out a city-wide search for other pharmacies that held medication 
records of the e-MATIC patients, and additional records were collected if applicable. 
MPR of ICS was calculated as the medication possession ratio (MPR), as reported in 
paragraph “data-analysis”. Dispensing records of fluticason (Flixotide®, GlaxoSmith-
Kline), beclomethason with extra-fine particles (QVAR®, TEVA) or fluticason/salmeterol 
(Seretide®, GlaxoSmithKline) were included in the MPR.
Medication adherence based on EM-data is an objective and reliable measure 6, 20 
and was therefore used as reference standard. The EM device (e-haler® / adhaler®, 
manufactured by Evalan BV in Amsterdam) was connected to the ICS containing pMDI 
and each time the pMDI was actuated, the dose was electronically registered and sent 
to the research data-base. Patients received the device for 12 months, or until they left 
the study prematurely. Co-variables collected in the e-MATIC study, were also avail-
able for the current study. EM taking-adherence was defined as the percentage of days 
of the follow-up period on which exactly the prescribed number of ICS doses were 
registered, separated by a time window of at least 15 minutes. In addition, EM timing-
adherence was calculated as the percentage of planned ICS-doses that were registered 
within a 6-hour timeframe (+/- 3 hours) around the planned time of inhalation. EM data 
only became available for analysis after the last patient finished the study.
data-analysis
In order to calculate the MPR, all ICS-dispenses were first converted into treatment 
episodes of consecutive use of ICS following the method of Catalan 21. Switches from 
one to another type of ICS and changes in dose regimen were allowed. The MPR is the 
ratio of the total number of daily ICS dosages dispensed in the observation period, 
including carry-over from before the inclusion date, and the number of days in the 
observation period 22. 
Scatter plots of EM taking-adherence and refill-adherence were used to visually 
inspect the association between both. The correlation was analysed with linear regres-
sion analysis. The distribution of the adherence data was visualised in histograms. Con-
founding by co-variables was considered not relevant since MPR and EM-adherence 
were both measured in the same patients. 
Both MPR and EM-adherence were dichotomized. The reference standard was arbi-
trarily defined as EM-adherence less than 50%, which was considered as a clinically 
relevant cut-off value. In addition, mean adherence rates reported in literature were 
in the range of 50% 2, 6, 23. As other cut-off values for medication adherence have been 
reported in literature as well 1, EM adherence was also cut-off at 30% and 70% as part 
of a sensitivity analysis. Receiver Operator Characteristics (ROC) curves were used 
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to select an optimal cut-off value for refill-adherence. Our focus was on identifying 
patients who were non-adherent to ICS needing additional support to prevent loss of 
asthma control. Therefore, we aimed at optimal sensitivity for EM-adherence <50%, 
while keeping specificity at an acceptable level, arbitrarily set at >50%. To test whether 
refill-adherence gives a better prediction of non-adherence than chance, the area 
under the ROC-curve was required to be significantly higher than 0.5. 
Refill-adherence scores were dichotomized at the selected cut-off value and 2x2 
tables were calculated against dichotomized EM-adherence. Sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV), positive likelihood-
ratio (PLR), negative likelihood-ratio (NLR) and accuracy (ACC) were calculated with 
refill-adherence as index test and EM-adherence cut-off at 50% as reference standard, 
appendix I 24.
Data were analysed on an intention to treat basis, according to the inclusion and ex-
clusion criteria mentioned before. A per-protocol analysis was carried out for patients 
with an MPR>0%, in which patients were excluded who filled medication prescriptions 
during the observation period, but not for ICS. This approach was used to study the 
impact of patients filling prescriptions at multiple pharmacies that may have been 
partially unknown to the investigators. 
In the sensitivity analyses diagnostic test characteristics were also calculated for 
timing-adherence to ICS as alternative reference standard. In addition, alternative cut-
off values for the reference standards (i.e. <30% and <70%) were investigated, both for 
timing-adherence and taking-adherence.
rESuLTS
Participants
Out of the 111 children in the control group of the e-MATIC study 19, 93 were included 
in the current study. Reasons for exclusion were: a follow-up of less than 90 days 
or unavailability of medication-dispensing records (Figure 8.1). All 93 children were 
analysed in the intention to treat analysis. In the per-protocol analysis, 13 of them were 
excluded, since their medication-dispensing records contained multiple dispenses in 
the observation period, but not for ICS. 
The 93 children in the intention to treat analysis were aged 4.0-11.6 years. Baseline 
characteristics are presented in table 8.1.
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Figure 8.1 Patient flow chart 
 
  
Figure 8.1 Patient flow chart
Table 8.1 Patient characteristics
Category N = 93
Age at inclusion (mean, SD) Years 7.7 (2.1)
Gender (n, %) Male 63 (67.7)
Type ICS (n, %) Fluticasone 
Fluticasone / salmeterol 
Beclomethasone (extra fine particles)
14 (15.1)
14 (15.1)
65 (69.9)
Dosing frequency ICS (n, %) Once daily
Twice daily
9 (9.7)
84 (90.3)
ICS dose (mean, SD) Percentage of adult DDD 35.9 (22.3)
Family status (n, %) Two parent family
Single parent family 
85 (91.4)
8 (8.6)
Ethnicity (n, %) Dutch
Non-Dutch
64 (68.8)
29 (31.2)
Parental level of education (n, %) None / Primary school
Secondary school
Intermediate vocational education
Higher vocational education
University
Unknown
8 (4.3)
25 (13.4)
63 (33.9)
60 (32.3)
28 (15.1)
2 (1.1)
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Outcome measures
Median MPR was 76.7% (IQR: 33.2%-100.0%) with a mean of 64.7% (sd. 33.1%). Me-
dian EM taking-adherence was 45.6% (IQR: 26.3%-74.9%); mean: 48.1% (sd. 27.1%). Both 
adherence measures were significantly positively correlated, p=0.009 (figure 8.2). 
EM-adherence and refill-adherence data were not normally distributed (figure 8.3) and 
were dichotomized. In 13 children who filled prescriptions for other medicines than 
ICS, but not for ICS, MPR was 0%. In 26 children MPR was 100%. The sensitivity analysis 
showed an EM timing-adherence of 67.0% (median, IQR: 41.7%-87.4%). 
Table 8.1 Patient characteristics (continued)
Category N = 93
Parental Dutch language skills (n, %) Poor/moderate
Good
Excellent 
Unknown
16 (8.6)
14 (7.5)
154 (82.8)
2 (1.1)
Asthma control at inclusion (mean, SD) Total c-ACT1 score 20.4 (4.1)
Poorly controlled asthma at inclusion 
(n, %)
Total c-ACT1 score ≤ 19 34 (36.6)
Asthma-specific quality of life at 
inclusion (mean, SD)
PAQLQ2 score 5.9 (0.9)
Medication Beliefs at inclusion3 
BMQ3 necessity score (mean, SD)
BMQ3 necessity score >15 (n (%))
BMQ3 concerns score (mean, SD)
BMQ3 concern score >15 (n, %)
18.5 (3.5)
78 (83.9)
12.7 (3.2)
21 (22.6)
1c-ACT: 7-item questionnaire for detecting poorly controlled asthma in children aged 4-11 years.25 
Ranges: 0-27 points, cut-off score: 19 points (≤19 points: uncontrolled asthma, ≥20 points: controlled 
asthma). c-ACT questionnaires at baseline were completed by 91 out of 93 patients.
2 PAQLQ: 23 item questionnaire for measuring Pediatric Asthma Quality of Life Questionnaire.26 Do-
mains include activities, asthma symptoms and emotional function. Range: 1-7. 
3BMQ: Beliefs about Medicines Questionnaire Specific (BMQ Specific), which has one scale for beliefs 
in the necessity of ICS and one for concerns about long term toxicity and disruptive effects of ICS. Both 
scales range from 5 to 25, with higher scores indicating stronger beliefs.27 
Abbreviations: SD = standard deviation, ICS = Inhaled corticosteroid, DDD = Defined Daily Dose defined 
by the World Health Organization
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Figure 8.2: Scatter plot of MPR versus EM taking adherence




	
 
Figure 8.3: Histograms of MPR and EM taking adherence 
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dichotomization of MPr
An optimal cut-off value for MPR was selected by generating a Receiver Operator 
Characteristics (ROC) curve with EM adherence cut-off at 50% as a reference standard 
(figure 8.4). The focus was on optimal sensitivity and positive predictive value for EM 
non-adherence <50%, combined with acceptable specificity (>50%). In the sensitiv-
ity analyses, also other cut-off values (30%, 70%) were explored, both for EM taking-
adherence and EM-timing adherence. The optimal cut-off value for MPR was <80%. 
The corresponding area under the ROC-curve was 0.714 (95% CI: 0.608-0.819), which 
was significantly higher than 0.50 and therefore informative.
diagno4tic test characteristics 
At a cut-off value for MPR of <80%, diagnostic test characteristics were calculated 
according to the description in appendix I: the sensitivity and the positive predictive 
value were both 70%, the specificity and the negative predictive value were both 
65%, accuracy was 68% (table 8.2 and table 8.3). In the sensitivity analyses, binary 
classification characteristics were also calculated for other cut-off values of EM taking-
adherence and EM timing-adherence, i.e. <30% and <70%, both with an intention to 
treat and with a per protocol approach (appendix II). 
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Figure 8.3: Receiver Operator Characteristics (ROC) curve for MPR versus EM taking-adherence < 50%
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dISCuSSION
We aimed to investigate the reliability of MPR of ICS for predicting non-adherence 
to ICS in children with asthma. We found that MPR of ICS is a quick and easy-to-use 
adherence measure. MPR was positively correlated with EM-adherence (p=0.009). The 
optimal cut-off value of MPR was <80%. The corresponding area under the ROC-curve 
was 0.714 (95% CI: 0.608-0.819), which was significantly higher than 0.5 and therefore 
informative. 
We found a mean MPR of 64.7% (sd. 37.1%) and EM taking-adherence of 48.1% (sd. 
27.1%), which corresponds well with the results of the only comparable study of 
Jentzsch et al. in 102 children and adolescents with asthma 18, in which adherence 
rates were reported of 70.0% and 51.5% respectively. In that study, no diagnostic test 
characteristics were reported. Our study results confirm the earlier conclusions that 
MPR is well correlated with EM-adherence to ICS, but systematically overestimates 
adherence to ICS by 15-30%. This overestimation of adherence by MPR is probably 
Table 8.2 Two by two table of MPR < 80% versus EM taking-adherence < 50% 
EM taking adherence 
0:≥50% 1: <50%
 0 1 total
MPr 0 28 15 43
0:≥80%, 1:<80% 1 15 35 50
total 43 50 93
Table 8.3 Diagnostic test characteristics of refill-adherence (MPR) < 80% versus EM taking-adherence 
<50% 
MPr < 80% versus
EM taking adherence <50%
SENS 0.700
SPEC 0.651
PPV 0.700
NPV 0.651
PLR 2.007
NLR 0.461
ACC 0.677
SENS = sensitivity; SPEC = specificity; PPV = positive predictive value; NPV = negative predictive value; 
PLR = positive likelihood ratio, NLR = negative likelihood ratio, ACC = accuracy.
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caused by ICS prescriptions that were correctly filled, but not, or only partially, taken 
adherently. 
MPR < 80% had a good sensitivity (70.0%) and positive predictive value (70.0%) for 
EM-adherence <50%, while specificity (65.1%) and negative predictive value (65.1%) 
were both acceptable. The results of the sensitivity analyses (Appendix II) indicated 
that MPR was a robust measure for adherence to ICS. Alternative reference standards, 
i.e. other cut-off values ( <30% and <70%) showed a similar sensitivity and specificity 
values as the primary analysis. Also, sensitivity and specificity values based on EM 
timing-adherence as reference standard were comparable to those based on EM-
taking-adherence. By contrast, positive predictive values were lower and negative 
predictive values higher. EM taking-adherence appeared to be a stricter reference 
standard than EM timing-adherence, probably since all ICS-doses on a day needed to 
be taken in order to count as adherent, while timing-adherence was still 50% if one out 
of two ICS-doses were taken correctly. This was also reflected in the median adherence 
rates: EM taking-adherence: 45.6%, EM timing-adherence: 67.0% and MPR: 67.7%. 
Diagnostic test characteristics of the ITT analysis were comparable to those of the 
PP-analysis, in which 13 out of 93 patients were excluded since no refills of ICS had 
been registered while other medication was dispensed during the observation period. 
This may be explained by the fact that only 2 out of the 13 children with MPR=0% had 
an EM-adherence of 50% or more, which indicates that for 11 out of 13 patients the MPR 
of 0% had already correctly predicted EM-adherence to be lower than 50%. A possible 
explanation for the two high EM-adherence rates in patients with MPR=0% is that they 
may have refilled ICS prescriptions in other pharmacies than their own. Also, patients 
may have collected a supply of unused ICS-inhalers from dispenses before start of the 
observation period, and used it during the observation period. Although carry-over 
was taken into account from the episode immediately before start of the observation 
period, the use of stocked supplies of ICS may have caused a underestimation of the 
MPR. In this study, we included the patients with MPR=0 in the primary analysis, since 
we think this approach is most realistic in clinical practice. When other medications 
but ICS are regularly dispensed, this gives little rise to doubt about the absence of ICS 
refills. However, to quantify the impact of this subgroup on the main results, we carried 
out the sensitivity analysis.
A strength of our study was that we were one of the first to investigate the reliability 
of MPR as a screening tool for non-adherence to ICS. Although MPR has already been 
widely used in research and is a common tool for community pharmacists for detect-
ing underuse of medication in daily care, it has not been thoroughly validated against 
an objective and reliable reference standard like EM-adherence for ICS. 
Using MPR as an adherence measure has a number of general limitations: it is an 
indirect adherence measure that is relative insensitive to individuals who fill all their 
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ICS-prescriptions, but who take less than half of their ICS-doses. Also, the MPR might 
not have been 100% accurate for all patients, because they might have used differ-
ent pharmacies that were not screened in our study. Although all pharmacies in the 
region of the pharmacy that was pointed out by the patient, were included into our 
search, we cannot rule out that we missed a small part of the medication-dispensing 
records. The possible underestimation of MPR in this study was limited by the high 
quality Information and Communication Technology (ICT) infrastructure in The Neth-
erlands in which medication-dispenses were structurally administered and which was 
accessible for retrieving information by allied healthcare providers. The reliability of 
MPR was also enhanced by the fact that most patients in The Netherlands have one 
dominant community pharmacy 28, to which other pharmacies are required to send 
a notification of incidental medication dispensing. A limitation of MPR as a screening 
tool for poor adherence, may be the complexity of the calculations. The MPR for an 
individual patient is easily estimated based on medication-dispensing records from 
a community pharmacy data-base. However, for MPR calculation of large groups of 
patients, specialized software and analysis techniques are required. Although this 
service and the other requirements for reliable MPR-calculation, are available in the 
Netherlands 29, this may not be the case in other countries. A specific limitation of 
MPR of ICS are the relatively large quantity of ICS that is supplied in one refill, making 
MPR-calculations vulnerable for intermediate dose-adjustments or discontinuations 
of ICS during episodes. Long ICS-episodes also limit the use of MPR for early identifica-
tion of non-adherence. Finally, participation in a clinical trial may in itself stimulate 
medication adherence 13. However, in our study this so-called Hawthorne effect would 
have occurred for both EM-adherence and in MPR and may therefore have levelled out 
to a certain extent. Since the overall level of adherence may have increased during 
the study, we performed an additional analysis of the MPR for the period immediately 
preceding the study (data not reported). The MPR’s were comparable in the 12 months 
before (median 80.3%, IQR 48.5-100.0%, mean 70.7%, sd 32.8%) and the 12 months af-
ter the inclusion date (median 76.7, IQR 33.2-100.0%, mean 64.7%, sd 37.1%). Therefore, 
participation in the study appears not to have increased the MPR of ICS.
In clinical practice, screening for children with MPR <80% can be used for identifica-
tion of severe non-adherence to ICS. Selected individuals should be monitored more 
intensively e.g. by electronic monitoring. If adherence to ICS and asthma control turn 
out to be poor, further deterioration of asthma control may be prevented by offering 
adherence improving interventions, e.g. educational interventions, alert systems for 
non-adherence in public pharmacies or real time medication monitoring (RTMM) with 
SMS-reminders. If adherence is persistently poor, but asthma control sufficient, dose-
adjustment or tapering of ICS should be considered.
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A recommendation for future research is the combined use of MPR and patient 
reported adherence, like the Medication Adherence Report Scale 30, 31. This may yield 
additional information since the latter focuses on intentional non-adherence and the 
reasons for deviating from the prescribed dosing regimen, while, theoretically, poor 
MPR can be the result of both intentional and unintentional non-adherence. Investiga-
tors using MPR may avoid underestimation of the MPR by verifying that ICS use is still 
clinically indicated during the entire observation period.
CONCLuSIONS
MPR of ICS is an objective and easy to use adherence measure. Although MPR sys-
tematically overestimated mean EM-adherence by 15-30%, sensitivity for identifying 
children with severe non-adherence to ICS for asthma was 70%. In clinical practice, 
MPR can be used to screen for patients who may benefit from additional monitoring 
or adherence improving interventions.
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APPENdICES
Appendix I
Definitions and calculation of diagnostic test characteristics
- sensitivity (SENS): a/(a+c): proportion of patients who are truly non-adherent (low 
EM adherence) that have a low MPR. 
- specificity SPEC): d/(b+d), ): proportion of patients who are truly adherent (high EM 
adherence) that have a high MPR.
- positive predictive value (PPV): a/(a+b): proportion of patients with a low MPR who 
are truly non-adherent (low EM adherence)
- negative predictive value (NPV): d/(c+d): proportion of patients with a high MPR 
who are truly adherent (high EM adherence)
- positive likelihood-ratio (PLR): SENS/(1-SPEC): ratio of the proportion of patients 
with a low MPR in patients who are truly non-adherent (low EM score) versus in 
patients who are truly adherent (high EM adherence) 
- negative likelihood-ratio (NLR): (1-SENS)/SPEC: ratio of the proportion of patients 
with a high MPR in patients who are truly non-adherent (low EM score) versus in 
patients who are truly adherent (high EM adherence) 
- accuracy (ACC): (a+d)/(a+b+c+d): proportion of all patients that had whether both 
low EM adherence and a low MPR, or had both high EM adherence and high patient 
reported adherence (low MARS-A score).
Index test (refill adherence) and reference test (EM adherence) for calculation of binary classification 
characteristics, with positive test results indicating non-adherence.
Positive reference test 
(EM adherence < cut-off)
Negative reference test
(EM adherence ≥ cut-off)
Positive index test
(MPR < cut-off)
a b
Negative index test
(MPR > cut-off)
c d
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Appendix II 
Sensitivity and per-protocol analyses of diagnostic test characteristics of MPR (index test) versus EM 
taking-adherence and EM-timing adherence to ICS (reference standard)
Intention to treat analysis (n=93)
EM taking
adh < 30%
EM taking
adh <50%
EM taking
adh <70%
EM timing
adh < 30%
EM timing
adh <50%
EM timing
adh <70%
SENS 0.679 0,700 0.636 0.625 0.667 0.686
SPEC 0.523 0.651 0.704 0.481 0.524 0.643
PPV 0.380 0.700 0.840 0.200 0.400 0.700
NPV 0.791 0.651 0.442 0.860 0.767 0.628
PLR 1.423 2.007 2.148 1.203 1.400 1.922
NLR 0.614 0.461 0.517 0.780 0.636 0.488
ACC 0.570 0.677 0.656 0.505 0.570 0.667
Per protocol analysis (n=80, patients with MPR=0% were excluded)
EM taking
adh < 30%
EM taking
adh <50%
EM taking
adh <70%
EM timing
adh < 30%
EM timing
adh <50%
EM timing
adh <70%
SENS 0,609 0,615 0,556 0,500 0,583 0,590
SPEC 0,596 0,683 0,731 0,544 0,589 0,659
PPV 0,378 0,649 0,811 0,162 0,378 0,622
NPV 0,791 0,651 0,442 0,860 0,767 0,628
PLR 1,509 1,941 2,063 1,097 1,420 1,727
NLR 0,656 0,563 0,608 0,919 0,707 0,623
ACC 0,600 0,650 0,613 0,538 0,588 0,625
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MAIN FINdINgS
The background of this thesis is described in the general introduction (Chapter 1). 
Asthma is a highly prevalent chronic disease in children and is associated with impair-
ment of quality of life and considerable healthcare use and costs. An important risk 
factor for uncontrolled asthma is non-adherence to ICS, which may develop through 
several mechanisms. Intentional non-adherence is provoked by perceptual barriers 
like negative beliefs about the necessity of treatment, concerns about side effects or 
a limited illness perception. Unintentional factors include practical barriers that may, 
for example, lead to forgetting of medication intake. Many interventions for improving 
medication adherence have been studied. Interventions typically aim at removing in-
tentional or unintentional barriers for good adherence. Interventions are very hetero-
geneous, often complex and multidisciplinary. They only sporadically aim at tailoring 
support to individual patient needs. The effect on medication adherence is generally 
small and varies between adherence measures. Also, only few studies have reported 
effects on both adherence and treatment outcomes. This thesis aims to investigate 
methods for identifying and improving adherence to inhaled corticosteroids (ICS) in 
children with asthma. 
In Chapter 2 we examine the effect of poor adherence to ICS on the risk of exacer-
bations in children with asthma. In a nested case-control study using data from the 
Dutch PHARMO Record Linkage System, children who had an asthma exacerbation 
needing oral corticosteroids or hospital admission were matched to children without 
exacerbations. Refill adherence was calculated as medication possession ratio (MPR) 
from ICS-dispensing records. In children that used long acting beta agonists (LABA), 
good adherence to ICS was associated with a higher risk of asthma exacerbations, but 
no association was found in children not using LABA. We hypothesized that children 
using LABA had more severe asthma and may therefore have been better motivated 
for using ICS. These results suggest that the interaction between medication adher-
ence and asthma control is more complex than we may think.
In Chapter 3 we describe a prospective, observational multicentre study in which we 
studied the association of ethnicity with electronically measured adherence to ICS in 
a population of Moroccan and native Dutch children with asthma in Amsterdam. In a 
population of 87 children aged 1-11 years, native Dutch children showed significantly 
higher adherence than Moroccans: 55.9% vs. 42.5%. Ethnicity was independently as-
sociated with adherence. These results show that poor adherence to ICS is a concern 
in childhood asthma, but especially in children with Moroccan ethnicity. 
In Chapter 4 and 5, a multicenter randomized controlled trial, the e-MATIC study, is 
described in which we aimed to improve adherence to ICS by electronically monitor-
ing adherence to ICS and by sending tailored SMS reminders, only when a dose was 
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at risk of omission. We included 209 children aged 4-12 years. Mean adherence was 
significantly higher in the intervention group: 69.3% vs. 57.3%. No differences were 
found for asthma control, asthma specific quality of life, asthma exacerbations and 
costs. 
As part of the e-MATIC study, we carried out three online focus groups in 24 children 
aged 9-12, parents of children aged 9-12 and in parents of children aged 4-8. The results 
are presented in chapter 6. We investigated whether asthma self-management by 
tailoring ICS intakes on asthma symptoms, is a promising approach in children with 
asthma. Five themes were addressed: the daily routine of ICS intake, forgetting ICS 
intakes, recognizing asthma symptoms, medication beliefs and the child’s social envi-
ronment. A daily routine for ICS use proved to be essential for good adherence. Most 
children take the initiative for taking ICS themselves and are able to recognize asthma 
symptoms, but only few manage to respond without parental help. Self-management 
behaviour seems to be a result of habituation, rather than reflective thinking. Self-
management is also limited by misunderstanding the differences between controller 
medication (i.e. ICS) and reliever medication, and by the lack of belief in the efficacy 
of ICS. Physicians should pay special attention to these barriers when promoting self-
management of asthma in children.
Electronic monitoring is an objective and reliable method for measuring adher-
ence, but it is costly and time consuming. In chapter 7 and 8, two more affordable 
and easier to use adherence measures were studied for identifying patients who are 
non-adherent to ICS. In both studies, electronically measured (EM) taking adherence, 
cut-off at <50%, was used as a reference standard for non-adherence. In chapter 7 the 
reliability of the Dutch version of the self-reported 9-item asthma-specific Medication 
Adherence Report Scale questionnaire (MARS-A) was studied in 87 children with per-
sistent asthma aged 12 years or younger, and their parents. The total MARS-A score 
and two sub-scores for intentional and unintentional non-adherence were separately 
analysed. Sensitivity for non-adherence was 64.1% for the intentional sub-score cut-
off at 10; and 70.3% for the unintentional sub-score cut off at 2. Overall accuracy was 
66.7% and 62.1% respectively. In clinical practice, the MARS-A can be used to screen for 
patients who may benefit from early additional monitoring or adherence improving 
interventions.
In chapter 8, for 93 children aged 4-11 years who participated in the e-MATIC study, 
refill-adherence to ICS was calculated as the Medication Possession ratio (MPR) 
based on medication-dispensing records. The MPR was considerably higher than EM-
taking-adherence: median 76.7% vs. 45.6%. The optimal cut-off for the MPR was <80%. 
Sensitivity for EM-adherence <50% and PPV were both 70.0%, the specificity and the 
NPV were both 65.1%, overall accuracy was 67.7%. The MPR of ICS is an objective and 
easy to use adherence measure. Although the MPR systematically overestimated EM-
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adherence by 15-30%, sensitivity for identifying children with severe non-adherence to 
ICS for asthma was good. In clinical practice, MPR can be used to screen for patients 
who may benefit from additional monitoring or adherence improving interventions.
A number of questions remain unanswered. What are the mechanisms that cause 
differences	between	ethnic	minority	ad	non-minority	children?	What	is	the	nature	of	
the	relation	between	adherence	and	asthma	control?	What	is	the	optimal	strategy	to	
identify patients at risk of non-adherence, explore their medication taking behavior 
and	use	these	data	to	target	individual	barriers	for	good	adherence?	How	can	the	ef-
ficacy	of	reminder	interventions	be	further	improved?	Can	asthma	self-management	
by children contribute to better control of asthma symptoms and to more efficient use 
of	ICS?	These	and	other	issues	will	be	discussed	in	the	next	paragraphs.
EThNICITy ANd NON-AdhErENCE
In chapter 3 we found that Moroccan ethnicity was independently associated with non-
adherence to ICS. These results are in agreement with earlier reports that a minority 
background is associated with poor adherence to ICS 1-4 and are of clinical importance 
since minority children have worse asthma status than non-minority children and 
exhibit much higher admission rates and emergency department use 5, 6. However, 
finding a solution requires insight in the causal background of these associations. 
The apparent role of ethnicity may well be not more than a proxy for other factors 
that in fact provoke non-adherence, like medication beliefs, illness perceptions, health 
literacy, communication with healthcare providers and socio-economic factors.
One explanation for the intercultural differences in adherence may be presented by 
more negative medication beliefs in ethnic minority patients. Beliefs about necessity 
are predictive of non-adherence to ICS in children with asthma 7. Some studies have re-
ported that minority patients are more likely to have negative views about medication 
8, 9. Our study presented in Chapter 3 connects the three elements of ethnicity, medica-
tion beliefs and adherence to ICS. BMQ scores on necessity exceeded concerns in 35% 
of Moroccan children and in 9% of Dutch children. BMQ scores showed a borderline 
association with adherence. Moreover, adherence was 13% lower in Moroccan children. 
However, Moroccan ethnicity remained significantly associated with non-adherence 
to ICS after adding BMQ-scores to the regression model, which means that medica-
tion beliefs did not fully explain the ethnical differences in adherence. This conclusion 
confirms the results of an earlier focus group study 10 in a multi-ethnic population of 
asthmatic children in The Netherlands, in which the beliefs about ICS and perceptions 
about asthma of mothers and children with different cultural backgrounds showed 
striking similarities. On the other hand, our results contrast to a study from the USA 
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which reported that medication beliefs mediated the association between ethnic 
minority status and adherence to ICS 11. The results were independent of a number 
of socio-economic factors that were significantly different between minority and 
non-minority groups. However, fundamental differences existed between both study 
populations in terms of ethnical background (75% African-American/Hispanic vs 50% 
Moroccan) and socio-economic status. In conclusion, ethnical differences in medica-
tion beliefs and illness perceptions may play a role, but do not fully explain ethnical 
difference in adherence to ICS.
Another parameter that may explain ethnical differences in medication adherence 
and asthma outcomes is health literacy 12. It is defined as “the degree to which indi-
viduals have the capacity to obtain, process, and understand basic health information 
and services needed to make appropriate health decisions” 13. Adherence to therapy 
is generally better in patients with a high level of health literacy 14. Poor health literacy 
may reduce adherence through several mechanisms, including poor understanding 
of medication regimes 15, 16 or negative medication beliefs 17, 18. Interventions aimed at 
improving health literacy can increase adherence to treatment, especially in minority 
patients. This suggests that especially vulnerable populations benefit from health 
literacy interventions 14. Health literacy may even mediate the relation between ethnic-
ity and either health status or medication adherence 19. In a multi-ethnic population 
of 353 African-American, Latino and white adults with asthma, 20% of the observed 
ethnical disparities in asthma outcomes and quality of life were explained by differ-
ences in health literacy 20. In another multi-cultural study population of 284 American 
adults with asthma, the correlation between health literacy and medication adherence 
became non-significant after adding ethnicity to the regression model 21. Therefore, 
health literacy may contribute to ethnical disparities in medication adherence. Improv-
ing patient education and optimizing communication between healthcare providers 
and patients, especially those with a minority background, may result in improved 
medication adherence 2, 22. Special attention should be paid to cultural competence of 
healthcare providers and to overcoming language barriers 23.
As discussed in chapter 1, a low income level is more prevalent in ethnic minority 
patients and has been inconsistently associated to medication adherence. In a cross-
sectional study in children with asthma in the USA, only among children from families 
with incomes less than half the federal poverty level did non-Hispanic black children 
have a higher risk of asthma than non-Hispanic white children. No black vs. white dif-
ferences existed at other income levels 24. Although very low income may provoke 
non-adherence, it is unlikely that this explained the lower adherence levels in Moroc-
can children reported in chapter 3, since obligatory and free health insurance covers 
all medication costs for children in The Netherlands. 
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A downside of approaching an ethnic population as a homogeneous group, is 
the risk of stigmatisation and disregard of inter-individual difference. Therefore, we 
believe that focus is needed on factors that drive adherence behaviour in individual 
patients. Some of these factors show considerable inter-individual variation, and some 
even vary within patients, e.g. over time or between medicines. In the end, it’s not 
plausible that a predefined determinant, like country of birth, determines a patient’s 
medication adherence. More likely, it is a complex and variable mixture of individually 
defined factors that does.
INTENTIONALITy OF NON-AdhErENCE
As discussed in chapter 1, mechanisms leading to non-adherence to medication can be 
divided into intentional factors and unintentional factors. In this thesis, several meth-
ods were used to measure the so-called intentional and unintentional non-adherence. 
In Chapter 7, self-reported non-adherence was measured using the MARS-A question-
naire, both with intentional and unintentional subscales. Eight out of 9 items of the 
MARS-A addressed intentional factors, while the single remaining item was about 
forgetting of ICS intakes. Interestingly, both subscales showed a similar correlation 
with EM-adherence. This may be caused by the fact that our reference standard EM-
adherence could not be differentiated for intentional or unintentional backgrounds. 
The EM-adherence rate was simply calculated from the registered pMDI-actuations, ir-
respective of the reasons that lead to omission of ICS-doses. Another patient reported 
measure related to medication adherence, is the Beliefs about Medicines Question-
naire (BMQ), which measures perceptions about medicines. The BMQ was used in the 
COMPLIANCE study (Chapter 2) and the e-MATIC study (Chapter 4 and 5). Although 
the BMQ scores on beliefs about necessity of ICS use and concerns about side effects 
can predict adherence to ICS 25, it is an indirect method that measures intentions, not 
the resulting ICS taking behavior. By definition, patient reported adherence measures, 
like the MARS-A and the BMQ, are less sensitive for unintentional non-adherence, since 
this is often a subconscious process 26. Moreover, self-reported adherence may overes-
timate true medication adherence due to social desirability bias. This was confirmed in 
Chapter 7, in which the sensitivity of the MARS-A was in the range of 65-75%, implying 
that 25-35% of patients over-reported their medication adherence. 
Another adherence measure, not filling ICS prescriptions resulting in a low MPR 
(chapter 2 and 8), is most easily interpreted as a conscious action, especially if non-
adherence is considerable and persistent. The MPR is not a sensitive measure for oc-
casional forgetting of ICS intakes, since refills typically occur every 3-6 months or even 
less. Also, part of the community pharmacies in The Netherlands provide a reminder 
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service for refilling prescriptions for chronic users. It is plausible that such a service 
would reduce the forgetting of ICS-refills, but it is unclear whether this would improve 
the intake of ICS as well. 
In the e-MATIC study (Chapter 4 and 5) adherence was electronically measured and 
no distinction was made between intentional and unintentional motives. SMS-remind-
ers were aimed to reduce the forgetting of ICS intakes. However, it cannot be ruled 
out that the persistent feedback on forgotten ICS intakes has also confronted patients 
with the concepts of asthma and the need for treatment, which might have enhanced 
intentional adherence as well. It has been suggested that intentional and unintentional 
barriers for adherence may not be strictly separated. In a large observational study 
in adults with chronic disease 27, unintentional non-adherence was not random, but 
appeared to be predicted by medication beliefs and mediated the effect of medication 
beliefs on intentional non-adherence. This implies that negative medication beliefs 
may subconsciously lead to forgetting of medication intakes. The association between 
intentional and unintentional behavior may also provide an alternative explanation for 
the similarities we found for the intentional and unintentional sub-scores of the MARS-
A in Chapter 7. However, more research is needed to further elucidate the nature of 
the relation between medication beliefs and the intentionality of non-adherence, and 
more specifically, to differentiate between mediation and co-linearity by unintentional 
non-adherence. Differences in medication beliefs between parents and children, and 
their impact on adherence also need further study 28.
AdhErENCE ANd ASThMA CONTrOL: A COMPLEX rELATION
Non-adherence to ICS is associated with an increased risk of insufficient asthma control 
and a higher risk of severe asthma exacerbations. However, the results presented in 
this thesis show a less straightforward relation between adherence to ICS and asthma 
control. In chapter 2, we found an inverse relation between both: in children using long 
acting beta agonists (LABA), good adherence to ICS was associated with a higher risk 
of asthma exacerbations, but no association was found in children not using LABA. In 
the e-MATIC study (chapter 4 and 5), the mean adherence was significantly higher in 
the intervention group receiving tailored SMS-reminders: 69.3% vs. 57.3%. However, 
no differences were found for asthma control (c-ACT score 21.1 vs. 22.2), quality of life 
(mean PAQLQ score 6.2 vs 6.3) or asthma exacerbations (annual rate 0.23 vs. 0.37). 
A closer look into previous studies on this topic, reveals that our findings are not the 
first that conflict with the established theory that good adherence to ICS leads to better 
asthma outcomes. Several studies reported a reverse association between adherence 
and risk of severe asthma exacerbations 29-32. For example, Rust et al 33 found that 1.9% 
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of children with refill adherence to ICS <50% had a hospital admission for asthma vs. 
3.2% in children with refill rate > 50% (p<0.01). In another study patients reduced their 
prescribed controller medication without negative consequences 34, whereas other 
patients continued to have poor outcomes despite good adherence 35. 
In chapter 2 and 5, possible explanations have been proposed for the observed rela-
tion between adherence and asthma control. In chapter 2, it was argued that children 
with exacerbations might have had a lower level of asthma control, which would have 
motivated them to take their ICS more adherently. In chapter 5, a considerable part of 
the population had sufficiently controlled asthma, which provided limited room for 
improvement. Also, considering the high level of asthma control, patients may have 
received higher ICS doses than needed. These hypotheses suggest a bidirectional 
relation between adherence and asthma control: good adherence leads to better 
asthma control, but patients with good asthma control may become less motivated to 
adherence to ICS therapy (Figure 9.1). 
It is hypothesized that the relation between adherence and asthma control is medi-
ated by a number of factors. Each patient has a critical adherence level that is needed 
for just maintaining asthma control. If patients are not 100% adherent, but maintain 
adherence above the critical level, no clinical consequences would be expected. This 
critical level would be higher in patients with persistent, insufficiently controlled 
asthma, than in patients with asthma in clinical remission 36. The critical level would be 
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Figure 9.1 P oposed bi irecti al relation betwee  adhere ce to ICS and asthma control, and he role 
of exceeding the critical level of exposure to ICS.
# Factors contributing to exposure to ICS include: the prescription of high doses of ICS, a good inha-
lation technique and a good adherence to ICS at baseline. Factors lowering the critical level of ICS 
exposure needed for maintaining good asthma control include: asthma in clinical remission or the 
absence of asthma triggers. 
170 Chapter 9
lower in patients who have been prescribed higher ICS doses than needed, and higher 
in patients with a poor inhalation technique. The existence of a critical level of expo-
sure to medication for achieving treatment response is known from other diseases, 
e.g. HIV 37, but the findings in this thesis suggest that this concept is also relevant for 
asthma. This hypothesis provides an explanation for our observations in chapter 5 
that differences in adherence level are not necessarily reflected in the level of asthma 
control, probably since the critical level of asthma control was not reached in the 
intervention group or since a large part of the population already had a high level of 
adherence at baseline, that exceeded the critical level for maintaining asthma control. 
The same mechanism seems to work the other way around, e.g. in the study of Chan et 
al., in which adherence to ICS and asthma control were considerably improved in the 
first 2 months by sending SMS-reminders. However, the reduced frequency of asthma 
exacerbations lasted no longer than 2 months. This was probably due to the gradual 
decline of adherence rates by approximately 12% during the 6 months of follow-up, 
ending up under the critical level for maintaining asthma control 38. 
The postulated critical level of ICS exposure needed for only just maintaining 
asthma control (figure 9.1) is likely to show considerable variation. Sources of intra-
individual include seasonal changes in asthma control, presumably caused by varia-
tions in exposure to e.g. allergens and viral infections 39. The seasonal variability of the 
relation between asthma control and adherence to ICS is considerable: in months of 
the year when asthma control is generally good, the level of adherence to ICS drops, 
and the other way around 40. Inter-individual variation might occur because of genetic 
variations 41 or differences in asthma severity, although evidence for the latter is incon-
clusive 42. Therefore, the critical level of exposure to ICS probably shows considerable 
inter-individual and inter-individual variation. Although this hypothesis might explain 
some of the findings reported in this thesis, it needs to be tested further in clinical 
practice. Implications are to be expected for the frequency in which ICS dosing regi-
mens are evaluated, which is typically 2-4 times a year during visits to the outpatient 
clinic. This may not be sufficient for asthmatics of whom the level of asthma control 
and, therefore, the need for ICS fluctuate over time. As a result, children with asthma 
are continuously at risk of being undertreated or overtreated with ICS. The latter is 
more likely since therapy is usually intensified until symptoms are well controlled. 
However, it is questionable whether ICS-doses are reduced or even tapered again in 
months with few triggers for asthma or if asthma is in clinical remission. A solution to 
this problem might be to monitor patients more intensely. By fine-tuning ICS therapy 
throughout the year, the exposure to ICS is limited to the lowest level needed for main-
taining asthma control. This may even improve patient beliefs about the necessity of 
ICS, since any non-adherence is likely to cause a reduction of asthma control. As a 
result, adherence may improve, which would contribute to a more efficient use of ICS. 
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A downside of (too) rigorous tapering ICS doses to the bare minimum is that patients 
may become more sensitive to unexpected triggers for deterioration of asthma con-
trol. Therefore, patients should be carefully instructed to closely monitor their asthma 
symptoms and how to act in case of worsening asthma symptoms, possibly as part of 
guided asthma self-management as recommended by GINA guidelines 43.
LESSONS FOr FuTurE rESEArCh LEArNEd FrOM uSINg ELECTrONIC 
MONITOrINg, ThE MArS-A ANd ThE MPr 
general
A general concern of any adherence study, is the required duration of the follow-up 
period. In chapter 5, the results of the e-MATIC study show that adherence gradually 
declines over time in the first 6 months of follow-up and from that point onward re-
mains quite stable. This observation is in agreement with results from earlier studies 
reporting electronically measured adherence to ICS 38, 44-46. After a while, patients may 
start getting used to the intervention, leading to a decline of the effect. Also, the so 
called Hawthorne effect may start to wear-off, which means a decline of the initial rise 
of awareness and of medication adherence caused by participation in a study 47. As 
discussed earlier, a reason for measuring adherence for at least 12 months is the exis-
tence of seasonal variability of asthma control. Adherence to ICS varies over the year 
as well, showing a peak when asthma control is at a minimum 40, presumably since 
good asthma control reduces motivation adhering to ICS therapy (figure 9.1). Only if 
adherence data are available for all months of the year, the results can be adjusted for 
seasonal fluctuations.
Electronic monitoring (EM)
There are various ways of calculating adherence from EM-data. In chapter 7 and 8, the 
primary adherence measure was taking-adherence, which was defined as the propor-
tion of days on which the exact prescribed ICS-dose was taken. In chapter 3, 4 and 5, 
the main adherence measure was timing-adherence, which was the percentage of ICS-
doses that were taken within a predefined time-frame. We used a 6-hour time-interval, 
from 3 hours before until 3 hours after the planned time of inhalation, because that is 
a common measure for twice-daily dosing-regimens 48-51. However, considering that it 
takes days or even weeks of ICS treatment until the pharmacological effect starts, or 
ends (in case of discontinuation), timing adherence may not give the best reflection 
of the number of effectively administered ICS doses. In chapters 3-5 timing-adherence 
probably gave a good reflection of taking-adherence, since ICS-doses that were initially 
omitted, were only sporadically registered at a later moment (outside of the 6-hour 
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time-frame) on the same day. In chapter 7 and 8, both timing-adherence and taking-
adherence have been calculated. In both studies, EM taking-adherence appeared to be 
considerably stricter (i.e. lower) than EM timing-adherence: median taking-adherence: 
21.1% vs. median timing-adherence: 45.7% (chapter 7) and median taking-adherence: 
45.6% vs. median timing-adherence: 67.0% (chapter 8). The differences between 
both were probably explained by the fact that -in our definitions- all prescribed 
daily ICS-doses needed to be taken in order to have 100% taking-adherence, while 
timing-adherence was still 50% if one out of two ICS-doses were taken correctly. In the 
COMPLIANCE study (chapter 3) and the e-MATIC study (chapter 4 and 5), additional 
adherence measures were calculated as well, including the percentage of days with 
at least 1 or at least 2 ICS doses and the percentage of missed doses or extra doses 
(data not reported). All of these measures showed different adherence estimates, with 
20-25% difference between the most and the least strict measure. The differences 
between adherence measures showed only moderate inter-individual variation. In 
the e-MATIC study (chapter 5), for example, the effect of the SMS-intervention on 
timing-adherence and on taking-adherence were comparable (data not reported). This 
is in agreement with previous findings that the variability in dose-timing was highly 
predictive for sub-optimal taking adherence 52. Therefore, in children with asthma, 
EM-adherence is considered a robust adherence measure for monitoring ICS intakes: 
several definitions of EM-adherence can be used as valid outcome measures, as long 
as the selected method is consequently used for calculating inter-individual or intra-
individual variations. However, different research questions, patient populations or 
types of medication may require different types of EM-adherence measures. 53, 54. 
Different patients who have identical percentages of EM-adherence can have radi-
cally different ICS-taking patterns. For example, adherence of 50% can be caused by 
structurally taking the morning dose but not taking the evening dose, by being fully 
adherent but discontinuing therapy halfway through the observation period of by 
randomly taking or not-taking half of the prescribed ICS doses. This illustrates that the 
exact calculation of the adherence level has only limited clinical consequence for indi-
vidual patients. Instead, electronic monitoring may help to gain insight into a patient’s 
medication taking pattern, which may provide some information on the underlying 
barriers for good adherence 55-57. A selection of different ICS-taking patterns from the 
COMPLIANCE study (chapter 3, not reported) is shown in figure 9.2: patient who takes 
ICS twice daily (9.2a), normal pattern but sleeping late in weekends (9.2b), taking ICS 
as needed instead (9.2c), patient taking a (drug-)holiday (9.2d), initially forgetting part 
of the ICS doses, then discontinuation of ICS use (9.2e), patient taking only 1 out of 2 
daily doses (9.2f, patients with extra ICS doses possibly related to the occurrence of 
asthma symptoms combined with not understanding the difference between SABA 
and ICS (9.2 g and 9.2h). Most of these patterns show signs of non-adherence, but the 
Discussion 173
underlying barriers for good adherence are likely to be different. Each barrier requires 
a different approach for adherence improvement; this is further discussed later in this 
chapter. 
The insight into individual medication taking behaviour is one of the major strengths 
of electronic monitoring 58. If EM is used real time (RTMM) it is possible to undertake im-
mediate action if non-adherence is observed, e.g. with SMS-reminders (chapter 4 and 
5). Another strength of EM is that it is an objective and reliable method for measuring 
adherence 59 with only few degrees of freedom between actuation of the pMDI and the 
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actual inhalation of ICS. Nevertheless, adherence may still be overestimated because 
children may have been aware that they were being observed and therefore may have 
taken their medication more adherently than normal. Another common critique of 
electronic medication monitoring, is that it cannot be confirmed that the medication 
is actually taken. Only drug assays can confirm ingestion. However, studies comparing 
the sequence of medication events with projected and periodically measured concen-
trations of the drug in plasma, confirmed the validity of medication event monitors. 
Mismatches between medication events and actual dosing occur, but are too rare to 
create substantial differences between projected and actual concentrations of the 
drug in plasma 60-63. Registered ICS doses may also have been administered with an 
incorrect inhalation technique. This could have interfered with the pharmacological 
action of ICS and therefore with the patients’ motivation to adhere to ICS therapy, and 
with the effect of ICS on asthma control and quality of life 64. 
Medication Adherence report Scale for Asthma (MArS-A)
In chapter 7, we used the MARS-A as a (proxy) questionnaire on parents that was 
filled out by trained health care professionals. In theory, this might provoke social 
desirable responses, but data also exist that indicate that adherence estimates do not 
differ with interview mode, e.g. audio computer-assisted self-interviewing, face-to-
face interviewing or paper questionnaires 65. An advantage of filling out adherence 
questionnaires by a trained interviewer is that it helps to cope with written language 
barriers. e.g. in non-native patients. It also may reduce differences in interpretation 
of questionnaire items. Several recommendations for future research on the MARS-A 
should be mentioned: it is suggested to add a scale for social desirability, which is 
a weakness of any adherence questionnaire 66. Also, the test-retest reliability should 
be investigated and a recall period should be added, e.g. 30 days, for longitudinal 
adherence measurement 67. As an alternative for the current proxy questionnaire for 
parents, a direct questionnaire may be developed for older children, e.g. eight years or 
older. Some evidence exists that self-reported adherence by children is more reliable 
than adherence estimated by parents 65.
Medication Possession ratio (MPr)
It is important to calculate adherence for all patients in the population for whom ICS 
were prescribed, but only for periods in which ICS use was actually clinically indicated. 
If a first ICS dispensing is used as starting point for MPR calculation, adherence in the 
first few month may be overestimated if the initial ICS prescription is filled too late or 
not filled at all. MPR may also overestimate adherence if a minimum number of ICS 
refills (i.e. 2, like in chapter 2) is defined to exclude patients who discontinue ICS use 
shortly after initiation. If a 1-year observation period is used, exclusion of patients with 
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less than 2 refills of 90-days ICS-medication excludes all patients with an MPR under 
50%. By contrast, the MPR may underestimate adherence due to unknown discontinu-
ations of ICS-prescriptions by healthcare providers. These issues are problematic for 
database studies as presented in chapter 2. However, the validity of MPR calculation 
may be improved, if medicine-dispensing records are retrospectively retrieved for 
patients who have participated in a prospective study cohort study, like in chapter 
8. In this approach, the actual number of ICS refills can be used, on the condition that 
carry-over from earlier refills from before the observation period are taken into ac-
count. Also, no minimum number of ICS-refills or maximum permissible gaps between 
consecutive refills need to be defined, since the prospective patient inclusion has 
made sure ICS therapy was clinically indicated during the entire follow-up period. The 
predefined observation period can be used as denominator of the MPR calculation, 
even if the first ICS prescription was filled a considerable period of time after start of 
the observation period or if no further refills were registered. 
A concern of the MPR calculated from real-life pharmacy records is how to deal with 
patients who have one dominant public pharmacy, but do not have any ICS-refills in the 
observation period. This is especially troublesome if other prescriptions are filled, but 
those for ICS are not. The most logical explanation for these cases is that ICS use is so 
low that no refills are needed, which may be a sign of non-adherence. However, it may 
also be that large quantities of unused ICS supplies may have been stocked and are 
now being used; this phenomenon is known as “carry over”. Alternatively, ICS prescrip-
tions may be filled at more than one pharmacy. This should have a limited effect on 
MPR calculation, since less than 1% of Dutch patients structurally visits more than one 
pharmacy, while 94% only visits one single pharmacy and 5% fills prescriptions at one 
pharmacy most of the time 68. This should not be a problem if other pharmacies send 
notifications of incidental medication dispensing to the patient’s dominant community 
pharmacy, as is the custom in The Netherlands. Nevertheless, it is recommended to 
ask patients at which pharmacies they have filled ICS prescriptions. In addition, phar-
macies in certain regions can look into each other’s medicines-dispensing databases. 
If a patient agrees to it, this facility can be well used for MPR calculation. A limitation 
of using this type of data-exchange, is that it requires a high quality Information and 
Communication Technology (ICT) infrastructure in which medication-dispenses are 
structurally administered and which is easily accessible for retrieving information by 
allied healthcare providers. A limitation of MPR as a screening tool for poor adher-
ence, may be the complexity of the calculations. The MPR for an individual patient 
is easily estimated based on medication-dispensing records from a community phar-
macy database. However, for MPR calculation of large groups of patients, specialized 
software and analysis techniques are required. Although this service and the other 
requirements for reliable MPR-calculation, are available in the Netherlands 69, this may 
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not be the case in other countries. A specific limitation of MPR of ICS is the relatively 
large quantity of ICS that is supplied in one refill, making MPR-calculations vulnerable 
for intermediate dose-adjustments or discontinuations of ICS during episodes. Long 
ICS-episodes also limit the use of MPR for early identification of non-adherence. 
IMPrOVINg AdhErENCE
As discussed in chapter 1, many methods for improvement of medication adherence 
have been investigated. Six categories of adherence improving interventions have 
been distinguished 70: technical adherence interventions (e.g. simplifying dosing regi-
mens), behavioral interventions (e.g. memory aids or reminders providing feedback, 
support of rewards), educational interventions (teaching and providing knowledge), 
social support interventions (providing practical, emotional or unidimensional social 
support 71), structural interventions (e.g. initiatives targeted towards specific patient 
groups or adherence issues), and complex / multi-faceted interventions (e.g. combin-
ing cognitive, behavioral and affective strategies). Some interventions, e.g. reminder-
interventions, are aimed at reducing unintentional non-adherence, e.g. forgetting 
of medication intake. Others can be used to reduce intentional non-adherence, e.g. 
educational or emotional social support interventions. However, the improvement 
of adherence due to interventions is generally small and short-lived, and efficacy on 
clinical outcomes is mostly lacking 72. 
The tailored SMS intervention presented in chapter 4 and 5 improved the mean 
adherence to ICS, but no differences were found for asthma control, quality of life and 
asthma exacerbations. The lack of effect on clinical outcomes and subsequent health-
care use explained why no differences in costs were found between treatment groups. 
One of the explanations was that the e-MATIC study was carried out in a general 
population of children that mostly already had good asthma control at baseline, so 
there was limited room for improvement. Therefore, a suggestion for future research 
is to investigate the effect of a tailored SMS reminder intervention in a population with 
insufficiently controlled asthma.
Maximizing medication adherence is not an end to itself. First, there should be a 
clinical problem, e.g. an insufficient level of asthma control. One of the possible ex-
planations is poor adherence to ICS, which should be objectified before entering the 
stage of adherence improvement. A different approach is screening patients for non-
adherence in an effort to prevent the loss of asthma control. The next step is to find out 
what the primary barrier is for adhering to ICS therapy, which is needed for selecting 
an adherence improving intervention that specifically targets the underlying cause of 
non-adherence. Earlier studies have successfully assessed self-efficacy, beliefs about 
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illness and about medicines, and practical barriers before choosing an adherence 
improving intervention 73, 74. The RTMM devices used in the e-MATIC study (chapter 4 
and 5) were capable of sending tailored SMS-reminders if a dose was at risk of omis-
sion. The device may be even more effective if certain features would be added to it. 
One of these is the detection of a poor inhalation technique, e.g. not shaking the pMDI 
before use, not keeping it straight while actuating, not attaching a spacer or breath-
ing with an inappropriate flow. Other potentially interesting functionalities include 
sending preventive SMS-reminders at moments that are at risk of non-adherence, e.g. 
weekends or holidays (chapter 6, 55), at moments that the individual patient has shown 
non-adherence before, or at times of the year when asthma exacerbations are most 
prevalent, e.g. at start of the school year in the beginning of September 40. Physicians 
may also discuss RTMM-based medication taking patterns with patients in order to find 
solutions for moments at special risk for non-adherence 55, 75. Introducing educational 
and motivational messages may also be effective for patients that earlier showed a 
low level of health literacy or poor medication beliefs respectively 76, 77. In addition, if 
patients could fill asthma control questionnaires (e.g. the ACT) on their smart phones 
and could share these data with their health care professional, this would provide the 
opportunity to act earlier in case of an upcoming asthma exacerbation. Also, fine-
tuning ICS therapy in between visits to the outpatient clinic based on ACT-scores may 
be an option, especially if patients could visualize and share their RTMM-data on ICS 
intakes as well. These options have the potential to support self-management of ICS 
therapy by patients (see also paragraph “asthma self-management”).
A STrATEgy FOr IdENTIFyINg, INVESTIgATINg ANd rEduCINg NON-
AdhErENCE
Several aspects of the applied adherence measures have been discussed in the previ-
ous sections. This paragraph discusses the optimal application of each method and of 
combinations of methods into a strategy for early identification of non-adherence to 
ICS, investigating patterns and mechanisms of suboptimal medication use, and finally, 
selection of suitable interventions for improving adherence.
Identifying non-adherence
Adherence measures can be generally categorised as either screening tools for non-
adherence or tools for acquiring insight into adherence patterns or underlying mecha-
nisms of non-adherence. Methods reported in this thesis that belong to the former 
category, include refill-adherence (MPR) and patient-reported adherence (MARS-A). 
Electronic monitoring (EM) can also be used as a screening tool that can deliver 
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reliable estimations of adherence, but costs are still too high to use it for all patients 
with asthma. Based on the good sensitivity and positive predictive value reported in 
chapter 7 and 8, the MARS-A and the MPR are proposed as suitable tools for routinely 
screening patients for non-adherence. 
Identifying barriers for adherence
When a patient is identified as (potentially) non-adherent, barriers for good adherence 
should be investigated before suitable interventions can be initiated. Two main types 
of barriers for adherence exist: practical barriers, including memory barriers and daily 
routine barriers, and perceptual barriers, including necessity and concerns barriers 
78. In the previous section, the MARS-A and the MPR were proposed as screening 
measures for non-adherence, but these give limited insight into underlying mecha-
nisms or in clues for improving adherence. Only the MARS-A differentiates between 
several subtypes of non-adherent behaviour, primarily about intentional barriers for 
adherence, but the validity of the individual items from the questionnaire has not been 
established. More suitable techniques are available for retrieving information about 
barriers for medication taking behaviour, including , questionnaires for medication 
beliefs (e.g. the BMQ 79), illness perceptions (the Illness Perception Questionnaire, IPQ 
80), self-efficacy (e.g. the MUSE 81), self-management skills (Patient Activation Measure 
(e.g. the PAM 82) and health literacy (e.g. the Functional Communicative and Critical 
Health Literacy, FCCHL 83). Perceptual barriers for adherence may also be identified 
by interviewing patients about their medication beliefs and habits 78. In this thesis, 
however, patients were only interviewed as part of OFG’s (chapter 6). One of the addi-
tional values of patient interviewing is the opportunity for follow-up questions. Other 
factors like, illness perceptions, treatment expectations, daily routine issues, language 
barriers and medication habits can be explored as well. EM provides highly detailed 
and personal profiles of time and date of all pMDI actuations, which give insight into 
moments on which practical barriers exist for good adherence (figure 9.2). Especially 
if the observed patterns are discussed with the patients involved, cues for improving 
medication taking behaviour may emerge 84. 
Improving adherence
As discussed in the previous section, interventions for improving adherence should 
be tailored to the observed barriers for good adherence. For example, patients with 
unintentional non-adherence may require a reminder-intervention (chapter 4 and 5), 
educational interventions may be more suitable, if a knowledge gap or limited health 
literacy are the primary barriers for adherence 14 , and motivational interventions 85 are 
appropriate in case of negative medication beliefs. 
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Combined strategy for identifying, investigating and reducing non-adherence
Combining the discussed methods for adherence measurement, a strategy is pro-
posed for approaching insufficient asthma control in children. As visualized in figure 
9.3, it involves subsequently identifying non-adherence to ICS and acquiring insight 
into adherence patterns or underlying mechanisms (“barriers for adherence”). Finally, 
a suitable intervention for improving adherence should be selected. In this approach, 
evaluation of asthma treatment is a potential starting point for looking further into 
non-adherence and its background. In each part of the proposed strategy, a selection 
should be made based on patient characteristics and the properties of the individual 
methods. For example, the MARS-A questionnaire can be easily applied in any patient 
even when ICS therapy is about to start. For calculation of the MPR, on the other hand, 
a minimum number of 2-3 ICS-refills is needed, requiring that the patient has used 
ICS for at least 6-12 months. Electronic monitoring is a prospective method that is 
only feasible if sufficient funding and know-how are present. If needed, it provides the 
possibility of sending reminders using the same device. If perceptual barriers prohibit 
optimal adherence, motivational or educational interventions are required. Finally, the 
results of the adherence improving intervention should again be measured as part of a 
re-evaluation of asthma treatment. Following the proposed strategy, asthma therapy, 
and adherence to it, can be continuously evaluated, optimized and re-evaluated.
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Figure 9.3 Strategy for identifying, investigating and reducing non-adherence in children with insuf-
ficient asthma control
1Medication Adherence Report Scale for Asthma (chapter 7), 2Medication Possession Ratio (chapter 8), 
3 Electronic medication Monitoring (chapter 3,4 and 5), 4Beliefs about Medicines Questionnaire (chap-
ter 3, 4 and 5), 5Illness Perception Questionnaire 80, 6Medication Understanding and Use Self-Efficacy 
Scale 81, 7Patient Activation Measure 82, 8Functional Communicative and Critical Health Literacy 83
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ASThMA SELF-MANAgEMENT
In the previous sections, asthma self-management of ICS medication was suggested 
as a promising approach for reducing non-adherence and for tailoring ICS therapy to 
the patient’s needs. Moreover, a potential limitation of the strategy proposed in figure 
9.3 is that it requires the involvement of a healthcare provider at every step. The fine-
tuning of unstable asthma treatment may ask more time and effort than the 2 to 4 
annual outpatient visits that most physicians can offer. Especially the seasonality of 
asthma and the related fluctuations of asthma control require frequent re-evaluation 
of therapy. In fact, there probably is only one person who can offer such involvement, 
constantly monitoring asthma symptoms and disease activity: the asthma patient him-
self. This is the reason that guided asthma self-management has been receiving more 
and more attention in asthma guidelines: the healthcare provider is still involved, but 
the degree of involvement ranges from patient-directed self-management to doctor-
directed self-management. In the former, patients make changes in accordance to a 
prior written action plan without having to consult their physician, while in the latter, 
patients refer to their health care professional for most major treatment decisions. 
In both cases, essential components of effective guided asthma self-management 
include: self-monitoring of symptoms, responding to worsening asthma and having 
a regular review of asthma control, treatment and skills by a healthcare provider 43. 
Guided asthma self-management has proven to be effective. Educational programs 
addressing the previously mentioned components have shown to improve lung func-
tion and feelings of self control, reduce absenteeism from school, number of days 
with restricted activity, number of visits to an emergency department, and possibly 
number of disturbed nights 86. A Cochrane review has evaluated 4 pediatric studies 
comparing daily ICS use with intermittent ICS use, that is only started with worsening 
asthma symptoms. Between groups, there was no significant difference quality of life, 
airway hyper-reactivity, adverse effects, hospitalizations or emergency department 
visits. Also, intermittent ICS use was associated with greater growth. However, fewer 
symptom-free days, fewer asthma control days and more use of SABA were reported 
87. 
By contrast, the level of self-management with ICS in children participating in the 
e-MATIC study was only moderate (chapter 6). Although most of the children aged 
8 years or older participating in the online focus groups, were actively involved in 
taking ICS and many said to be able to recognize asthma symptoms, only a minority 
managed to properly respond to deteriorating asthma control without parental help. 
The reported self-management behaviour seemed to be a result of habituation, rather 
than reflective thinking. A possible explanation may have been the absence of written 
action plans, which were hardly mentioned in the OFG’s. The children may also have 
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been too young, since children at the age of 11 have been reported to take only about 
50% of ICS responsibilities 88. A lack of guidance by healthcare providers and parents 
may also have contributed to the limited level of self-management.
In conclusion, guided asthma self-management provides a potentially valuable way 
of individualizing and intensifying asthma therapy. In fact, improved patient involve-
ment should not be replacing, but adding-up to the strategy presented in figure 9.3. 
Instead of focusing on maximizing patient adherence to fixed ICS-dosing regimens, 
ICS therapy should be fine-tuned to the fluctuating demands of individual patients. 
Healthcare providers remain in control of asthma treatment and play an essential role 
in composing a written action plan. This should also provide individualized instruc-
tions for what patients can do to manage their own asthma. As a result, time-gaps 
between outpatient visits can be filled by the patient self-assessing asthma control, 
tailoring the intake of ICS to it, evaluating ICS-taking patterns provided by electronic 
monitoring, self-adjusting ICS therapy within the confinements of the written action 
plan, but also knowing under which circumstances to consult their physician. 
A challenge will be to decide what is the proper level of self-management for an in-
dividual patient. Also, the concept of adherence will remain important, but will change 
from adherence to a fixed dosing-regimen to motivating patients to adhere to their 
individual written action plans. 
CONCLuSIONS
This thesis aimed to investigate opportunities for identifying and reducing non-adher-
ence to ICS in children with asthma. Our findings indicate that adherence is poor in 
general, but especially in children with Moroccan ethnicity. Non-adherence to ICS clini-
cally relevant, but the relation between adherence and asthma control is complex and 
may be bidirectional. Better adherence may improve asthma control, but good asthma 
control may again reduce the perceived need for adhering to ICS therapy. We believe 
the relation is strongest if the actual level of exposure to ICS dose does not exceed a 
critical level that is needed for only just maintaining asthma control. The postulated 
critical level of ICS exposure shows both intra-individual and inter-individual variation. 
A method for improving unintentional adherence is by continuously measuring ICS-in-
takes using electronic monitoring and sending automatic tailored SMS-reminders only 
if an ICS-dose is about to be forgotten. The clinical effectiveness and cost-effectiveness 
of the SMS-reminders may be further improved by targeting patients who may benefit 
most from the intervention, e.g. those with uncontrolled asthma or with poor adher-
ence. The latter group can be identified by screening patients for non-adherence with 
adherence questionnaires like the 9-item MARS-A or by calculating the MPR based 
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on ICS-dispensing records. Interventions aimed at improving adherence should be 
tailored to the barriers that limit adherence in the individual patient. These barriers 
are either intentional/perceptual or unintentional/practical and can be identified 
with patient questionnaires, by interviewing patients about their habits and beliefs 
about asthma and its treatment, and by assessing detailed ICS taking patterns using 
electronic medication monitoring. Stimulating asthma self-management according to 
a written action plan is a promising approach to individualize asthma treatment. The 
use of electronic monitoring may enhance self-management by providing insight into 
ICS-taking behavior and (in future) inhalation technique and giving feedback on it, 
enabling fine-tuning of ICS therapy to the patient’s needs. 
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Astma is een veel voorkomende chronische ziekte bij kinderen. Een aanzienlijk deel 
van deze kinderen heeft hun astma onvoldoende onder controle. Dit kan gepaard 
gaan met een verminderde kwaliteit van leven, intensief gebruik van medische zorg 
en aanzienlijke kosten voor de gezondheidszorg. Astma kan worden behandeld met 
diverse geneesmiddelen. Erg belangrijk zijn de zogenaamde inhalatiecorticosteroïden 
(ICS). Dit zijn geneesmiddelen die de ontsteking van de longen bij astma remmen. Ze 
worden via inhalatie toegediend en voorkomen dat de ziekte steeds erger wordt. 
Het niet trouw gebruiken van de ICS medicatie is een belangrijke oorzaak van astma 
die onvoldoende onder controle is. Therapieontrouw kan worden veroorzaakt door 
zogenaamde theoretische barrières, ook wel perceptuele barrières genoemd. Voor-
beelden zijn het niet beseffen dat astma een ernstige, chronische aandoening is die 
moet worden behandeld, of het erop nahouden van negatieve opvattingen over de 
medicatie, bijvoorbeeld angst voor bijwerkingen of een gebrek aan vertrouwen in het 
effect van ICS. Ook kan therapieontrouw worden veroorzaakt door praktische barri-
ères, zoals het vergeten om de geneesmiddelen in te nemen of het verkeerd begrijpen 
van doseeradviezen. In de loop van de tijd zijn verschillende interventies onderzocht 
met als doel de therapietrouw aan ICS te verbeteren. Deze interventies waren zeer div-
ers en de therapietrouwverbetering was over het algemeen matig en varieerde sterk 
per interventie. Een interventie die de therapietrouw wèl consequent verbeterde, 
was	 het	 versturen	 van	 herinnerings-SMS-jes	 naar	 patiënten.	 Het	 bleek	 echter	 dat	
de	 therapietrouw	wel	beter	werd,	maar	dat	de	patiënten	nog	evenveel	 last	van	hun	
astma hielden. De meeste onderzoeken waren echter te kort om een verbeterde ast-
macontrole te kunnen aantonen. Bovendien werden de herinnerings-SMS-jes op vaste 
tijdstippen	verstuurd,	waardoor	patiënten	er	aan	gewend	raakten	en	het	effect	van	de	
herinneringen langzaam afnam. Inmiddels is het technisch mogelijk om herinnerings-
SMS-jes alleen te versturen als een toediening dreigt te worden overgeslagen, maar 
dit is nog nauwelijks onderzocht bij kinderen. In dit proefschrift worden daarom meth-
odes onderzocht om therapieontrouw aan ICS bij kinderen met astma te verminderen 
door het versturen van herinnerings-SMS-jes. Ook worden methoden onderzocht om 
therapieontrouw op te sporen.
In hoofdstuk 2 beschrijven we ons onderzoek naar het effect van slechte thera-
pietrouw aan ICS op het optreden van astma-aanvallen bij kinderen. We maakten 
gebruik van geneesmiddelverstrekkingen van apotheken en ziekenhuisregistraties uit 
de PHARMO databank. We selecteerden kinderen die een astma-aanval hadden gehad 
waarvoor een ziekenhuisopname of een stootkuur met orale corticosteroïden nodig 
was. De therapietrouw aan ICS van deze kinderen hebben we vergeleken met die van 
kinderen met astma die geen astma-aanval hadden gehad. De therapietrouw werd 
berekend op basis van geregistreerde ICS-afleveringen als het percentage van de tijd 
dat	patiënten	voldoende	ICS	in	huis	hadden	om	100%	therapietrouw	te	kunnen	zijn.	
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Binnen de groep kinderen die naast ICS ook langwerkende luchtwegverwijders (LABA) 
gebruikten zagen we wel verschillen. In deze groep werd een betere therapietrouw 
gevonden bij de kinderen die een astma-aanval hadden gehad dan bij de kinderen 
zonder astma-aanval. Bij kinderen die ICS zonder LABA gebruiken, werd dit verband 
niet gevonden. Onze hypothese is dat kinderen die naast ICS ook LABA gebruikten, 
zieker waren en daardoor beter gemotiveerd waren om hun ICS trouw te gebruiken 
omdat ze zo hun astma beter onder controle zouden kunnen houden. Vooraf was onze 
verwachting echter dat therapie-ontrouw zou leiden tot astma-aanvallen. Die relatie 
lijkt dus omgekeerd, althans bij kinderen die ook LABA gebruiken. De resultaten laten 
daarmee zien dat de relatie tussen therapietrouw en astmacontrole complexer is dan 
gedacht en aandacht verdient.
In hoofdstuk 3 beschrijven we het onderzoek waarin de relatie is onderzocht tussen 
culturele	achtergrond	van	kinderen	en	therapietrouw	aan	ICS.	Hiertoe	is	een	patiën-
tenonderzoek in drie Amsterdamse ziekenhuizen uitgevoerd onder 87 kinderen met 
astma met een Nederlandse of Marokkaanse culturele achtergrond. Alle kinderen (0-
12 jaar) ontvingen gedurende drie maanden een opzetstuk voor hun ICS-inhalator met 
ingebouwde real time medication monitoring (RTMM) technologie. Op elk moment 
waarop de inhalator werd afgevuurd, werd via het mobiele telefoon netwerk direct 
een databericht verstuurd naar de onderzoeksdatabank. De therapietrouw werd 
berekend door de geregistreerde ICS-giften te vergelijken met de voorgeschreven do-
seringen. De autochtone kinderen hadden een hogere therapietrouw dan de kinderen 
met Marokkaanse achtergrond: 55,9% tegen 42,5%. Etniciteit bleek een onafhankelijke 
voorspeller van therapietrouw te zijn. De resultaten van dit onderzoek laten zien dat 
therapietrouw bij kinderen met astma in het algemeen slecht is, maar in het bijzonder 
bij kinderen met een Marokkaanse achtergrond. We hebben in dit onderzoek geen 
verklaring kunnen vinden voor het gevonden therapietrouwverschil. Het is echter 
niet waarschijnlijk dat etniciteit zelf direct invloed heeft op de therapietrouw. Deze 
lijkt eerder een uiting te zijn van andere, mogelijk cultureel bepaalde factoren, zoals 
opvattingen over astma en astmamedicatie, kennis van astma en astmabehandeling 
en de kwaliteit van de communicatie met de arts, die bijvoorbeeld kan zijn verminderd 
ten gevolge van taalbarrières.
In hoofdstuk 4 en 5 beschrijven we het e-MATIC onderzoek: een gerandomiseerd 
onderzoek met als doel het verbeteren van therapietrouw aan ICS. De interventie voor 
therapietrouw verbetering betrof continue elektronische meting van therapietrouw 
met behulp van RTMM, gecombineerd met SMS-herinneringen. De SMS-berichten 
werden alleen verstuurd als een ICS-dosis dreigde te worden overgeslagen. Voor 
dit onderzoek werden in totaal 219 kinderen (4-11 jaar) met astma geworven op de 
polikliniek kindergeneeskunde van vijf ziekenhuizen. Alle kinderen kregen gedurende 
12 maanden een RTMM-opzetstuk voor hun ICS-inhalator, maar alleen degenen in 
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de interventiegroep ontvingen de SMS-herinneringen. In beide behandelgroepen 
werden de therapietrouw, astmacontrole, astma-specifieke kwaliteit van leven, astma-
aanvallen en astma-gerelateerde kosten gemeten. Gemeten over de hele onderzoek-
speriode bleek de gemiddelde therapietrouw significant hoger te zijn in de groep die 
de SMS-herinneringen kreeg dan in de groep die deze herinneringen niet kreeg (69,3% 
tegen 57,3%). Opvallend genoeg werd echter geen verschil gevonden op de andere 
onderzochte uitkomstmaten.
Bij 24 kinderen en hun ouders uit het e-MATIC onderzoek is een verkennend onder-
zoek uitgevoerd naar hoe zelfstandig kinderen omgaan met hun ICS gebruik. Daar-
naast is gekeken in hoeverre ze het gebruik ook zelf bijsturen, ook wel zelfmanage-
ment genoemd (hoofdstuk 6). Er werden drie gestructureerde online praatgroepen 
georganiseerd, zogenaamde online focus groups (OFG’s). In de OFG’s participeerden 
acht kinderen van 9-12 jaar, acht ouders van kinderen van 9-12 jaar en acht ouders 
van kinderen van 4-8 jaar. Er kwamen vijf onderwerpen aan bod: routines voor ICS-
gebruik, vergeten van ICS, het herkennen van astmasymptomen, opvattingen over 
geneesmiddelen	en	de	sociale	omgeving	van	de	patiënt.	Een	van	de	bevindingen	was	
dat een vaste routine voor ICS-gebruik essentieel was voor een goede therapietrouw. 
De meeste kinderen waren gewend zelf het initiatief te nemen voor het gebruiken 
van ICS. Tevens konden de meeste kinderen astmasymptomen bij zichzelf herkennen, 
maar het lukte slechts een enkeling om hierop ook actie te ondernemen zonder hulp 
van de ouders. Het zelfmanagement gedrag leek eerder gebaseerd op ingesleten 
gewoontes dan op bewuste afwegingen. Beperkende factoren voor zelfmanagement 
waren onvoldoende kennis over de werking van ICS en over het onderscheid tussen 
ICS en andere astma medicatie, zoals luchtwegverwijders. Aan deze factoren moet 
aandacht worden besteed bij het stimuleren van zelfmanagement met ICS. Daarnaast 
is het van belang dat kinderen hun ICS-gebruik een vaste plek geven in hun dagelijkse 
routine.
Elektronische meting van therapietrouw is een objectieve en betrouwbare thera-
pietrouwmaat, maar deze techniek is kostbaar en arbeidsintensief. In hoofdstuk 7 
en	 8	 worden	 twee	 alternatieve,	 goedkopere	 methodes	 onderzocht	 om	 patiënten	
met een slechte therapietrouw aan ICS op te sporen: een therapietrouwvragenlijst 
en therapietrouw berekend met ICS-aflevergegevens afkomstig van openbare apo-
theken. In beide onderzoeken werd de onderzochte therapietrouwmaat vergeleken 
met elektronisch gemeten therapietrouw. Het doel was om te onderzoeken of met 
deze	methodes	patiënten	kunnen	worden	opgespoord	die	een	elektronisch	gemeten	
therapietrouw hebben van minder dan 50%.
In hoofdstuk 7 beschrijven we een groep van 87 kinderen met astma jonger dan 
12	 jaar	 en	hun	ouders	 (zelfde	patiëntengroep	 als	 in	 hoofdstuk	 3)	 bij	wie	de	betrou-
wbaarheid van een in het Nederlands vertaalde therapietrouwvragenlijst, genaamd 
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Medication Adherence Report Scale for Asthma (MARS-A), werd bestudeerd. De 
MARS-A vragenlijst werd mondeling afgenomen bij de ouders en bestond uit negen 
vragen met elk vijf antwoordopties (maximaal 5 punten per vraag). Een hoge score 
betekende een slechtere therapietrouw. Ook werd onderzocht of de MARS-A vragen-
lijst geschikt was om opzettelijke en onbewuste therapieontrouw te onderscheiden. 
De	resultaten	lieten	zien	dat	circa	tweederde	van	de	werkelijk	ontrouwe	patiënten	kon	
worden opgespoord met de MARS-A vragenlijst, terwijl iets meer dan een kwart van 
de	patiënten	onterecht	als	therapieontrouw	werd	bestempeld.	De	MARS-A	bleek	dus	
een redelijk betrouwbare en bruikbare vragenlijst voor het opsporen van opzettelijke 
therapieontrouw, maar bleek onvoldoende geschikt voor identificeren van onbewuste 
therapieontrouw. 
In hoofdstuk 8 wordt het onderzoek beschreven waarin bij 93 kinderen uit de 
e-MATIC studiepopulatie de therapietrouw aan ICS is berekend op basis van ICS-
afleveringen door openbare apotheken. De therapietrouwmaat was het percentage 
van	 de	 tijd	 dat	 een	 patiënt	 voldoende	 ICS	 in	 huis	 had	 om	 100%	 therapietrouw	 te	
kunnen zijn. De aldus berekende therapietrouw was aanmerkelijk hoger dan de elek-
tronisch gemeten therapietrouw: 76,7% tegen 45,6%. Van de kinderen met een elek-
tronisch gemeten therapietrouw van minder dan 50%, bleek 70% te kunnen worden 
opgespoord door kinderen te selecteren van wie minder dan 80% van de medicatie 
was afgehaald bij de openbare apotheek. Hier tegenover stond dat ca. 35% van de 
kinderen onterecht als therapieontrouw werd aangemerkt. Therapietrouw berekend 
met ICS-aflevergegevens is een objectieve therapietrouwmaat die gemakkelijk en 
goedkoop kan worden bepaald. Ondanks dat de therapietrouw aan ICS wordt overs-
chat, is het mogelijk om met deze maat een groot deel van de kinderen met ernstige 
therapieontrouw op te sporen. De in hoofdstuk 7 en 8 onderzochte Nederlandstalige 
MARS-A vragenlijst en de therapietrouw berekend met ICS-aflevergegevens kunnen 
in de klinische praktijk worden gebruikt om kinderen op te sporen bij wie de therapi-
etrouw nader moet worden onderzocht of moet worden verbeterd. 
In hoofdstuk 9 worden de resultaten uit dit proefschrift samengevat en besproken. 
De gemiddelde therapietrouw aan ICS bij kinderen met astma is in het algemeen slecht, 
maar in het bijzonder bij kinderen met een Marokkaanse achtergrond. De achtergrond 
van dit etnische verschil is echter onduidelijk en moet nader worden onderzocht. 
Therapieontrouw is een klinisch relevant probleem, maar de relatie tussen thera-
pieontrouw en astmacontrole is complex. Mogelijk is er sprake van een wederzijdse 
beïnvloeding: verbetering van de therapietrouw kan leiden tot een betere astmacon-
trole, maar het hebben van een goede astmacontrole lijkt op zijn beurt de motivatie te 
verminderen om therapietrouw te zijn aan ICS. Verder lijkt er een bepaalde kritische 
ICS-dosis te bestaan waarop astma nog net onder controle blijft. Het is aannemelijk 
dat	 deze	 kritische	 ICS-dosis	 varieert	 tussen	 patiënten,	 maar	 ook	 binnen	 patiënten,	
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bijvoorbeeld. op verschillende momenten in het jaar. Therapietrouw kan worden ver-
beterd door continue elektronische therapietrouwmeting met RTMM, gecombineerd 
met SMS-herinneringen die alleen worden verstuurd als de ICS toediening overgesla-
gen dreigt te worden. De kosteneffectiviteit en het effect op klinische uitkomstmaten 
kan mogelijk worden vergroot als de interventie gerichter wordt ingezet, bijvoorbeeld 
bij kinderen met een slechte astmacontrole en/of een slechte therapietrouw. Deze 
laatste	groep	kan	deels	worden	opgespoord	door	middel	van	patiëntscreening	met	
een therapietrouwvragenlijst zoals de MARS-A of door de therapietrouw te berekenen 
met ICS-aflevergegevens uit de openbare apotheek. Interventies gericht op het 
verbeteren	van	therapietrouw	moeten	passen	bij	de	barrières	die	een	patiënt	ervan	
weerhoudt om therapietrouw te zijn. Een methode om deze barrières op te sporen 
is het interviewen van kinderen/ouders over medicatieovertuigingen, ziektebeleving 
en medicatiegewoontes. ICS-innamepatronen gemaakt met RTMM, zoals verkregen 
in de onderzoeken beschreven in hoofdstuk 3 en 5, kunnen ook inzicht verschaffen in 
barrières voor therapietrouw. Uit deze RTMM-patronen kan bijvoorbeeld blijken dat 
een	 patiënt	 is	 gestopt	met	 ICS	 gebruik,	 de	 dosis	 heeft	 gewijzigd,	 regelmatig	 giften	
vergeet of mogelijk niet goed het verschil kent tussen ICS en andere astma medicatie 
(luchtwegverwijders). Een veelbelovende manier om de astmabehandeling beter 
toe te snijden op de behoeftes van het kind, is het bevorderen van zelfmanagement 
volgens een vooraf met de arts opgesteld actieplan. De RTMM technologie zou hierin 
kunnen	ondersteunen,	onder	andere	door	patiënten	inzicht	te	verschaffen	in	en	terug-
koppeling te geven op hun eigen medicatiegebruik.
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1. Courses 
•	 (Epidm/EMGO) V01 Epidemiologisch onderzoek: opzet en interpreta-
tie, Kerkrade 
Sep 2010 40 h. 
•	 (Epidm/EMGO) V02 Principes van epidemiologische data-analyse, 
Amsterdam. 
Oct 2011 48 h. 
•	 GCP training (GlaxoSmithKline / The college Health Care) Feb 2012 8 h. 
•	 (EUR) Biomedical English Writing and Communication Aug-Dec 2012 118 h/4ECTS 
•	 ( Epidm/EMGO) V05 Regressietechnieken Apr 2013 35 h. 
•	 (Epidm/EMGO) Multi Level Analyse (K74) Jun 2015 24 h. 
Total: 273 h.
2. Seminars, (International) conferences and presentations
•	 International RTMM symposium (presentation), Utrecht Mar 2010 24 h. 
•	 Medische Aerosolen Denktank (MAD) (presentation), Utrecht Apr 2010 16 h. 
•	 Nederlandse Ziekenhuisfarmaciedagen (+ poster presentation), 
Nunspeet 
May 2011 16 h. 
•	 ISAM congress (+ presentation COMPLIANCE study), Rotterdam Jun 2011 21 h. 
•	 NVZA-west meeting, presentation e-MATIC study protocol. Jun 2011 8 h. 
•	 ISPE 2011 Chicago, poster (presentation PMLA van den Bemt) Aug 2011 8 h. 
•	 ESPACOMP (+poster presentation), Utrecht Nov 2011 8 h. 
•	 ESPACOMP (MARS/RTMM) (presentation L van Dijk) Nov 2013 8 h. 
•	 Nederlandse Ziekenhuisfarmaciedagen: presentation e-MATIC study 
(ranking as 2nd best abstract out of 60) and poster-presentation about 
MPR/RTMM study. 
Nov 2014 8 h. 
•	 NVK-congres: SLAM sessie e-MATIC (presentation H. Janssens) Win-
ner of best abstract of the SLAM session. 
Nov 2014 8 h. 
•	 ESPACOMP: presentation e-MATIC (by L van Dijk) Nov 2014 8 h. 
•	 FIGON/DMD: poster e-MATIC + poster MPR/RTMM study Oct 2014 4 h. 
•	 Sint Lucas Andreas Ziekenhuis annual scientific symposium: presenta-
tion COMPLIANCE study. 
Jun 2014 8 h. 
•	 ISPOR congress: presentation on cost-effectiveness of SMS-interven-
tion e-MATIC study (by L Goossens). 
Nov 2014 2 h. 
•	 ZONMW symposium GGG: presentation e-MATIC study (by PMLA van 
den Bemt) 
Apr 2015 4 h. 
•	 ICPE Boston: presentation e-MATIC study (by PMLA van den Bemt) Aug 2015 8 h. 
•	 Prisma symposium: presentation e-MATIC study May 2015 8 h. 
•	 ERS-congres Amsterdam (+ presentation e-MATIC study) Sep 2015 30 h. 
•	 NVKFB: presentation e-MATIC study (by PMLA van den Bemt) Apr 2016 4 h. 
•	 Groene Hart Ziekenhuis annual scientific symposium: presentation 
e-MATIC study 
Jun 2016 4 h.
Total 203 h.
3. Teaching 2010-2016
•	 Pharmacological education of medical students Groene Hart Zieken-
huis (5/year) 
2010-now 10 h./year 
•	 Pharmacological education of residents Internal Medicine Groene 
Hart Ziekenhuis (2/year) 
2010-now 16 h./year 
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•	 Pharmacological education of pharmacy technicians Groene Hart 
Ziekenhuis (2/year) 
2010-now 16 h./year 
•	 Pharmacological education of residents hospital pharmacy. Annual 
PAO Farmacie course on pulmonary medicine. 
2010-now 8 h./year 
•	 Pharmacological education about complex pharmacotherapy for 
nurses specialized in pulmonary medicine. 
2014-2015 40 h. 
Total 390 h.
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Ontzettend veel mensen hebben zich, veelal geheel belangeloos, ingezet voor de 
totstandkoming van dit proefschrift. Ik wil hen daarvoor allemaal zeer hartelijk bedan-
ken. Een aantal wil ik in het bijzonder noemen.
Allereerst de kinderen en hun ouders die hebben deelgenomen aan het COMPLIANCE 
en e-MATIC onderzoek: jullie bijdrage was essentieel. Verder dank ik de leden van 
de kleine en grote promotiecommissie voor het beoordelen van mijn proefschrift 
en voor het voeren van oppositie tijdens de verdediging ervan. A special thanks to 
professor Robert Horne for being a member of the examination committee and for 
coming over from the UK for the public examination. Ik dank ZonMw en de collega’s 
van GlaxoSmithKline, o.a. Annemarie Engbers en Joke Bax, voor het in ons gestelde 
vertrouwen. Hetzelfde geldt voor de mensen van Evalan, o.a. Henk Schwietert en 
Susan van Wissen: de door jullie verzorgde RTMM technologie vormt een rode draad 
door dit proefschrift. 
Patricia, je enthousiasme, mentale veerkracht en volharding was erg inspirerend. Voor 
een belangrijk deel door jouw inzet is het uiteindelijk gelukt om de benodigde fondsen 
voor het e-MATIC onderzoek bij elkaar te krijgen. Je hebt me afgelopen jaren geholpen 
het beste uit mezelf te halen. Je snelle en adequate commentaar op mijn stukken, 
veelal binnen één of enkele dagen, heeft hier zeker aan bijgedragen. Vast slot van elk 
overleg	was:	“Wensen,	klachten,	problemen?”,	meestal	niet.
Veel dank komt ook toe aan mijn andere co-promotor. Liset, je bent iets later aange-
haakt bij het promotieonderzoek, maar al snel was je niet meer weg te denken. Je 
bijdrage was onmisbaar, niet alleen in kwantitatief onderzoek, maar vooral ook in de 
kwalitatieve en gedragsmatige aspecten van onze studies. Volgens mij wedijverde je 
met Patricia om wie het snelste/beste commentaar kon leveren op de door mij aange-
leverde stukken. Onheilspellend was jouw feedback die begon met “Misschien moet je 
toch nog even kijken naar ...”, maar eigenlijk werd het er altijd beter van.
Arnold, toen we jou vroegen als promotor, plaatste je het onderzoek meteen in een 
breder kader, en dat ben je blijven doen gaande het hele promotietraject. Uiteraard is 
het van belang hóe je onderzoek doet en wát er moet gebeuren, maar jij hebt me ook 
laten zien waaróm we het moesten doen. Een typische reactie was: ”Wat zie je als je 
door	je	wimpers	naar	deze	data	kijkt?”.	Verder	heb	je	mij	en	mijn	co-promotoren	veel	
ruimte en vertrouwen gegeven, dank daarvoor.
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Aan iedereen die heeft meegeholpen met de dataverzameling: zonder jullie was het 
niet gelukt! Brenda, je hebt het e-MATIC onderzoek een enorme impuls gegeven. 
Karin,	jij	hebt	grotendeels	in	je	eentje	in	3	ziekenhuizen	de	patiëntinclusie	en	follow-up	
getrokken. Bedankt voor de fijne samenwerking. Verder heb ik hulp mogen ontvangen 
van een indrukwekkende lijst onderzoeksstudenten en research medewerkers: Loes 
Thomaes, Marloes van Hest, Chaled Abdel Gawad, Maarten Meerman, Lotte Edens, 
Batool Jadoon, Sufian Alariachi, Saidan Karaman and Mahmut Yilmaz, Ruben de Groot, 
Kirby Tong Minh, Annemieke von Königslöw en Esther Lems. Collega’s uit het BovenIJ 
ziekenhuis: Inge Berger, Caroline Dijkstra en Charlotte Pieters bedankt voor jullie gast-
vrijheid en hulp bij verzamelen medicatieafleverhistories voor het e-MATIC onderzoek. 
Dat laatste geldt ook voor Ellen Huisman en de apothekersassistentes van het ASP van 
het GHZ, en alle openbare apothekers die hebben geholpen met het aanleveren van 
de medicatiehistories. Verder de medewerkers van de deelnemende kinderpoli’s en de 
GHZ-longverpleegkundigen: fijn dat jullie af en toe wilden inspringen voor tussentijdse 
patiënt	bezoeken.	
Mijn bijzondere dank gaat uit naar de betrokken kinderartsen. De manier waarop 
jullie vrijwillig en onbezoldigd raad en assistentie verleenden was hartverwarmend. 
Bart en Nordin, jullie stonden aan de wieg van het COMPLIANCE onderzoek en zijn 
eigenlijk het hele traject betrokken gebleven. Ellen, we hebben elkaar maar een paar 
keer gezien, maar het liep altijd als een speer in het BovenIJ. Hettie, jouw bijdrage 
was van grote waarde bij de opzet en uitvoering van het e-MATIC onderzoek. Over de 
kinderhaven heb ik weinig zorgen gehad. Florens, ik ken weinig collega’s met zoveel 
onderzoekservaring. Bedankt voor al je tips en het delen van je connecties. 
Een eervolle vermelding is ook op zijn plaats voor Svetlana Belitser: wat begon als 
een leuk projectje op een moment dat we nog geen uitzicht hadden op financiering, 
werd gaandeweg het moeilijkste en misschien wel meest interessante manuscript van 
mijn hele boekje. Ik heb erg veel van je geleerd en heb goede herinneringen aan de 
vele uren achter de PC waarin jij voor mij onbegrijpelijke “R” code aan het kloppen 
was. Uiteindelijk is het gelukt om de reviewers te overtuigen van de waarde van onze 
onverwachte bevindingen. Patrick Souverein, jij hebt in alle projecten waarin we refill-
rate gebruiken een belangrijke rol gespeeld; bedankt voor al je rekenwerk. Maureen, 
je vriendelijke en inhoudelijk scherpe opmerkingen heb ik erg gewaardeerd. Lucas, ik 
ken weinig mensen die qua biostatistiek zo boven de stof staan en het ook nog kunnen 
en willen uitleggen. 
In de apotheek van het Erasmus MC heb ik volgens mij in de loop der jaren bij iedereen 
al een keer op de kamer gezeten. Jullie gezelligheid was een welkome afleiding van 
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onderzoeksfrustaties en vierkante ogen. De laatste jaren heb ik een aantal generaties 
farmaciestudenten voorbij zien komen op de stagiair-kamer, erg leuk om jullie te leren 
kennen. Gevraagde en ongevraagde tips heb ik in dank aanvaard, vooral van mijn 
vaste vraagbaak Rianne, maar ook bijvoorbeeld van Monique, Floor en Heleen. Tilly, 
bedankt voor het warme welkom en je hulp bij het bemachtigen van een werkplek of 
van een plekje in Arnolds agenda. Ik ga m’n vaste dinsdag in het Erasmus echt missen! 
Collega’s uit het GHZ: bedankt voor jullie steun en interesse. Voor sommigen was het 
moeilijk voor te stellen wat ik op dinsdag allemaal deed in Rotterdam. Ik hoop met dit 
boekje iets van de onduidelijkheid te hebben weggenomen. Mignon, bedankt voor je 
ondersteuning van mijn duale werk/onderzoeksconstructie. 
De basis voor dit onderzoek is gelegd tijdens mijn registratieonderzoek in Amsterdam. 
Oud-collega’s uit het SLAZ, bedankt voor jullie hulp en interesse. Jan, de door jou 
gearrangeerde meerjarengelden van Agis en later je introductie bij GlaxoSmithKline 
zijn van groot belang geweest voor mijn onderzoek. Je inventiviteit heeft me altijd 
geïnspireerd. Verder kon ik altijd op je steun rekenen, dank! Marjo en Fatma, jullie hulp 
bij het COMPLIANCE onderzoek was zeer waardevol. 
Een constante factor die me op de been heeft gehouden, zijn mijn vaste Kempo/
Systema sportavonden. Mijn trainingmaatjes wisten me altijd vrij snel weer met beide 
benen (of geheel) op de grond te krijgen. 
Niels: super bedankt voor het ontwerp van de cover. Deze is prachtig geworden!
Sam en Martijn, mijn onderzoek werd door jullie vaak gekscherend aangeduid als vrij-
willigerswerk naast mijn parttime baantje als ziekenhuisapotheker. Hopelijk geloven 
jullie nu dat ik afgelopen jaren niet één dag per week in de zon heb gelegen. Bedankt 
voor jullie jarenlange support als vriend, en nu als paranimf.
Ivar en Jurriaan, mannen van het eerste uur, jullie hebben je altijd ingespannen om me 
van mijn studie af te houden, regelmatig met succes. We zien elkaar niet zo vaak als 
we zouden willen, maar dat gaat vast weer komen.
Andere lieve vrienden en familie, bedankt voor jullie interesse en steun afgelopen 
jaren. Pap en mam, jullie steun tijdens eerdere opleidingen vormde de basis voor deze 
promotie. Astrid, jij hebt dit pad vele jaren eerder bewandeld, ik had nooit gedacht dat 
ik je achterna zou gaan. Eric, Gemma, Fem en Kas: wat heb ik het getroffen met zulke 
lieve en geïnteresseerde schoonfamilie. 
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Bbd-ers, een aantal van jullie is me al voorgegaan in het doctoraat. Echt bijzonder om 
jullie nog regelmatig te zien. Hein, je hulp met de lineaire regressie heeft me enorm 
geholpen helemaal in het begin, toen ik nog maar half begreep wat ik aan het doen 
was.
Lieve Sanne, mijn onderzoek heeft ook heel wat van jou gevraagd, in het bijzonder 
tijdens de eindsprint. Zonder jouw hulp was het niet gelukt! Regelmatig heb ik dank-
baar gebruik gemaakt van je strategisch advies; we hebben aardig wat gebrainstormd. 
Vaak was er kunst en vliegwerk nodig in de ochtend en avonduren, maar na een lange 
onderzoeksdag was het heerlijk om jou, Hasse en Lysken weer in de armen te sluiten. 
Met de afronding van dit project, ontstaat weer meer tijd om van elkaar te genieten. 
Laten we ons blijven richten op de dingen waar we gelukkig van worden, zowel op het 
werk als privé.
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